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I. General Information
All reactions were performed under an atmosphere of dry nitrogen or argon.  CH2Cl2 and 
THF were purified and dried using a solvent-purification system that contained activated 
alumina under argon; THF was further dried using freshly activated 4Å  MS.  NiCl2•glyme 
(>97%, Strem), NiBr2•glyme (>97%, Strem), zinc powder (100 mesh, 99.9% metals basis, Alfa 
Aesar), 1,5-bis(diphenylphosphino)pentane (97%, Sigma-Aldrich), LiCl (anhydrous, beads, −10 
mesh, 99.998% trace metals basis, Sigma-Aldrich), and all commercially available alkyl iodides 
(Acros, Alfa Aesar, Oakwood, and Sigma-Aldrich) were used as received. 
1H and 13C NMR data were collected on a Bruker 400 MHz, a Varian 500 MHz, or a Varian 
300 MHz spectrometer at ambient temperature.  19F NMR data were collected on a Varian 300 
MHz spectrometer at ambient temperature.  HPLC analyses were carried out on an Agilent 
1100 series system with Daicel CHIRALPAK®  or Daicel CHIRALCEL®  columns (4.6 × 250 mm, 
particle size 5 μm).  SFC analyses were carried out on an Agilent 1260 Infinity II system with 
Daicel CHIRALPAK®  or Daicel CHIRALCEL®  columns (4.6 × 250 mm, particle size 5 μm).  
FT-IR measurements were carried out on a Thermo Scientific Nicolet iS5 FT-IR spectrometer 
equipped with an iD5 ATR accessory.  HRMS were acquired using an Agilent 6220 TOF-LCMS 
system.  Optical rotation data were obtained with a Jasco P‐2000 polarimeter at 589 nm and at 
22–24 °C, using a 100 mm path‐length cell in the solvent and at the concentration indicated.  
GC analyses were obtained on an Agilent 6890N GC.  Flash column chromatography was 
performed using silica gel (SiliaFlash®  P60, particle size 40-63 μm, Silicycle). 
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II. Preparation of Chiral Ligands
The yields have not been optimized. 
General Procedure 1 (GP-1) (22).  In an oven-dried round-bottom flask equipped with a stir 
bar, ZnCl2 (0.20 equiv) was melted by a propane flame under high vacuum and cooled under 
nitrogen.  Chlorobenzene (7 mL/mmol of isoquinoline-1-carbonitrile) was added, followed by 
isoquinoline-1-carbonitrile (1.0 equiv, as a solid under a positive flow of nitrogen) and the 
aminoalcohol (1.2 equiv, dissolved in chlorobenzene (1.0 mL/mmol of aminoalcohol)).  The 
resulting mixture was heated at 140 °C for 48 h.  Next, the mixture was allowed to cool to room 
temperature, and it was concentrated under reduced pressure.  The residue was added to 
CH2Cl2/H2O (3/2; for H2O: 4.0 mL/mmol of isoquinoline-1-carbonitrile), and the mixture was 
filtered through a sintered funnel that contained celite.  The resulting solution was extracted 
three times with CH2Cl2 (4.0 mL/mmol of isoquinoline-1-carbonitrile), and the combined organic 
layers were washed with brine, dried (Na2SO4), filtered, and concentrated under reduced 
pressure.  The residue was purified by flash chromatography on silica gel to provide the pure 
product. 
(S)-2-(Isoquinolin-1-yl)-4-neopentyl-4,5-dihydrooxazole.  The title compound was 
synthesized according to GP-1 from isoquinoline-1-carbonitrile (4.19 g, 27.2 mmol) and (S)-2-
amino-4,4-dimethylpentan-1-ol (34) (4.27 g, 32.6 mmol).  The product was purified by flash 
chromatography on silica gel (1:10  1:4 EtOAc/hexanes) to afford the product as a pale-
yellow solid (5.20 g, 71%), which was recrystallized in hexanes to provide the ligand as 
colorless needles (3.88 g, 53%, >99% ee). 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (10.0% 
2-PrOH in hexanes, 1.0 mL/min with tr = 10.2 min ((R)-L1), tr = 9.4 min ((S)-L1).
1H NMR (400 MHz, CDCl3) δ 9.37 – 9.23 (m, 1H), 8.65 (d, J = 5.5 Hz, 1H), 7.91 – 7.85 (m, 1H),
7.77 (dd, J = 5.6, 0.9 Hz, 1H), 7.76 – 7.66 (m, 2H), 4.71 (dd, J = 9.6, 8.0 Hz, 1H), 4.64 – 4.53 (m, 1H), 
4.11 (t, J = 8.4 Hz, 1H), 2.05 (dd, J = 13.9, 5.0 Hz, 1H), 1.59 (dd, J = 14.0, 7.6 Hz, 1H), 1.08 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 161.3, 146.4, 141.7, 136.7, 130.3, 128.4, 127.5, 127.3, 127.0, 123.2, 
73.7, 65.2, 50.7, 30.4, 30.0. 
FT-IR (film): 2952, 2900, 2865, 1363, 1131, 998, 830, 751 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H21N2O: 269.1648, found: 269.1650. 
[]24D = 32.7 (c 1.0, CHCl3).
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(3aS,8aR)-2-(Isoquinolin-1-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole.  The title 
compound was synthesized according to GP-1 from isoquinoline-1-carbonitrile (5.00 g, 32.5 
mmol) and (1S,2R)-1-amino-2,3-dihydro-1H-inden-2-ol (5.82 g, 39.0 mmol).  The product was 
purified by flash chromatography on silica gel (1:10  1:1 EtOAc/hexanes) to afford the product 
as a black solid (6.00 g, 65%), which was recrystallized in EtOAc/hexanes to provide the ligand 
as white needles (2.33 g, 25%, >99% ee). 
SFC analysis: The ee was determined via SFC on a CHIRALCEL OD-3 column (15.0% 2-
PrOH in supercritical CO2, 2.5 mL/min) with tr = 15.6 min ((S,R)-L2), tr = 16.3 min ((R,S)-L2). 
1H NMR (400 MHz, CDCl3) δ 9.21 (dq, J = 8.3, 1.0 Hz, 1H), 8.64 (d, J = 5.5 Hz, 1H), 7.87 – 7.80 
(m, 1H), 7.78 – 7.60 (m, 4H), 7.38 – 7.27 (m, 3H), 5.99 (dd, J = 8.0, 0.8 Hz, 1H), 5.63 (ddd, J = 8.2, 
4.9, 3.5 Hz, 1H), 3.66 – 3.51 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 162.4, 146.2, 141.7, 141.6, 139.9, 136.6, 130.3, 128.6, 128.4, 127.5, 
127.4, 127.3, 126.9, 125.5, 125.4, 123.3, 82.7, 77.8, 39.7. 
FT-IR (film): 3052, 2982, 2917, 1615, 1130, 1020, 1003, 832, 749, 644 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C19H14N2ONa: 309.0998, found: 309.1001. 
[]22D = 47.7 (c 1.0, CHCl3). 
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III. Preparation of Electrophiles
The yields have not been optimized. 
General Procedure 2 (GP-2): Preparation of an alkyl iodide from the corresponding alkyl 
bromide.  To a solution of NaI (2.5 equiv) in acetone (HPLC grade, 0.5 M in NaI) was added the 
alkyl bromide (1.0 equiv).  The reaction mixture was refluxed at 85 C for 2 h.  Next, the 
mixture was allowed to cool to room temperature, it was filtered through a sintered glass funnel, 
and then the solvent was evaporated in vacuo.  The resulting paste was diluted with Et2O (~5 
times the volume of original acetone), and the solution was washed with aqueous Na2S2O3 (0.1 
M).  The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure.  
The residue was purified by flash chromatography on silica gel to afford the pure product. 
General Procedure 3 (GP-3): Preparation of a propargylic bromide from the corresponding 
alcohol.  Imidazole (1.2 equiv) and PPh3 (1.2 equiv) were dissolved in CH2Cl2 (0.2 M in 
imidazole), and the resulting solution was cooled to 0 °C.  At this temperature, bromine (1.2 
equiv) was added slowly in portions over 10 min, and the resulting mixture was stirred for 10 
min.  Next, the propargylic alcohol (25) (1.0 equiv) was added, and the resulting mixture was 
allowed to warm to room temperature and stirred overnight.  Then, the reaction mixture was 
added to hexanes/Et2O (5/1; for hexanes: 10 mL/mmol of propargylic alcohol), stirred for 15 min, 
then filtered.  The filtrate was concentrated under reduced pressure, and the residue was 
purified by flash chromatography on silica gel to afford the pure product. 
(3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 4-
iodobutanoate.  The title compound was synthesized according to GP-2 from the 
corresponding alkyl bromide (35) (7.17 g, 13.4 mmol).  The product was purified by column 
chromatography on silica gel (1:10 hexanes/EtOAc).  7.33 g (12.6 mmol, 94% yield).  White 
solid. 
1H NMR (400 MHz, CDCl3) δ 5.39 (dd, J = 5.1, 1.8 Hz, 1H), 4.73 – 4.56 (m, 1H), 3.26 (t, J = 6.8 
Hz, 2H), 2.44 (t, J = 7.2 Hz, 2H), 2.39 – 2.29 (m, 2H), 2.14 (p, J = 7.0 Hz, 2H), 2.08 – 1.94 (m, 2H), 
1.93 – 1.79 (m, 3H), 1.68 – 1.44 (m, 7H), 1.43 – 1.24 (m, 4H), 1.24 – 1.06 (m, 7H), 1.04 (s, 3H), 1.04 – 
0.96 (m, 3H), 0.93 (d, J = 6.5 Hz, 3H), 0.89 (d, J = 1.9 Hz, 3H), 0.88 (d, J = 1.9 Hz, 3H), 0.70 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ 171.7, 139.5, 122.7, 74.2, 56.6, 56.1, 50.0, 42.3, 39.7, 39.5, 38.1, 
36.9, 36.5, 36.1, 35.8, 35.1, 31.9, 31.8, 28.5, 28.2, 28.0, 27.8, 24.3, 23.8, 22.8, 22.6, 21.0, 19.3, 18.7, 11.8, 
5.5. 
FT-IR (film): 2932, 2865, 1728, 1466, 1438, 1374, 1189, 1012 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C31H55IO2N: 600.3272, found: 600.3260. 
 
 
 
Benzyl(3-bromohept-1-yn-1-yl)diphenylsilane.  The title compound was synthesized 
according to GP-3 from 1-(benzyldiphenylsilyl)hept-1-yn-3-ol (9.52 g, 24.8 mmol) and purified 
by flash chromatography on silica gel (0  1% EtOAc/hexanes).  6.32 g (14.2 mmol, 57% yield).  
Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.62 – 7.52 (m, 4H), 7.45 – 7.39 (m, 2H), 7.39 – 7.33 (m, 4H), 7.20 
– 7.10 (m, 2H), 7.10 – 7.06 (m, 1H), 7.06 – 6.98 (m, 2H), 4.57 (t, J = 6.8 Hz, 1H), 2.71 (s, 2H), 2.09 – 
1.98 (m, 2H), 1.58 – 1.45 (m, 2H), 1.44 – 1.30 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.3, 134.9, 132.98, 132.97, 129.9, 129.0, 128.0, 127.9, 124.6, 
108.6, 86.8, 39.1, 36.7, 29.4, 24.2, 21.9, 13.9. 
FT-IR (film): 3067, 3024, 2956, 2930, 3173, 1428, 1115, 734, 700 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C26H31BrSiN: 464.1404, found: 464.1402. 
 
 
 
Benzyl(3-bromo-5-phenylpent-1-yn-1-yl)diphenylsilane.  The title compound was 
synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-5-methylhex-1-yn-3-ol (4.56 g, 10.6 
mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  4.17 g (8.4 
mmol, 80% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.44 (m, 4H), 7.37 – 7.30 (m, 2H), 7.30 – 7.24 (m, 4H), 7.24 
– 7.18 (m, 2H), 7.16 – 7.11 (m, 1H), 7.10 – 7.02 (m, 4H), 7.00 – 6.89 (m, 3H), 4.41 (t, J = 6.8 Hz, 1H), 
2.79 – 2.71 (m, 2H), 2.63 (s, 2H), 2.31 – 2.17 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 139.9, 137.2, 134.9, 132.9, 130.0, 129.0, 128.6, 128.0, 127.9, 126.3, 
124.7, 108.1, 87.4, 40.9, 35.8, 33.3, 24.2. 
FT-IR (film): 3066, 3025, 2926, 2171, 1493, 1428, 1112, 769, 734, 697 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C30H31BrSiN: 512.1404, found: 512.1393. 
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Benzyl(3-bromobut-1-yn-1-yl)diphenylsilane.  The title compound was synthesized 
according to GP-3 from 4-(benzyldiphenylsilyl)but-3-yn-2-ol (3.84 g, 11.2 mmol) and purified by 
flash chromatography on silica gel (0  1% EtOAc/hexanes).  3.81 g (9.4 mmol, 84% yield).  
Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.42 (m, 4H), 7.34 – 7.27 (m, 2H), 7.27 – 7.21 (m, 4H), 7.09 
– 7.01 (m, 2H), 7.01 – 6.88 (m, 3H), 4.54 (q, J = 6.9 Hz, 1H), 2.61 (s, 2H), 1.82 (d, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.2, 134.9, 132.8, 129.9, 129.0, 128.0, 127.9, 124.6, 109.5, 86.1, 
30.6, 27.0, 24.2. 
FT-IR (film): 3068, 3050, 3024, 2169, 1428, 1111, 908, 768, 733, 699 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C23H25BrSiN: 422.0934, found: 422.0938. 
 
 
 
Benzyl(3-bromo-5-methylhex-1-yn-1-yl)diphenylsilane.  The title compound was 
synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-5-methylhex-1-yn-3-ol (4.83 g, 12.6 
mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  4.71 g 
(10.6 mmol, 84% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.66 – 7.56 (m, 4H), 7.49 – 7.34 (m, 6H), 7.22 – 7.15 (m, 2H), 7.14 
– 7.09 (m, 1H), 7.09 – 7.02 (m, 2H), 4.62 (t, J = 7.5 Hz, 1H), 2.75 (s, 2H), 2.04 – 1.86 (m, 3H), 0.98 (d, 
J = 6.4 Hz, 3H), 0.97 (d, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.3, 134.9, 133.0, 129.9, 129.0, 128.0, 127.9, 124.6, 108.7, 86.7, 
48.3, 35.2, 26.8, 24.2, 21.9, 21.8. 
FT-IR (film): 3068, 3052, 3024, 2957, 2931, 2173, 1428, 1113, 770, 734, 701 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C26H31BrSiN: 464.1404, found: 464.1399. 
 
 
 
Benzyl(3-bromo-6-((tert-butyldimethylsilyl)oxy)hex-1-yn-1-yl)diphenylsilane.  The title 
compound was synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-6-((tert-
butyldimethylsilyl)oxy)hex-1-yn-3-ol (4.20 g, 8.4 mmol) and purified by flash chromatography 
on silica gel (0  1% EtOAc/hexanes).  1.00 g (1.8 mmol, 21% yield).  Colorless oil. 
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1H NMR (400 MHz, CDCl3) δ 7.61 – 7.52 (m, 4H), 7.48 – 7.38 (m, 2H), 7.38 – 7.29 (m, 4H), 7.18 
– 7.11 (m, 2H), 7.10 – 7.04 (m, 1H), 7.04 – 6.98 (m, 2H), 4.64 (t, J = 6.7 Hz, 1H), 3.66 (t, J = 6.1 Hz, 
2H), 2.71 (s, 2H), 2.18 – 2.07 (m, 2H), 1.81 – 1.69 (m, 2H), 0.91 (s, 9H), 0.06 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 137.3, 134.9, 132.9, 129.9, 129.0, 128.0, 127.9, 124.6, 108.4, 86.9, 
62.1, 36.6, 36.3, 30.4, 25.9, 24.2, 18.3, -5.3. 
FT-IR (film): 2952, 2928, 2857, 2173, 1429, 1255, 1108, 835, 772, 698 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C31H43BrOSi2N: 580.2061, found: 580.2058. 
 
 
 
Benzyl(7-(benzyloxy)-3-bromohept-1-yn-1-yl)diphenylsilane.  The title compound was 
synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-7-(benzyloxy)hept-1-yn-3-ol (6.23 g, 
12.7 mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  4.50 
g (8.2 mmol, 64% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.62 – 7.54 (m, 4H), 7.46 – 7.27 (m, 11H), 7.19 – 7.11 (m, 2H), 
7.10 – 6.99 (m, 3H), 4.58 (t, J = 6.7 Hz, 1H), 4.52 (s, 2H), 3.49 (t, J = 6.0 Hz, 2H), 2.72 (s, 2H), 2.07 (q, 
J = 7.0 Hz, 2H), 1.75 – 1.59 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 138.5, 137.3, 134.9, 132.9, 129.9, 129.0, 128.4, 128.0, 127.9, 127.6, 
127.5, 124.6, 108.4, 87.0, 72.9, 69.9, 39.1, 36.5, 28.8, 24.2, 24.1. 
FT-IR (film): 3053, 3024, 2941, 2856, 2172, 1428, 1110, 767, 734, 702 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C33H37BrOSiN: 570.1822, found: 570.1828. 
 
 
 
Benzyl(3-bromo-6-(naphthalen-2-yloxy)hex-1-yn-1-yl)diphenylsilane.  The title 
compound was synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-6-(naphthalen-2-
yloxy)hex-1-yn-3-ol (4.58 g, 8.9 mmol) and purified by flash chromatography on silica gel (0  1% 
EtOAc/hexanes).  4.39 g (7.6 mmol, 85% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.71 (m, 3H), 7.66 – 7.56 (m, 4H), 7.51 – 7.41 (m, 3H), 7.41 
– 7.33 (m, 5H), 7.22 – 7.13 (m, 4H), 7.13 – 7.02 (m, 3H), 4.73 (t, J = 6.6 Hz, 1H), 4.13 (t, J = 6.0 Hz, 
2H), 2.75 (s, 2H), 2.37 – 2.26 (m, 2H), 2.19 – 2.05 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 156.7, 137.3, 134.9, 134.5, 132.9, 130.0, 129.4, 129.05, 128.95, 
128.0, 127.9, 127.6, 126.7, 126.3, 124.7, 123.6, 118.8, 108.1, 106.5, 87.4, 66.7, 36.21, 36.20, 27.1, 24.2. 
FT-IR (film): 3056, 3024, 2927, 2174, 1628, 1601, 1258, 1216, 1181, 1115, 837, 742, 699 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C35H35BrOSiN: 592.1666, found: 592.1661. 
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Benzyl(3-bromo-6-(5,5-dimethyl-1,3-dioxan-2-yl)hex-1-yn-1-yl)diphenylsilane.  The title 
compound was synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-6-(5,5-dimethyl-1,3-
dioxan-2-yl)hex-1-yn-3-ol (3.51 g, 7.2 mmol) and purified by flash chromatography on silica gel 
(0  2% EtOAc/hexanes).  3.57 g (6.5 mmol, 90% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.63 – 7.53 (m, 4H), 7.47 – 7.40 (m, 2H), 7.40 – 7.31 (m, 4H), 7.21 
– 7.12 (m, 2H), 7.12 – 7.06 (m, 1H), 7.06 – 7.00 (m, 2H), 4.58 (t, J = 6.8 Hz, 1H), 4.49 – 4.40 (m, 1H), 
3.67 – 3.58 (m, 2H), 3.48 – 3.39 (m, 2H), 2.72 (s, 2H), 2.14 – 2.02 (m, 2H), 1.76 – 1.64 (m, 4H), 1.21 
(s, 3H), 0.74 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.2, 134.9, 132.9, 129.9, 129.0, 128.0, 127.9, 124.6, 108.4, 101.7, 
86.9, 77.2, 39.2, 36.4, 33.7, 30.1, 24.2, 23.0, 22.0, 21.8. 
FT-IR (film): 3024, 2953, 2849, 2171, 1429, 1115, 697 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C31H39BrO2SiN: 564.1928, found: 564.1929. 
 
 
 
Benzyl(3-bromotetradeca-1,11-diyn-1-yl)diphenylsilane.  The title compound was 
synthesized according to GP-3 from 1-(benzyldiphenylsilyl)tetradeca-1,11-diyn-3-ol (4.62 g, 9.7 
mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  4.14 g (7.7 
mmol, 79% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.63 – 7.53 (m, 4H), 7.46 – 7.40 (m, 2H), 7.40 – 7.34 (m, 4H), 7.21 
– 7.11 (m, 2H), 7.11 – 7.06 (m, 1H), 7.06 – 6.99 (m, 2H), 4.58 (t, J = 6.7 Hz, 1H), 2.72 (s, 2H), 2.24 – 
2.11 (m, 4H), 2.09 – 1.98 (m, 2H), 1.61 – 1.44 (m, 4H), 1.44 – 1.27 (m, 6H), 1.14 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.3, 134.9, 133.0, 129.9, 129.0, 128.0, 127.9, 124.6, 108.5, 86.9, 
81.7, 79.4, 39.4, 36.7, 29.1, 28.9, 28.7, 28.6, 27.2, 24.2, 18.7, 14.4, 12.4. 
FT-IR (film): 2930, 2856, 2173, 1429, 1110, 698 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C33H41BrSiN: 558.2186, found: 558.2177. 
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(Z)-Benzyl(3-bromododec-9-en-1-yn-1-yl)diphenylsilane.  The title compound was 
synthesized according to GP-3 from (Z)-1-(benzyldiphenylsilyl)dodec-9-en-1-yn-3-ol (5.44 g, 
12.0 mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  5.50 
g (10.7 mmol, 89% yield).  Pale-yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.67 – 7.57 (m, 4H), 7.49 – 7.43 (m, 2H), 7.43 – 7.36 (m, 4H), 7.24 
– 7.16 (m, 2H), 7.16 – 7.09 (m, 1H), 7.09 – 7.02 (m, 2H), 5.52 – 5.32 (m, 2H), 4.61 (t, J = 6.7 Hz, 1H), 
2.76 (s, 2H), 2.18 – 1.99 (m, 6H), 1.65 – 1.52 (m, 2H), 1.49 – 1.33 (m, 4H), 1.02 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.2, 134.9, 133.0, 131.8, 129.9, 129.0, 128.8, 127.95, 127.87, 
124.6, 108.5, 86.9, 39.3, 36.7, 29.5, 28.3, 27.2, 26.9, 24.2, 20.5, 14.4. 
FT-IR (film): 3004, 2931, 2172, 1429, 1113, 763, 733, 701 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C31H39BrSiN: 532.2030, found: 532.2027. 
 
 
 
Methyl 8-(benzyldiphenylsilyl)-6-bromooct-7-ynoate.  The title compound was 
synthesized according to GP-3 from methyl 8-(benzyldiphenylsilyl)-6-hydroxyoct-7-ynoate (4.46 
g, 10.1 mmol) and purified by flash chromatography on silica gel (0  2% EtOAc/hexanes).  
4.20 g (8.3 mmol, 83% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.61 – 7.53 (m, 4H), 7.47 – 7.40 (m, 2H), 7.40 – 7.33 (m, 4H), 7.20 
– 7.12 (m, 2H), 7.12 – 7.05 (m, 1H), 7.02 (d, J = 7.5 Hz, 2H), 4.58 (t, J = 6.6 Hz, 1H), 3.67 (s, 3H), 
2.72 (s, 2H), 2.33 (t, J = 7.4 Hz, 2H), 2.05 (q, J = 7.0 Hz, 2H), 1.75 – 1.64 (m, 2H), 1.57 (tt, J = 10.0, 5.7 
Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 173.7, 137.2, 134.9, 132.9, 129.9, 129.0, 128.0, 127.9, 124.6, 108.2, 
87.1, 51.5, 38.9, 36.2, 33.7, 26.8, 24.2, 24.0. 
FT-IR (film): 3024, 2171, 1737, 1429, 1208, 1114, 770, 735, 698 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C28H33BrO2SiN: 522.1458, found: 522.1460. 
 
 
 
7-(Benzyldiphenylsilyl)-5-bromohept-6-yn-1-yl acetate.  The title compound was 
synthesized according to GP-3 from 7-(benzyldiphenylsilyl)-5-hydroxyhept-6-yn-1-yl acetate 
(3.90 g, 8.8 mmol) and purified by flash chromatography on silica gel (0  2% EtOAc/hexanes).  
3.75 g (7.4 mmol, 84% yield).  Colorless oil. 
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1H NMR (400 MHz, CDCl3) δ 7.62 – 7.52 (m, 4H), 7.47 – 7.40 (m, 2H), 7.40 – 7.32 (m, 4H), 7.21 
– 7.13 (m, 2H), 7.13 – 7.04 (m, 1H), 7.04 – 6.98 (m, 2H), 4.59 (t, J = 6.6 Hz, 1H), 4.07 (t, J = 6.3 Hz, 
2H), 2.72 (s, 2H), 2.11 – 2.03 (m, 2H), 2.02 (s, 3H), 1.73 – 1.57 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 171.1, 137.2, 134.9, 132.9, 130.0, 129.0, 128.0, 127.9, 124.6, 108.1, 
87.2, 64.0, 38.8, 36.2, 27.7, 24.2, 23.8, 20.9. 
FT-IR (film): 3067, 3024, 2954, 2172, 1736, 1240, 1113, 768, 735, 698 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C28H33BrO2SiN: 522.1458, found: 522.1462. 
 
 
 
Benzyl(3-bromo-7-chlorohept-1-yn-1-yl)diphenylsilane.  The title compound was 
synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-7-chlorohept-1-yn-3-ol (4.65 g, 11.1 
mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  4.62 g (9.6 
mmol, 86% yield).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.58 (ddt, J = 6.6, 2.8, 1.5 Hz, 4H), 7.48 – 7.40 (m, 2H), 7.40 – 7.33 
(m, 4H), 7.21 – 7.12 (m, 2H), 7.12 – 7.06 (m, 1H), 7.06 – 6.99 (m, 2H), 4.59 (t, J = 6.6 Hz, 1H), 3.53 (t, 
J = 6.5 Hz, 2H), 2.73 (s, 2H), 2.12 – 2.00 (m, 2H), 1.89 – 1.77 (m, 2H), 1.77 – 1.63 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 137.2, 134.9, 132.8, 130.0, 129.0, 128.0, 127.9, 124.6, 108.0, 87.3, 
44.5, 38.5, 36.1, 31.6, 24.6, 24.2. 
FT-IR (film): 3067, 3053, 3024, 2954, 2170, 1600, 1428, 1112, 762, 736, 703 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C26H30BrClSiN: 498.1014, found: 498.1011. 
 
 
 
Benzyl(3-bromo-5-(5-methylfuran-2-yl)pent-1-yn-1-yl)diphenylsilane.  The title 
compound was synthesized according to GP-3 from 1-(benzyldiphenylsilyl)-5-(5-methylfuran-2-
yl)pent-1-yn-3-ol (6.71 g, 15.4 mmol) and purified by flash chromatography on silica gel (0  1% 
EtOAc/hexanes).  5.54 g (11.1 mmol, 72% yield).  Yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.65 – 7.57 (m, 4H), 7.48 – 7.42 (m, 2H), 7.42 – 7.35 (m, 4H), 7.22 
– 7.13 (m, 2H), 7.13 – 7.01 (m, 3H), 5.96 – 5.86 (m, 2H), 4.59 (t, J = 6.8 Hz, 1H), 2.85 (t, J = 7.4 Hz, 
2H), 2.75 (s, 2H), 2.37 (dt, J = 8.1, 7.0 Hz, 2H), 2.30 (d, J = 1.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 151.6, 150.9, 137.2, 134.9, 132.9, 130.0, 129.0, 128.0, 127.9, 124.7, 
108.0, 106.5, 105.9, 87.4, 37.8, 35.7, 25.9, 24.2, 13.5. 
FT-IR (film): 3068, 3024, 2920, 2175, 1428, 1208, 1110, 769, 701 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C29H31BrOSiN: 516.1353, found: 516.1334. 
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Benzyl(3-bromo-6-(((8R,9S,13S,14S)-13-methyl-6,7,8,9,11,12,13,14,15,16-
decahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-yl)oxy)hex-1-yn-1-
yl)diphenylsilane.  The title compound was synthesized according to GP-3 from 1-
(benzyldiphenylsilyl)-6-(((8R,9S,13S,14S)-13-methyl-6,7,8,9,11,12,13,14,15,16-
decahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-yl)oxy)hex-1-yn-3-ol (4.15 g, 
6.1 mmol) and purified by flash chromatography on silica gel (0  1% EtOAc/hexanes).  2.71 g 
(3.6 mmol, 60% yield).  Colorless sticky oil. 
1H NMR (400 MHz, CDCl3, mixture of diastereoisomers) δ 7.64 – 7.55 (m, 4H), 7.47 – 7.41 (m, 
2H), 7.41 – 7.34 (m, 4H), 7.23 (dd, J = 8.7, 1.1 Hz, 1H), 7.20 – 7.14 (m, 2H), 7.12 – 7.06 (m, 1H), 7.06 
– 7.02 (m, 2H), 6.72 (dd, J = 8.6, 2.7 Hz, 1H), 6.66 (d, J = 2.7 Hz, 1H), 4.68 (t, J = 6.6 Hz, 1H), 4.05 – 
3.86 (m, 6H), 2.96 – 2.79 (m, 2H), 2.74 (s, 2H), 2.40 – 2.32 (m, 1H), 2.31 – 2.20 (m, 3H), 2.13 – 1.97 
(m, 3H), 1.96 – 1.75 (m, 4H), 1.74 – 1.62 (m, 1H), 1.62 – 1.54 (m, 1H), 1.53 – 1.31 (m, 4H), 0.92 (s, 
3H). 
13C NMR (101 MHz, CDCl3, mixture of diastereoisomers) δ 156.6, 138.0, 137.2, 134.9, 132.85, 
132.79, 129.9, 129.0, 128.0, 127.9, 126.3, 124.6, 119.4, 114.4, 111.9, 108.1, 87.2, 66.6, 65.2, 64.5, 49.3, 
46.1, 43.6, 39.0, 36.24, 36.19, 34.2, 30.7, 29.8, 27.1, 27.0, 26.1, 24.2, 22.3, 14.3. 
FT-IR (film): 2933, 2873, 2171, 1605, 1494, 1254, 1107, 1043, 762, 734, 701 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C45H53BrO3SiN: 762.2973, found: 762.2967. 
 
 
 
(3-Bromohept-1-yn-1-yl)(ethyl)diphenylsilane.  The title compound was synthesized 
according to GP-3 from 1-(ethyldiphenylsilyl)hept-1-yn-3-ol (2.21 g, 6.9 mmol) and purified by 
flash chromatography on silica gel (0  1% EtOAc/hexanes).  1.80 g (4.7 mmol, 68% yield).  
Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.71 – 7.62 (m, 4H), 7.48 – 7.34 (m, 6H), 4.63 (t, J = 6.8 Hz, 1H), 
2.15 – 2.05 (m, 2H), 1.66 – 1.53 (m, 2H), 1.47 – 1.33 (m, 2H), 1.22 – 1.08 (m, 5H), 0.95 (t, J = 7.3 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 134.7, 133.9, 129.7, 127.9, 107.7, 87.3, 39.3, 36.9, 29.5, 21.8, 13.9, 
7.4, 6.1. 
FT-IR (film): 3068, 2958, 2933, 2173, 1428, 1114, 717, 704 cm-1. 
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HRMS (ESI-MS) m/z [M+NH4]+ calcd for C21H29BrSiN: 402.1247, found: 402.1236. 
(3-Bromohept-1-yn-1-yl)triphenylsilane.  The title compound was synthesized according 
to GP-3 from 1-(triphenylsilyl)hept-1-yn-3-ol (5.95 g, 16.1 mmol) and purified by flash 
chromatography on silica gel (0  1% EtOAc/hexanes).  2.40 g (5.6 mmol, 35% yield).  White 
solid. 
1H NMR (400 MHz, CDCl3) δ 7.71 – 7.62 (m, 6H), 7.52 – 7.36 (m, 9H), 4.65 (t, J = 6.8 Hz, 1H), 
2.17 – 2.07 (m, 2H), 1.67 – 1.54 (m, 2H), 1.47 – 1.33 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 135.5, 133.1, 130.0, 128.0, 108.5, 87.0, 39.2, 36.8, 29.5, 21.8, 13.9. 
FT-IR (film): 3050, 3067, 2956, 2932, 2171, 1428, 1113, 710, 698 cm-1. 
HRMS (ESI-MS) m/z [M+NH4]+ calcd for C25H29BrSiN: 450.1247, found: 450.1242. 
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IV.  Preparation of Nucleophiles 
 
The yields have not been optimized. 
 
General Procedure 4 (GP-4): Preparation of -bromo amides from ,-unsaturated 
carboxylic acids. 
 
A solution of the carboxylic acid and HBr (33% in AcOH, 1 mL/mmol of the carboxylic acid) 
was stirred at room temperature for 6 h.  The AcOH was then removed via rotary evaporation 
in a fume hood (any remaining AcOH can be removed by vigorously flushing the flask with air 
overnight).  The product was used in the next step without further purification. 
EDCHCl (1.1 equiv) and DMAP (0.05 equiv) were added in turn as solids to a solution of the 
unpurified -bromo carboxylic acid (1.0 equiv) in CH2Cl2 (0.4 M) at 0 C.  This solution was 
stirred at 0 C for 5 min, and then the secondary amine (1.1 equiv) was added in one portion.  
The reaction mixture was stirred at 0 C for 5 h, and then it was allowed to warm to room 
temperature for 1 h.  Next, the mixture was transferred to a separatory funnel, and Et2O (~4 
times the volume of CH2Cl2) was added.  This mixture was washed with aqueous HCl (2 M) 
and then brine, dried over Na2SO4, filtered, and concentrated.  The residue was purified by 
flash chromatography on silica gel, which afforded the pure -bromo amide. 
 
General Procedure 5 (GP-5):  Preparation of -bromo amides via aldol reactions. 
 
A solution of LDA (1.1 equiv, 3 M in THF, freshly prepared) was added dropwise to a 
solution of acetamide (1.0 equiv, 0.4 M) in THF at 78 C.  The resulting mixture was stirred at 
78 C for 1 h, and then the aldehyde (1.1 equiv) was added dropwise.  The reaction mixture 
was stirred at 78 C for 1 h, and then it was allowed to slowly warm to room temperature 
overnight.  Next, the reaction was quenched with aqueous saturated NH4Cl, and the mixture 
was extracted with Et2O (3 mL/mmol of acetamide  3).  The combined organic layers were 
dried (Na2SO4), filtered, and concentrated under reduced pressure.  The residue was passed 
through a short column of silica gel (EtOAc/hexanes) to afford the aldol adduct (>80% purity), 
which was used in the next step without further purification. 
Imidazole (1.2 equiv) and PPh3 (1.2 equiv) were dissolved in CH2Cl2 (0.2 M), and the 
resulting solution was cooled to 0 °C.  Bromine (1.2 equiv, neat) was added dropwise, and the 
resulting mixture was stirred at 0 °C for 10 min.  Next, the unpurified alcohol (1.0 equiv, 
dissolved in CH2Cl2 (3.0 mL/mmol of alcohol)) was added, and the resulting mixture was 
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allowed to slowly warm to room temperature overnight.  Then, the reaction mixture was 
added to hexanes/Et2O (5/1, for hexanes: 10 mL/mmol of alcohol), stirred for 15 min, and filtered.  
The filtrate was concentrated under reduced pressure, and the residue was purified by flash 
chromatography on silica gel, which afforded the pure -bromo amide. 
 
 
 
N-Benzyl-3-bromo-N-phenylbutanamide.  The title compound was synthesized according 
to GP-4 from trans-pent-2-enoic acid (5.1 mL, 50.0 mmol) and N-benzylaniline (10.1 g, 55.0 
mmol).  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  10.52 g (30.5 mmol, 61% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.16 (m, 8H), 7.02 (d, J = 6.8 Hz, 2H), 5.00 (d, J = 14.3 Hz, 
1H), 4.88 (d, J = 14.3 Hz, 1H), 4.53 (tt, J = 9.6, 4.9 Hz, 1H), 2.74 (dd, J = 16.0, 8.6 Hz, 1H), 2.61 (dd, J 
= 16.0, 5.1 Hz, 1H), 1.90 – 1.79 (m, 1H), 1.79 – 1.67 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.6, 141.7, 137.2, 129.7, 128.8, 128.6, 128.4, 128.3, 127.4, 54.0, 
53.2, 43.2, 31.9, 12.2. 
FT-IR (film): 2963, 1647, 1496, 1001, 773, 705 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H21BrNO: 346.0801, found: 346.0792. 
 
 
 
N-Benzyl-3-bromo-N-phenylhexanamide.  The title compound was synthesized according 
to GP-5 from N-benzyl-N-phenylacetamide (6.75 g, 30.0 mmol) and butyraldehyde (3.31 g, 33.0 
mmol).  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  9.20 g (25.6 mmol, 85% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.33 (m, 3H), 7.32 – 7.19 (m, 5H), 7.06 – 6.97 (m, 2H), 5.00 
(d, J = 14.2 Hz, 1H), 4.88 (d, J = 14.3 Hz, 1H), 4.67 – 4.48 (m, 1H), 2.74 (dd, J = 16.0, 8.8 Hz, 1H), 
2.60 (dd, J = 16.0, 5.0 Hz, 1H), 1.80 – 1.68 (m, 2H), 1.61 – 1.34 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.5, 141.7, 137.2, 129.6, 128.8, 128.6, 128.3, 128.2, 127.4, 53.1, 
51.9, 43.6, 40.7, 20.8, 13.3. 
FT-IR (film): 2958, 2930, 2872, 1655, 1594, 1494, 1401, 772 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H23BrNO: 360.0958, found: 360.0968. 
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N-Benzyl-3-bromo-N-phenyloctanamide.  The title compound was synthesized according
to GP-4 from trans-2-octenoic acid (5.69 g, 40.0 mmol) and N-benzylaniline (8.1 g, 44.0 mmol). 
The product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  
10.10 g (26.1 mmol, 65% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.33 (m, 3H), 7.30 – 7.26 (m, 3H), 7.25 – 7.20 (m, 2H), 7.01 
(dd, J = 7.5, 2.2 Hz, 2H), 4.99 (d, J = 14.3 Hz, 1H), 4.88 (d, J = 14.3 Hz, 1H), 4.56 (tt, J = 8.6, 5.1 Hz, 
1H), 2.73 (dd, J = 15.9, 8.7 Hz, 1H), 2.60 (dd, J = 15.9, 5.1 Hz, 1H), 1.81 – 1.67 (m, 2H), 1.53 – 1.19 
(m, 6H), 0.89 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.5, 141.7, 137.2, 129.6, 128.8, 128.6, 128.4, 128.2, 127.4, 53.2, 
52.3, 43.6, 38.7, 31.0, 27.2, 22.4, 14.0. 
FT-IR (film): 2954, 2928, 2857, 1655, 1594, 1494, 1401, 772, 728 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H27BrNO: 388.1271, found: 388.1277. 
N-Benzyl-3-bromo-6-methyl-N-phenylheptanamide.  The title compound was synthesized
according to GP-5 from N-benzyl-N-phenylacetamide (6.12 g, 27.2 mmol) and 4-methylpentanal 
(3.00 g, 29.9 mmol).  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  4.42 g (11.4 mmol, 42% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.32 (m, 3H), 7.31 – 7.21 (m, 5H), 7.02 (dd, J = 7.4, 2.2 Hz, 
2H), 4.98 (d, J = 14.3 Hz, 1H), 4.90 (d, J = 14.3 Hz, 1H), 4.54 (tt, J = 8.6, 4.9 Hz, 1H), 2.74 (dd, J = 
16.0, 8.7 Hz, 1H), 2.61 (dd, J = 16.0, 5.1 Hz, 1H), 1.86 – 1.66 (m, 2H), 1.61 – 1.48 (m, 1H), 1.45 – 
1.19 (m, 2H), 0.89 (d, J = 5.1 Hz, 3H), 0.87 (d, J = 5.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.5, 141.7, 137.2, 129.6, 128.8, 128.6, 128.4, 128.2, 127.4, 53.2, 
52.5, 43.6, 36.7, 36.6, 27.5, 22.7, 22.3. 
FT-IR (film): 2953, 2927, 2868, 1655, 1594, 1494, 1401, 1254, 1208, 1165, 772, 731 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H27BrNO: 388.1271, found: 388.1276. 
N-Benzyl-3-bromo-6-((tert-butyldimethylsilyl)oxy)-N-phenylhexanamide.  The title
compound was synthesized according to GP-5 from N-benzyl-N-phenylacetamide (5.16 g, 23.0 
mmol) and 4-((tert-butyldimethylsilyl)oxy)butanal (5.10 g, 25.2 mmol).  The product was 
purified by column chromatography on silica gel (1:30 EtOAc/hexanes).  4.70 g (9.6 mmol, 42% 
yield over 2 steps).  Colorless oil. 
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1H NMR (400 MHz, CDCl3) δ 7.35 – 7.28 (m, 3H), 7.28 – 7.20 (m, 3H), 7.20 – 7.14 (m, 2H), 6.96 
(dd, J = 7.4, 2.2 Hz, 2H), 4.95 (d, J = 14.3 Hz, 1H), 4.82 (d, J = 14.3 Hz, 1H), 4.53 (tt, J = 9.0, 4.6 Hz, 
1H), 3.57 (t, J = 6.2 Hz, 2H), 2.70 (dd, J = 16.0, 8.9 Hz, 1H), 2.55 (dd, J = 16.0, 4.8 Hz, 1H), 1.90 – 
1.78 (m, 1H), 1.77 – 1.61 (m, 2H), 1.61 – 1.47 (m, 1H), 0.84 (s, 9H), -0.00 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 169.4, 141.7, 137.2, 129.6, 128.8, 128.6, 128.3, 128.2, 127.4, 62.2, 
53.2, 52.0, 43.6, 35.3, 30.8, 25.9, 18.3, -5.3. 
FT-IR (film): 2951, 2927, 2854, 1655, 1594, 1402, 1252, 1072, 834, 774 cm-1. 
HRMS (ESI-MS) m/z [MTBS+2H]+ calcd for C19H23BrNO2: 376.0907, found: 376.0909. 
N-Benzyl-3-bromo-7-methoxy-N-phenylheptanamide.  The title compound was
synthesized according to GP-5 from N-benzyl-N-phenylacetamide (5.56 g, 24.7 mmol) and 5-
methoxypentanal (3.15 g, 27.2 mmol).  The product was purified by column chromatography 
on silica gel (1:15 EtOAc/hexanes).  4.38 g (10.9 mmol, 44% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.33 (m, 3H), 7.32 – 7.25 (m, 3H), 7.25 – 7.19 (m, 2H), 7.01 
(dd, J = 7.5, 2.2 Hz, 2H), 4.99 (d, J = 14.3 Hz, 1H), 4.88 (d, J = 14.3 Hz, 1H), 4.56 (tt, J = 8.6, 4.9 Hz, 
1H), 3.37 (t, J = 6.2 Hz, 2H), 3.33 (s, 3H), 2.73 (dd, J = 16.0, 8.7 Hz, 1H), 2.60 (dd, J = 16.0, 5.0 Hz, 
1H), 1.89 – 1.72 (m, 2H), 1.66 – 1.40 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 169.4, 141.7, 137.2, 129.6, 128.8, 128.6, 128.3, 128.2, 127.4, 72.4, 
58.5, 53.2, 51.9, 43.5, 38.5, 28.8, 24.3. 
FT-IR (film): 2924, 2863, 1655, 1594, 1494, 1401, 1116, 772, 733 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H27BrNO2: 404.1220, found: 404.1219. 
N-Benzyl-6-(benzyloxy)-3-bromo-N-phenylhexanamide.  The title compound was
synthesized according to GP-5 from N-benzyl-N-phenylacetamide (3.33 g, 14.8 mmol) and 4-
(benzyloxy)butanal (2.90 g, 16.3 mmol).  The product was purified by column chromatography 
on silica gel (1:15 EtOAc/hexanes).  2.62 g (5.6 mmol, 38% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.26 – 7.19 (m, 7H), 7.18 – 7.08 (m, 6H), 6.94 – 6.82 (m, 2H), 4.87 
(d, J = 14.2 Hz, 1H), 4.75 (d, J = 14.3 Hz, 1H), 4.47 (tt, J = 8.8, 4.6 Hz, 1H), 4.37 (s, 2H), 3.36 (t, J = 
6.0 Hz, 2H), 2.63 (dd, J = 16.0, 8.8 Hz, 1H), 2.48 (dd, J = 16.0, 4.8 Hz, 1H), 1.87 – 1.76 (m, 1H), 1.76 
– 1.65 (m, 2H), 1.65 – 1.55 (m, 1H).
13C NMR (101 MHz, CDCl3) δ 169.4, 141.7, 138.4, 137.1, 129.6, 128.8, 128.6, 128.3, 128.2, 127.6,
127.5, 127.4, 72.9, 69.3, 53.2, 51.8, 43.5, 35.5, 27.8. 
FT-IR (film): 2924, 2856, 1650, 1594, 1494, 1402, 735 cm-1. 
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HRMS (ESI-MS) m/z [M+H]+ calcd for C26H29BrNO2: 466.1376, found: 466.1381. 
 
 
 
N-Benzyl-3-bromo-7-chloro-N-phenylheptanamide.  The title compound was synthesized 
according to GP-5 from N-benzyl-N-phenylacetamide (8.48 g, 37.7 mmol) and 5-chloropentanal 
(5.00 g, 41.5 mmol).  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  9.61 g (23.6 mmol, 63% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.32 (m, 3H), 7.32 – 7.18 (m, 5H), 7.01 (dd, J = 7.5, 2.1 Hz, 
2H), 4.98 (d, J = 14.3 Hz, 1H), 4.87 (d, J = 14.3 Hz, 1H), 4.55 (tt, J = 9.0, 4.8 Hz, 1H), 3.51 (td, J = 6.5, 
2.3 Hz, 2H), 2.75 (dd, J = 16.0, 8.3 Hz, 1H), 2.61 (dd, J = 16.1, 5.4 Hz, 1H), 1.90 – 1.69 (m, 4H), 1.69 
– 1.61 (m, 1H), 1.61 – 1.48 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 169.1, 141.5, 137.0, 129.5, 128.6, 128.3, 128.2, 128.1, 127.2, 53.0, 
51.3, 51.2, 44.4, 43.4, 37.6, 31.5, 24.7. 
FT-IR (film): 2936, 1651, 1594, 1494, 1401, 773, 731 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C20H24BrClNO: 408.0724, found: 408.0737. 
 
 
 
N-Benzyl-3-bromo-N-phenylbutanamide.  The title compound was synthesized according 
to GP-4 from crotonic acid (4.30 g, 50.0 mmol) and N-benzylaniline (10.1 g, 55.0 mmol).  The 
product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  9.06 g 
(27.4 mmol, 55% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.33 (m, 3H), 7.33 – 7.25 (m, 3H), 7.25 – 7.17 (m, 2H), 7.01 
(dd, J = 7.4, 2.2 Hz, 2H), 4.98 (d, J = 14.3 Hz, 1H), 4.88 (d, J = 14.3 Hz, 1H), 4.68 (dqd, J = 8.3, 6.7, 
5.5 Hz, 1H), 2.75 (dd, J = 16.0, 8.3 Hz, 1H), 2.56 (dd, J = 16.0, 5.5 Hz, 1H), 1.69 (d, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.3, 141.6, 137.1, 129.7, 128.8, 128.5, 128.4, 128.2, 127.4, 53.1, 
45.5, 45.2, 26.2. 
FT-IR (film): 3062, 3029, 2922, 1651, 1494, 1400, 772, 731 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C18H19BrNO: 332.0645, found: 332.0653. 
 
 
 
3-Bromo-N-cyclohexyl-N-phenylpentanamide.  The title compound was synthesized 
according to GP-5 from N-cyclohexyl-N-phenylacetamide (8.37 g, 38.6 mmol) and 
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propionaldehyde (2.69 g, 46.3 mmol).  The product was purified by column chromatography 
on silica gel (1:20 EtOAc/hexanes).  6.44 g (19.1 mmol, 49% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.31 (m, 3H), 7.16 (d, J = 7.4 Hz, 1H), 7.10 – 6.93 (m, 1H), 
4.61 (tt, J = 12.1, 3.6 Hz, 1H), 4.43 (tdd, J = 8.4, 5.5, 4.3 Hz, 1H), 2.49 (dd, J = 16.0, 8.3 Hz, 1H), 2.40 
(dd, J = 16.0, 5.5 Hz, 1H), 1.90 – 1.60 (m, 6H), 1.60 – 1.50 (m, 1H), 1.46 – 1.29 (m, 2H), 1.11 – 0.97 
(m, 2H), 0.94 (t, J = 7.3 Hz, 3H), 0.92 – 0.82 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 138.6, 130.7, 130.1, 129.3, 129.1, 128.3, 54.3, 54.1, 43.8, 31.8, 
31.5, 25.70, 25.68, 25.3, 12.1. 
FT-IR (film): 2932, 2856, 1651, 1401, 707 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C17H25BrNO: 338.1114, found: 338.1135. 
 
 
 
3-Bromo-1-(indolin-1-yl)pentan-1-one.  The title compound was synthesized according to 
GP-4 from 2-pentenoic acid (3.00 g, 30.0 mmol) and indoline (3.93 g, 33.0 mmol).  The product 
was purified by column chromatography on silica gel (1:10 EtOAc/hexanes).  5.31 g (18.9 mmol, 
63% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 8.1 Hz, 1H), 7.27 – 7.18 (m, 2H), 7.05 (td, J = 7.4, 1.1 
Hz, 1H), 4.66 – 4.51 (m, 1H), 4.28 – 4.12 (m, 1H), 4.12 – 3.98 (m, 1H), 3.30 – 3.18 (m, 2H), 3.13 (dd, 
J = 16.0, 7.8 Hz, 1H), 2.97 (dd, J = 16.1, 5.7 Hz, 1H), 2.05 (dtd, J = 14.5, 7.2, 4.1 Hz, 1H), 1.91 (ddq, J 
= 14.4, 8.6, 7.2 Hz, 1H), 1.13 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 167.8, 142.6, 131.2, 127.5, 124.5, 123.9, 117.2, 53.0, 48.1, 44.9, 32.1, 
27.9, 12.2. 
FT-IR (film): 2976, 1656, 1596, 1479, 1461, 1412, 1394, 773 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C13H17BrNO: 282.0488, found: 282.0493. 
 
 
 
3-Bromo-N,N-dibutylpentanamide.  The title compound was synthesized according to GP-
5 from N,N-dibutylacetamide (8.07 g, 47.2 mmol) and propionaldehyde (3.01 g, 51.9 mmol).  
The product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  7.88 
g (27.1 mmol, 57% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 4.50 (dddd, J = 8.7, 7.9, 5.7, 4.1 Hz, 1H), 3.44 – 3.34 (m, 1H), 3.33 
– 3.23 (m, 2H), 3.19 (ddd, J = 15.1, 9.5, 6.0 Hz, 1H), 3.00 (dd, J = 15.6, 7.9 Hz, 1H), 2.76 (dd, J = 15.6, 
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5.7 Hz, 1H), 1.96 (dqd, J = 14.4, 7.3, 4.1 Hz, 1H), 1.91 – 1.76 (m, 1H), 1.64 – 1.46 (m, 4H), 1.40 – 
1.24 (m, 4H), 1.08 (t, J = 7.2 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.1, 54.3, 47.8, 46.0, 42.1, 32.1, 31.3, 29.8, 20.2, 20.0, 13.82, 
13.77, 12.2. 
FT-IR (film): 2957, 2929, 2872, 1639, 1454, 1427, 730 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C13H27BrNO: 292.1271, found: 292.1272. 
 
 
 
3-Bromo-N-methoxy-N-methylpentanamide.  The title compound was synthesized 
according to GP-4 from 2-pentenoic acid (4.00 g, 40.0 mmol) and N,O-dimethylhydroxylamine 
hydrochloride (4.29 g, 44.0 mmol).  The product was purified by column chromatography on 
silica gel (1:4 EtOAc/hexanes).  4.25 g (19.1 mmol, 48% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 4.46 (tdd, J = 8.5, 5.4, 4.4 Hz, 1H), 3.74 (s, 3H), 3.23 (s, 3H), 3.22 
– 3.13 (m, 1H), 2.90 (dd, J = 16.3, 5.4 Hz, 1H), 2.02 – 1.91 (m, 1H), 1.91 – 1.81 (m, 1H), 1.10 (t, J = 
7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.9, 61.4, 52.7, 41.1, 32.0 (2C), 12.1. 
FT-IR (film): 2965, 2937, 1658, 1443, 1415, 1386, 1011, 990, 788 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C7H15BrNO2: 224.0281, found: 224.0283. 
 
 
 
3-Bromo-N-butyl-N-phenylpentanamide.  The title compound was synthesized according 
to GP-5 from N-butyl-N-phenylacetamide (9.28 g, 48.6 mmol) and propionaldehyde (3.11 g, 53.5 
mmol).  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  10.3 g (33.1 mmol, 68% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.43 (m, 2H), 7.43 – 7.34 (m, 1H), 7.25 – 7.14 (m, 2H), 4.47 
(tdd, J = 8.5, 5.4, 4.4 Hz, 1H), 3.85 – 3.64 (m, 2H), 2.68 (dd, J = 15.9, 8.5 Hz, 1H), 2.53 (dd, J = 15.9, 
5.3 Hz, 1H), 1.89 – 1.77 (m, 1H), 1.77 (ddt, J = 14.5, 8.6, 7.3 Hz, 1H), 1.58 – 1.46 (m, 2H), 1.41 – 1.29 
(m, 2H), 0.99 (t, J = 7.2 Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.2, 142.1, 129.8, 128.5, 128.1, 54.1, 49.2, 43.3, 31.9, 29.7, 20.0, 
13.8, 12.1. 
FT-IR (film): 2960, 2931, 2872, 1650, 1594, 1493, 1403, 773, 732 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C15H23BrNO: 312.0958, found: 312.0967. 
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3-Bromo-N-cyclohexyl-N-phenylnonanamide.  The title compound was synthesized
according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and heptanal (3.42 
g, 30.0 mmol).  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  5.64 g (14.4 mmol, 58% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.30 (m, 3H), 7.16 (d, J = 8.1 Hz, 1H), 7.09 – 6.90 (m, 1H), 
4.60 (tt, J = 12.1, 3.6 Hz, 1H), 4.46 (tt, J = 8.5, 5.0 Hz, 1H), 2.49 (dd, J = 16.0, 8.3 Hz, 1H), 2.40 (dd, J 
= 16.0, 5.4 Hz, 1H), 1.90 – 1.75 (m, 2H), 1.75 – 1.50 (m, 5H), 1.49 – 1.13 (m, 10H), 1.10 – 0.95 (m, 
2H), 0.95 – 0.86 (m, 1H), 0.84 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 138.6, 130.7, 130.1, 129.3, 129.1, 128.3, 54.2, 52.4, 44.2, 38.7, 
31.54, 31.48, 28.4, 27.5, 25.69, 25.67, 25.3, 22.5, 14.0. 
FT-IR (film): 2928, 2856, 1659, 1650, 1401, 708 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H33BrNO: 394.1740, found: 394.1754. 
3-Bromo-N-cyclohexyl-N,4-diphenylbutanamide.  The title compound was synthesized
according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and 2-
phenylacetaldehyde (3.60 g, 30.0 mmol).  The product was purified by column 
chromatography on silica gel (1:20 EtOAc/hexanes).  3.81 g (9.5 mmol, 38% yield over 2 steps). 
White solid. 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.38 (m, 3H), 7.35 – 7.22 (m, 3H), 7.22 – 7.13 (m, 3H), 7.06 
– 6.96 (m, 1H), 4.77 – 4.58 (m, 2H), 3.15 (dd, J = 14.2, 6.3 Hz, 1H), 3.07 (dd, J = 14.2, 7.9 Hz, 1H),
2.51 (dd, J = 16.1, 7.7 Hz, 1H), 2.47 (dd, J = 16.1, 5.8 Hz, 1H), 1.95 – 1.80 (m, 2H), 1.80 – 1.68 (m,
2H), 1.65 – 1.53 (m, 1H), 1.42 (qq, J = 13.3, 3.4 Hz, 2H), 1.15 – 0.99 (m, 2H), 0.93 (qt, J = 13.1, 3.7 Hz,
1H).
13C NMR (101 MHz, CDCl3) δ 168.7, 138.5, 138.0, 130.6, 130.1, 129.3, 129.13, 129.10, 128.34, 
128.28, 126.7, 54.3, 51.2, 44.8, 43.2, 31.5, 25.68, 25.66, 25.3. 
FT-IR (film): 2929, 2856, 1644, 1492, 1407, 710 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C22H27BrNO: 400.1271, found: 400.1280. 
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3-Bromo-N-cyclohexyl-5-methyl-N-phenylhexanamide.  The title compound was 
synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and 
3-methylbutanal (2.58 g, 30.0 mmol).  The product was purified by column chromatography on 
silica gel (1:20 EtOAc/hexanes).  5.42 g (14.8 mmol, 59% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.31 (m, 3H), 7.17 (d, J = 7.4 Hz, 1H), 7.10 – 6.95 (m, 1H), 
4.62 (tt, J = 12.1, 3.6 Hz, 1H), 4.57 – 4.47 (m, 1H), 2.50 (dd, J = 16.0, 8.3 Hz, 1H), 2.40 (dd, J = 16.0, 
5.3 Hz, 1H), 1.92 – 1.76 (m, 3H), 1.76 – 1.67 (m, 2H), 1.67 – 1.52 (m, 2H), 1.51 – 1.30 (m, 3H), 1.13 – 
0.97 (m, 2H), 0.97 – 0.89 (m, 1H), 0.88 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 161.9, 131.6, 123.8, 123.2, 122.3, 122.1, 121.4, 47.3, 43.8, 40.7, 37.6, 
24.54, 24.51, 19.4, 18.74, 18.72, 18.3, 15.9, 13.9. 
FT-IR (film): 2931, 2856, 1651, 1401, 1263, 708 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H29BrNO: 366.1427, found: 366.1479. 
 
 
 
7-(Benzyloxy)-3-bromo-N-cyclohexyl-N-phenylheptanamide.  The title compound was 
synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and 
5-(benzyloxy)pentanal (5.76 g, 30.0 mmol).  The product was purified by column 
chromatography on silica gel (1:20 EtOAc/hexanes).  8.02 g (17.0 mmol, 68% yield over 2 steps).  
Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.28 (m, 3H), 7.27 – 7.17 (m, 5H), 7.10 (d, J = 7.5 Hz, 1H), 
7.03 – 6.86 (m, 1H), 4.55 (tt, J = 12.2, 3.6 Hz, 1H), 4.41 (s, 3H), 3.37 (t, J = 6.1 Hz, 2H), 2.43 (dd, J = 
16.0, 8.3 Hz, 1H), 2.34 (dd, J = 16.0, 5.4 Hz, 1H), 1.84 – 1.58 (m, 6H), 1.58 – 1.43 (m, 4H), 1.42 – 
1.25 (m, 3H), 1.07 – 0.76 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 138.6, 138.5, 130.8, 130.1, 129.4, 129.2, 128.4, 128.3, 127.6, 
127.5, 72.9, 70.0, 54.3, 52.2, 44.2, 38.5, 31.5, 29.0, 25.8, 25.7, 25.3, 24.3. 
FT-IR (film): 3033, 2931, 2856, 1651, 1400, 1101, 734, 708 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C26H35BrNO2: 472.1846, found: 472.1850. 
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3-Bromo-N-cyclohexyl-6-(5,5-dimethyl-1,3-dioxan-2-yl)-N-phenylhexanamide.  The title
compound was synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 
25.0 mmol) and 4-(5,5-dimethyl-1,3-dioxan-2-yl)butanal (5.59 g, 30.0 mmol).  The product was 
purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  4.62 g (9.9 mmol, 40% 
yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.34 (m, 3H), 7.16 (d, J = 6.9 Hz, 1H), 7.08 – 6.97 (m, 1H), 
4.60 (tt, J = 12.1, 3.6 Hz, 1H), 4.46 (tt, J = 8.4, 5.1 Hz, 1H), 4.36 (t, J = 4.6 Hz, 1H), 3.56 (dt, J = 11.1, 
1.4 Hz, 2H), 3.38 (d, J = 10.6 Hz, 2H), 2.48 (dd, J = 16.0, 8.4 Hz, 1H), 2.41 (dd, J = 16.0, 5.3 Hz, 1H), 
1.91 – 1.65 (m, 6H), 1.65 – 1.50 (m, 4H), 1.50 – 1.30 (m, 3H), 1.15 (s, 3H), 1.10 – 0.94 (m, 2H), 0.94 – 
0.81 (m, 1H), 0.69 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.7, 138.6, 130.7, 130.1, 129.3, 129.1, 128.3, 101.8, 77.1, 54.2, 
52.1, 44.1, 38.6, 34.0, 31.5, 30.1, 25.71, 25.69, 25.3, 22.9, 22.2, 21.8. 
FT-IR (film): 2929, 2854, 1651, 1401, 1133, 708 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H37BrNO3: 466.1951, found: 466.1962. 
3-Bromo-N-cyclohexyl-5-(5-methylfuran-2-yl)-N-phenylpentanamide.  The title
compound was synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 
25.0 mmol) and 3-(5-methylfuran-2-yl)propanal (4.14 g, 30.0 mmol).  The product was purified 
by column chromatography on silica gel (1:20 EtOAc/hexanes).  6.47 g (15.5 mmol, 62% yield 
over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.29 (m, 3H), 7.15 (d, J = 7.3 Hz, 1H), 7.10 – 6.92 (m, 1H), 
5.85 (d, J = 3.0 Hz, 1H), 5.80 (d, J = 3.0 Hz, 1H), 4.61 (tt, J = 12.1, 3.7 Hz, 1H), 4.54 – 4.43 (m, 1H), 
2.81 – 2.60 (m, 2H), 2.54 (dd, J = 16.0, 8.4 Hz, 1H), 2.42 (dd, J = 16.0, 5.3 Hz, 1H), 2.21 (s, 3H), 2.14 
– 2.00 (m, 1H), 1.99 – 1.76 (m, 3H), 1.76 – 1.66 (m, 2H), 1.61 – 1.52 (m, 1H), 1.47 – 1.30 (m, 2H),
1.14 – 0.81 (m, 3H).
13C NMR (101 MHz, CDCl3) δ 168.5, 152.4, 150.4, 138.5, 130.7, 130.1, 129.3, 129.1, 128.4, 106.0, 
105.8, 54.3, 51.3, 44.1, 37.0, 31.51, 31.47, 26.2, 25.71, 25.69, 25.3, 13.4. 
FT-IR (film): 2924, 2858, 1642, 1400, 782, 713 cm-1. 
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HRMS (ESI-MS) m/z [M+H]+ calcd for C22H29BrNO2: 418.1376, found: 418.1374. 
 
 
 
(5S)-3-Bromo-N-cyclohexyl-5,9-dimethyl-N-phenyldec-8-enamide.  The title compound 
was synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) 
and (S)-3,7-dimethyloct-6-enal (4.63 g, 30.0 mmol).  The product was purified by column 
chromatography on silica gel (1:20 EtOAc/hexanes).  4.63 g (10.7 mmol, 43% yield over 2 steps).  
Colorless oil. 
1H NMR (400 MHz, CDCl3, mixture of diastereoisomers) δ 7.48 – 7.36 (m, 3H), 7.18 (d, J = 7.4 
Hz, 1H), 7.10 – 6.95 (m, 1H), 5.06 (q, J = 6.3 Hz, 1H), 4.68 – 4.48 (m, 2H), 2.59 – 2.33 (m, 2H), 2.01 
– 1.77 (m, 4H), 1.75 – 1.64 (m, 6H), 1.62 – 1.53 (m, 5H), 1.46 – 1.32 (m, 3H), 1.29 – 1.13 (m, 1H), 
1.13 – 0.77 (m, 7H). 
13C NMR (101 MHz, CDCl3, mixture of diastereoisomers) δ 168.9, 168.8, 138.7, 138.6, 131.3, 
131.2, 130.80, 130.75, 130.2, 129.3, 129.1, 128.4, 128.3, 124.5, 54.3, 50.9, 50.5, 46.4, 45.8, 44.9, 44.3, 
37.4, 35.4, 31.54, 31.51, 30.9, 30.8, 25.74, 25.72, 25.67, 25.66, 25.4, 25.3, 25.1, 19.6, 18.3, 17.6. 
FT-IR (film): 2928, 2855, 2359, 1651, 1397, 707 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H37BrNO: 434.2053, found: 434.2062. 
 
 
 
(Z)-3-Bromo-N-cyclohexyl-N-phenyldodec-9-enamide.  The title compound was 
synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and 
(Z)-dec-7-enal (4.62 g, 30.0 mmol).  The product was purified by column chromatography on 
silica gel (1:20 EtOAc/hexanes).  6.87 g (15.9 mmol, 64% yield over 2 steps).  Colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.30 (m, 3H), 7.16 (d, J = 8.0 Hz, 1H), 7.08 – 6.92 (m, 1H), 
5.40 – 5.21 (m, 2H), 4.61 (tt, J = 12.1, 3.6 Hz, 1H), 4.47 (tt, J = 8.6, 5.0 Hz, 1H), 2.49 (dd, J = 16.0, 8.3 
Hz, 1H), 2.40 (dd, J = 16.0, 5.5 Hz, 1H), 2.07 – 1.91 (m, 4H), 1.90 – 1.76 (m, 2H), 1.76 – 1.59 (m, 4H), 
1.55 (dt, J = 13.1, 3.4 Hz, 1H), 1.50 – 1.17 (m, 8H), 1.11 – 0.97 (m, 2H), 0.97 – 0.82 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 168.8, 138.6, 131.6, 130.7, 130.1, 129.3, 129.1, 128.9, 128.3, 54.3, 
52.4, 44.2, 38.7, 31.5, 29.4, 28.4, 27.4, 26.9, 25.71, 25.69, 25.3, 20.4, 14.3. 
FT-IR (film): 3003, 2931, 2855, 1652, 1595, 1401, 1262, 1072, 706 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H37BrNO: 434.2053, found: 434.2072. 
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Methyl 6-bromo-8-(cyclohexyl(phenyl)amino)-8-oxooctanoate.  The title compound was 
synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and 
methyl 6-oxohexanoate (4.32 g, 30.0 mmol).  The product was purified by column 
chromatography on silica gel (1:20 EtOAc/hexanes).  4.31 g (11.9 mmol, 48% yield over 2 steps).  
Pale-yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.32 (m, 3H), 7.16 (d, J = 7.3 Hz, 1H), 7.11 – 6.95 (m, 1H), 
4.60 (tt, J = 12.1, 3.7 Hz, 1H), 4.45 (tt, J = 9.1, 4.9 Hz, 1H), 3.64 (s, 3H), 2.50 (dd, J = 16.0, 8.1 Hz, 
1H), 2.39 (dd, J = 16.0, 5.6 Hz, 1H), 2.28 (t, J = 7.4 Hz, 2H), 1.89 – 1.48 (m, 10H), 1.45 – 1.32 (m, 3H), 
1.12 – 0.95 (m, 2H), 0.95 – 0.86 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 173.8, 168.7, 138.6, 130.7, 130.1, 129.4, 129.2, 128.4, 54.3, 51.9, 
51.5, 44.2, 38.3, 33.8, 31.5, 27.1, 25.73, 25.71, 25.3, 24.1. 
FT-IR (film): 2932, 2857, 1737, 1658, 1650, 1402, 708 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C21H31BrNO3: 424.1482, found: 424.1470. 
 
 
 
3-Bromo-7-chloro-N-cyclohexyl-N-phenylheptanamide.  The title compound was 
synthesized according to GP-5 from N-cyclohexyl-N-phenylacetamide (5.43 g, 25.0 mmol) and 
5-chloropentanal (3.60 g, 30.0 mmol).  The product was purified by column chromatography 
on silica gel (1:20 EtOAc/hexanes).  4.80 g (12.0 mmol, 48% yield over 2 steps).  White solid. 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.32 (m, 3H), 7.15 (d, J = 7.3 Hz, 1H), 7.09 – 6.96 (m, 1H), 
4.60 (tt, J = 12.1, 3.6 Hz, 1H), 4.46 (dddd, J = 9.0, 7.9, 5.8, 4.1 Hz, 1H), 3.50 (t, J = 6.6 Hz, 2H), 2.52 
(dd, J = 16.0, 7.9 Hz, 1H), 2.41 (dd, J = 16.0, 5.8 Hz, 1H), 1.91 – 1.67 (m, 8H), 1.67 – 1.45 (m, 3H), 
1.45 – 1.31 (m, 2H), 1.11 – 0.96 (m, 2H), 0.90 (qt, J = 13.1, 3.8 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 168.7, 138.5, 130.7, 130.1, 129.4, 129.2, 128.4, 54.3, 51.6, 44.6, 44.2, 
37.8, 31.7, 31.5, 25.72, 25.70, 25.3, 24.9. 
FT-IR (film): 2932, 2855, 1656, 1648, 1400, 1261, 707 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H28BrClNO: 400.1037, found: 400.1069. 
 
 
General Procedure 6 (GP-6): Preparation of -zincated amide reagents.  In the air, an 
oven-dried 100-mL Schlenk tube was charged with zinc powder (1.5 equiv, ~100 mesh, Alfa, 
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99.9%) and a stir bar.  The tube was heated with a heat gun (~250 C) under high vacuum (~200 
mtorr) for 10 min.  The Schlenk tube was then evacuated and back-filled with nitrogen (three 
cycles).  The Schlenk tube was allowed to cool to room temperature, the cap was removed, and 
then THF (0.3 mL/mmol of alkyl bromide) was added via syringe under a positive flow of 
nitrogen to the un-capped (open) Schlenk tube.  Iodine (0.05 equiv) was added in one portion, 
leading initially to a red color that faded after ~5 sec of vigorous stirring (1500 rpm).  A 
solution of the alkyl bromide (1.0 equiv) in THF (0.3 mL/mmol of alkyl bromide), prepared in a 
20-mL vial equipped with a nitrogen balloon, was added via syringe in one portion to the gray 
suspension of zinc powder.  The vial that contained residual alkyl bromide was rinsed with 
THF (0.1 mL/mmol of bromide), and the solution was transferred via syringe to the Schlenk 
tube.  Then, the Schlenk tube was capped tightly under a nitrogen atmosphere and transferred 
to an oil bath.  The reaction mixture was stirred vigorously at 85 C for 14 h (the disappearance 
of the alkyl iodide and the formation of the alkylzinc reagent can readily be monitored via GC 
analysis of the quenched alkylzinc reagent; a small amount of the ,-unsaturated amide can 
also be observed via GC analysis).  After the alkyl bromide had been consumed, the gray 
mixture was filtered through a syringe filter (PTFE, 0.45 M) to afford a colorless-to-slightly-
yellow solution, which can be stored in a freezer at 35 C for several weeks without 
deterioration.
The alkylzinc solution was titrated by the method of Knochel, using iodine in THF (0.6–0.9 
M) (36).
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V. Enantioconvergent Couplings
Note: To ensure reproducible results, the couplings should be set up using standard Schlenk 
techniques, as described below. 
General Procedure 7 (GP-7): Enantioconvergent couplings with primary alkyl iodides (Fig. 
2).  In the air, NiCl2glyme (13.2 mg, 0.060 mmol, 10%), chiral ligand L1 (19.3 mg, 0.072 mmol, 
12%), 1,5-bis(diphenylphosphino)pentane (26.4 mg, 0.060 mmol, 10%), and an oven-dried cross-
type stir bar were added sequentially to an oven-dried 40-mL vial.  The vial was closed with a 
PTFE septum cap and wrapped with electrical tape.  Next, the vial was evacuated and back-
filled with nitrogen on a Schlenk line (four cycles), and an argon-filled balloon was attached.  
Then, anhydrous THF (6.0 mL) was added via syringe, and the reaction mixture was allowed to 
stir at room temperature for 45 min, after which it turned to a pale-pink suspension.  Next, the 
solution of the alkylzinc bromide (0.90 mmol, 1.5 equiv) was added dropwise via syringe; the 
reaction mixture was stirred for 10 min, at which time it became dark-red and homogeneous.  
Then, the reaction mixture was cooled to 5 C and stirred at that temperature for 10 min.  
Next, the alkyl iodide (0.6 mmol) was added dropwise via microsyringe (if the iodide is a solid, 
it was dissolved in THF (0.5 mL) in a 4-mL vial under an argon atmosphere and transferred into 
the vial via syringe; the vial was rinsed with THF (0.3 mL), and the residual iodide was also 
transferred via syringe).  The argon balloon was removed, and then vacuum grease was 
liberally applied to cover the punctures in the septum cap.  The reaction mixture was stirred at 
5 C for 72 h, and then the reaction was quenched by the addition of MeOH (0.5 mL).  The
resulting mixture was concentrated under reduced pressure, and the residue was purified by
flash chromatography.
General Procedure 8 (GP-8): Enantioconvergent couplings with achiral secondary alkyl 
iodides (Fig. 2).  The procedure is the same as GP-7, except for changes in the following 
quantities: NiCl2glyme (15.8 mg, 0.072 mmol, 12%), chiral ligand L1 (24.1 mg, 0.090 mmol, 15%) 
and 1,5- bis(diphenylphosphino)pentane (23.8 mg, 0.054 mmol, 9%). 
General Procedure 9 (GP-9): Doubly enantioconvergent couplings with racemic 
propargylic bromides (Fig. 3).  In the air, NiBr2glyme (15.4 mg, 0.050 mmol, 10%), anhydrous 
LiCl (25.4 mg, 0.60 mmol; because LiCl is hygroscopic, it is recommended that it be stored and 
weighed in a glovebox, and then transferred out of the glovebox), and an oven-dried cross-type 
stir bar were added sequentially to an oven-dried 40-mL vial.  Next, the vial was capped with a 
PTFE septum cap and wrapped with electrical tape.  The vial was evacuated and back-filled 
with nitrogen on a Schlenk line (four cycles), and then an argon-filled balloon was attached.  
Next, anhydrous THF (4.0 mL) was added via syringe, and the reaction mixture was allowed to 
stir for 15 min, during which it turned to a blue, homogeneous solution.  Next, chiral ligand L2 
(18.6 mg, 0.065 mmol, 13%) was dissolved in anhydrous THF (1.0 mL) in a 4-mL vial under an 
argon atmosphere.  The solution of the ligand was added via syringe into the reaction vial, and 
the resulting mixture was allowed to stir for 40 min, after which it was a cloudy yellow 
suspension.  Next, the propargylic bromide (0.50 mmol, sticky colorless oil or solid, dissolved 
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in THF (0.5 mL) in a 4-mL vial under an argon atmosphere) was added via syringe, the 4-mL 
vial was rinsed with THF (0.3 mL), and the rinse was also added to the reaction vial.  Next, the 
solution of the alkylzinc bromide (0.50 mmol) was added quickly (within 5 sec) as a stream, 
leading to a dark-red reaction mixture.  The argon balloon was removed, and then vacuum 
grease was liberally applied to cover the punctures in the septum cap.  The reaction mixture 
was stirred (~800 rpm) at room temperature for 20 h.  The reaction mixture was then passed 
through a short pad of silica gel, with Et2O as the eluent (~30 mL).  The resulting mixture was 
concentrated, and the residue was purified by flash chromatography on silica gel. 
 
 
 
N-Benzyl-3-ethyl-N-phenylnonanamide (Fig. 2, entry 1).  The title compound was 
synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-1.  The product 
was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  Colorless oil. 
(R)-L1: 201 mg, 95% yield, 90% ee; (S)-L1: 198 mg, 94% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK AD column (5.0% 2-PrOH 
in supercritical CO2, 3.5 mL/min); retention times for compound obtained using (R)-L1: 10.7 min 
(major), 12.3 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.19 (m, 2H), 6.97 
(dd, J = 7.8, 1.9 Hz, 2H), 4.94 (d, J = 14.2 Hz, 1H), 4.89 (d, J = 14.3 Hz, 1H), 2.06 – 1.97 (m, 2H), 1.95 
– 1.83 (m, 1H), 1.37 – 1.09 (m, 12H), 0.89 (t, J = 7.0 Hz, 3H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0, 
38.6, 36.5, 33.3, 31.8, 29.6, 26.5, 26.2, 22.6, 14.1, 10.8. 
FT-IR (film): 2956, 2923, 2854, 1655, 1595, 1494, 1392, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H34NO: 352.2635, found: 352.2633. 
[]24D = 13.9 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
 
N-Benzyl-3-ethyl-N,6-diphenylhexanamide (Fig. 2, entry 2).  The title compound was 
synthesized according to GP-7 from (3-iodopropyl)benzene and zinc nucleophile Zn-1.  The 
product was purified by column chromatography on silica gel (1:15  1:6 EtOAc/hexanes).  
Colorless oil. 
(R)-L1: 189 mg, 82% yield, 91% ee; (S)-L1: 186 mg, 81% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AS-H column (5.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 10.6 min 
(major), 12.5 min (minor). 
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1H NMR (400 MHz, CDCl3) δ 7.36 – 7.25 (m, 8H), 7.25 – 7.19 (m, 3H), 7.19 – 7.14 (m, 2H), 7.03 
– 6.86 (m, 2H), 4.94 (d, J = 14.3 Hz, 1H), 4.89 (d, J = 14.3 Hz, 1H), 2.57 (t, J = 7.7 Hz, 2H), 2.15 – 
1.86 (m, 3H), 1.61 – 1.45 (m, 2H), 1.40 – 1.11 (m, 4H), 0.76 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.6, 142.6, 142.5, 137.7, 129.4, 128.8, 128.5, 128.33, 128.28, 
128.2, 127.8, 127.2, 125.5, 53.0, 38.5, 36.4, 36.1, 33.0, 28.5, 26.1, 10.8. 
FT-IR (film): 2928, 2855, 1652, 1594, 1494, 1393, 746 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C27H32NO: 386.2478, found: 386.2477. 
[]24D = 17.7 (c 1.0, CHCl3); 91% ee from (S)-L1. 
 
 
 
N-Benzyl-5-cyclohexyl-3-ethyl-N-phenylpentanamide (Fig. 2, entry 3).  The title 
compound was synthesized according to GP-7 from (2-iodoethyl)cyclohexane and zinc 
nucleophile Zn-1.  The product was purified by column chromatography on silica gel (1:15 
EtOAc/hexanes).  Colorless oil. 
(R)-L1: 222 mg, 98% yield, 90% ee; (S)-L1: 219 mg, 97% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 11.2 min 
(minor), 12.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.21 (m, 3H), 7.20 – 7.15 (m, 3H), 7.14 – 7.10 (m, 2H), 6.93 
– 6.83 (m, 2H), 4.86 (d, J = 14.3 Hz, 1H), 4.77 (d, J = 14.2 Hz, 1H), 1.98 – 1.87 (m, 2H), 1.77 (hept, J 
= 6.4 Hz, 1H), 1.65 – 1.50 (m, 5H), 1.23 – 0.99 (m, 8H), 0.98 – 0.88 (m, 2H), 0.82 – 0.70 (m, 2H), 0.66 
(t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0, 
38.6, 37.9, 36.7, 34.2, 33.4, 30.4, 26.7, 26.4, 26.1, 10.8. 
FT-IR (film): 2919, 2849, 1653, 1594, 1494, 1393, 728 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C26H36NO: 378.2791, found: 378.2790. 
[]24D = 16.2 (c 1.0, CHCl3); 91% ee from (S)-L1. 
 
 
 
N-Benzyl-3-(cyclohexylmethyl)-N-phenylpentanamide (Fig. 2, entry 4).  The title 
compound was synthesized according to GP-7 from (iodomethyl)cyclohexane and zinc 
nucleophile Zn-1.  The product was purified by column chromatography on silica gel (1:15 
EtOAc/hexanes).  Colorless oil. 
(R)-L1: 211 mg, 97% yield, 91% ee; (S)-L1: 213 mg, 98% yield, 91% ee. 
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HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AS-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 8.6 min 
(major), 12.5 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.20 (m, 2H), 6.97 
(dd, J = 7.8, 1.8 Hz, 2H), 4.91 (s, 2H), 2.06 – 1.90 (m, 3H), 1.74 – 1.55 (m, 5H), 1.33 – 1.22 (m, 2H), 
1.21 – 1.09 (m, 4H), 1.09 – 0.94 (m, 2H), 0.91 – 0.78 (m, 2H), 0.75 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.4, 128.8, 128.6, 128.3, 127.7, 127.2, 53.0, 
41.6, 38.9, 34.8, 33.54, 33.45, 26.7, 26.44, 26.36, 10.6. 
FT-IR (film): 2918, 2848, 1654, 1594, 1494, 1392, 729 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H34NO: 364.2635, found: 364.2634. 
[]24D = 23.2 (c 1.0, CHCl3); 91% ee from (S)-L1. 
 
 
 
N-Benzyl-3-ethyl-7-methyl-N-phenyloct-6-enamide (Fig. 2, entry 5).  The title compound 
was synthesized according to GP-7 from 5-iodo-2-methylpent-2-ene and zinc nucleophile Zn-1.  
The product was purified by column chromatography on silica gel (1:20  1:15 EtOAc/hexanes).  
Colorless oil. 
(R)-L1: 172 mg, 82% yield, 92% ee; (S)-L1: 170 mg, 81% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 14.0 min 
(minor), 15.2 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.19 (m, 2H), 6.97 
(dd, J = 7.7, 1.9 Hz, 2H), 5.07 (tt, J = 7.1, 1.3 Hz, 1H), 4.91 (s, 2H), 2.10 – 1.98 (m, 2H), 1.97 – 1.79 
(m, 3H), 1.68 (d, J = 1.4 Hz, 3H), 1.58 (d, J = 1.3 Hz, 3H), 1.37 – 1.17 (m, 4H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.6, 142.6, 137.8, 131.1, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 
124.6, 53.0, 38.5, 36.2, 33.4, 26.0, 25.7, 25.2, 17.6, 10.7. 
FT-IR (film): 2960, 2921, 2854, 1653, 1594, 1494, 1393, 728 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C24H31NONa: 372.2298, found: 372.2298. 
[]24D = 29.1 (c 1.0, CHCl3); 92% ee from (S)-L1. 
 
 
 
N-Benzyl-7-((tert-butyldimethylsilyl)oxy)-3-ethyl-N-phenylheptanamide (Fig. 2, entry 6).  
The title compound was synthesized according to GP-7 from tert-butyl(4-
iodobutoxy)dimethylsilane and zinc nucleophile Zn-1.  The product was purified by column 
chromatography on silica gel (1:20 EtOAc/hexanes).  Colorless oil. 
(R)-L1: 245 mg, 90% yield, 91% ee; (S)-L1: 257 mg, 94% yield, 90% ee. 
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HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (0.5% 2-
PrOH in hexanes, 0.5 mL/min); retention times for compound obtained using (R)-L1: 42.8 min 
(minor), 44.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 3H), 7.24 – 7.19 (m, 3H), 7.18 – 7.14 (m, 2H), 6.96 
– 6.87 (m, 2H), 4.85 (s, 2H), 3.52 (t, J = 6.6 Hz, 2H), 2.03 – 1.91 (m, 2H), 1.91 – 1.75 (m, 1H), 1.50 – 
1.32 (m, 2H), 1.28 – 1.07 (m, 6H), 0.85 (s, 9H), 0.71 (t, J = 7.4 Hz, 3H), 0.00 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.7, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 63.1, 
53.0, 38.5, 36.5, 33.10, 33.07, 26.1, 26.0, 22.7, 18.3, 10.8, -5.3. 
FT-IR (film): 2927, 2855, 1656, 1595, 1494, 1391, 1094, 833, 773 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C28H44NO2Si: 454.3136, found: 454.3141. 
[]24D = 13.7 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
 
N-Benzyl-3-ethyl-7,7,7-trifluoro-N-phenylheptanamide (Fig. 2, entry 7).  The title 
compound was synthesized according to GP-7 from 1,1,1-trifluoro-4-iodobutane and zinc 
nucleophile Zn-1.  The product was purified by column chromatography on silica gel (1:15 
EtOAc/hexanes).  Colorless oil. 
(R)-L1: 172 mg, 76% yield, 90% ee; (S)-L1: 176 mg, 78% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 14.2 min 
(major), 16.3 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.31 (m, 3H), 7.31 – 7.25 (m, 3H), 7.25 – 7.18 (m, 2H), 6.97 
(dd, J = 7.7, 2.0 Hz, 2H), 4.91 (s, 2H), 2.15 – 1.85 (m, 5H), 1.53 – 1.38 (m, 2H), 1.37 – 1.18 (m, 4H), 
0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.3, 142.4, 137.6, 129.5, 128.8, 128.5, 128.3, 127.9, 127.3, 127.1 
(q, J = 276.8 Hz), 53.0, 38.3, 36.1, 33.9 (q, J = 28.1 Hz), 32.4, 26.0, 19.0 (q, J = 2.9 Hz), 10.8. 
19F NMR (282 MHz, CDCl3) δ -66.37 (t, J = 10.9 Hz, 3F). 
FT-IR (film): 2960, 2935, 1652, 1495, 1393, 1252, 1147, 730 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C22H26F3NONa: 400.1859, found: 400.1863. 
[]24D = 1.4 (c 1.0, CHCl3); 89% ee from (S)-L1. 
 
 
 
N-Benzyl-5-(1,3-dioxolan-2-yl)-3-ethyl-N-phenylpentanamide (Fig. 2, entry 8).  The title 
compound was synthesized according to GP-7 from 2-(2-iodoethyl)-1,3-dioxolane and zinc 
 S–33 
nucleophile Zn-1.  The product was purified by column chromatography on silica gel (1:10  
1:2 EtOAc/hexanes).  Sticky colorless oil. 
(R)-L1: 179 mg, 81% yield, 91% ee; (S)-L1: 189 mg, 86% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (5.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 22.8 min 
(minor), 26.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.18 (m, 2H), 6.97 
(dd, J = 7.7, 1.9 Hz, 2H), 4.91 (s, 2H), 4.80 (t, J = 4.8 Hz, 1H), 3.99 – 3.89 (m, 2H), 3.89 – 3.79 (m, 
2H), 2.09 – 1.89 (m, 3H), 1.62 – 1.46 (m, 2H), 1.44 – 1.19 (m, 4H), 0.78 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.4, 142.4, 137.7, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 104.7, 
64.8, 53.0, 38.4, 36.2, 30.9, 27.3, 26.0, 10.7. 
FT-IR (film): 2957, 2926, 2874, 1652, 1594, 1494, 1394, 766 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H30NO3: 368.2220, found: 368.2220. 
[]24D = 18.2 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
 
7-(Benzyl(phenyl)amino)-5-ethyl-7-oxoheptyl acetate (Fig. 2, entry 9).  The title compound 
was synthesized according to GP-7 from 4-iodobutyl acetate and zinc nucleophile Zn-1.  The 
product was purified by column chromatography on silica gel (1:15  1:5 EtOAc/hexanes).  
Colorless oil. 
(R)-L1: 216 mg, 94% yield, 90% ee; (S)-L1: 214 mg, 93% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (5.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 21.0 min 
(minor), 23.8 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.23 – 7.17 (m, 2H), 6.97 
(dd, J = 7.9, 1.8 Hz, 2H), 4.92 (d, J = 14.2 Hz, 1H), 4.88 (d, J = 14.2 Hz, 1H), 4.03 (t, J = 6.7 Hz, 2H), 
2.05 (s, 3H), 2.04 – 1.95 (m, 2H), 1.95 – 1.83 (m, 1H), 1.66 – 1.48 (m, 2H), 1.32 – 1.17 (m, 6H), 0.76 
(t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.5, 171.2, 142.5, 137.7, 129.4, 128.8, 128.5, 128.3, 127.8, 127.3, 
64.5, 53.0, 38.5, 36.4, 32.9, 28.8, 26.1, 23.0, 21.0, 10.8. 
FT-IR (film): 2957, 2932, 1734, 1652, 1594, 1494, 1393, 1237, 1030, 729 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H32NO3: 382.2377, found: 382.2377. 
[]24D = 13.4 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
  
S–34 
Methyl 7-(benzyl(phenyl)amino)-5-ethyl-7-oxoheptanoate (Fig. 2, entry 10).  The title 
compound was synthesized according to GP-7 from methyl 4-iodobutanoate and zinc 
nucleophile Zn-1.  The product was purified by column chromatography on silica gel (1:15  
1:5 EtOAc/hexanes).  Colorless oil. 
(R)-L1: 206 mg, 94% yield, 90% ee; (S)-L1: 208 mg, 95% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AS-H column (10.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 11.8 min 
(major), 12.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.17 (m, 2H), 6.97 
(dd, J = 7.8, 1.8 Hz, 2H), 4.90 (s, 2H), 3.67 (s, 3H), 2.27 (t, J = 7.5 Hz, 2H), 2.12 – 1.84 (m, 3H), 1.60 – 
1.43 (m, 2H), 1.35 – 1.14 (m, 4H), 0.76 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 174.1, 172.4, 142.4, 137.7, 129.5, 128.8, 128.5, 128.3, 127.8, 127.2, 
53.0, 51.4, 38.4, 36.1, 34.2, 32.7, 26.0, 22.0, 10.7. 
FT-IR (film): 2955, 2926, 1735, 1651, 1494, 1393, 1194, 730 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H30NO3: 368.2220, found: 368.2223. 
[]24D = 11.8 (c 1.0, CHCl3); 91% ee from (S)-L1.
N-Benzyl-3-ethyl-7-oxo-N,7-diphenylheptanamide (Fig. 2, entry 11).  The title compound
was synthesized according to GP-7 from 4-iodo-1-phenylbutan-1-one and zinc nucleophile Zn-1. 
The product was purified by column chromatography on silica gel (1:10  1:5 EtOAc/hexanes).  
Sticky colorless oil. 
(R)-L1: 221 mg, 89% yield, 91% ee; (S)-L1: 212 mg, 85% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (10.0% 
2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 16.6 min
(minor), 18.1 min (major).
1H NMR (400 MHz, CDCl3) δ 8.04 – 7.91 (m, 2H), 7.64 – 7.54 (m, 1H), 7.53 – 7.43 (m, 2H), 7.36 
– 7.24 (m, 6H), 7.24 – 7.18 (m, 2H), 6.97 (dd, J = 7.8, 1.8 Hz, 2H), 4.90 (s, 2H), 2.94 (t, J = 7.4 Hz,
2H), 2.13 – 1.91 (m, 3H), 1.64 (dt, J = 14.9, 7.5 Hz, 2H), 1.41 – 1.19 (m, 4H), 0.77 (t, J = 7.4 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 200.3, 172.5, 142.4, 137.7, 137.0, 132.8, 129.5, 128.8, 128.50, 
128.49, 128.3, 128.0, 127.8, 127.2, 53.0, 38.7, 38.4, 36.2, 32.9, 26.1, 21.2, 10.8. 
FT-IR (film): 2957, 2927, 1682, 1650, 1594, 1494, 1393, 730 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C28H32NO2: 414.2428, found: 414.2432. 
[]24D = 25.4 (c 1.0, CHCl3); 90% ee from (S)-L1.
S–35 
N-Benzyl-8-cyano-3-ethyl-N-phenyloctanamide (Fig. 2, entry 12).  The title compound was
synthesized according to GP-7 from 6-iodohexanenitrile and zinc nucleophile Zn-1.  The 
product was purified by column chromatography on silica gel (1:10  1:2 EtOAc/hexanes). 
Sticky colorless oil. 
(R)-L1: 204 mg, 94% yield, 88% ee; (S)-L1: 202 mg, 93% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (10.0% 
2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 19.1 min
(minor), 21.1 min (major).
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.31 (m, 3H), 7.31 – 7.24 (m, 3H), 7.24 – 7.18 (m, 2H), 6.97 
(dd, J = 7.8, 1.8 Hz, 2H), 4.93 (d, J = 14.2 Hz, 1H), 4.88 (s, J = 14.4 Hz, 1H), 2.32 (t, J = 7.1 Hz, 2H), 
2.01 (qd, J = 15.0, 6.8 Hz, 2H), 1.94 – 1.82 (m, 1H), 1.68 – 1.56 (m, 2H), 1.46 – 1.33 (m, 2H), 1.33 – 
1.12 (m, 6H), 0.76 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.5, 142.5, 137.7, 129.5, 128.8, 128.5, 128.3, 127.8, 127.3, 119.8, 
53.0, 38.5, 36.4, 33.0, 28.8, 26.1, 25.8, 25.3, 17.1, 10.8. 
FT-IR (film): 2929, 2856, 2220, 1652, 1594, 1494, 1394, 728 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H31N2O: 363.2431, found: 363.2432. 
[]24D = 12.1 (c 1.0, CHCl3); 89% ee from (S)-L1.
N-Benzyl-9-chloro-3-ethyl-N-phenylnonanamide (Fig. 2, entry 13).  The title compound
was synthesized according to GP-7 from 1-chloro-6-iodohexane and zinc nucleophile Zn-1. 
The product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  
Colorless oil. 
(R)-L1: 189 mg, 82% yield, 91% ee; (S)-L1: 215 mg, 93% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OD-H column (0.5% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 23.0 min 
(major), 26.4 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.16 (m, 2H), 7.03 
– 6.92 (m, 2H), 4.93 (d, J = 14.2 Hz, 1H), 4.89 (d, J = 14.2 Hz, 1H), 3.54 (t, J = 6.7 Hz, 2H), 2.11 –
1.95 (m, 2H), 1.95 – 1.82 (m, 1H), 1.82 – 1.70 (m, 2H), 1.45 – 1.34 (m, 2H), 1.33 – 1.07 (m, 8H), 0.76
(t, J = 7.4 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 172.7, 142.6, 137.7, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 53.0, 
45.2, 38.5, 36.5, 33.2, 32.6, 29.1, 26.8, 26.4, 26.2, 10.8. 
FT-IR (film): 2957, 2927, 2855, 1651, 1594, 1494, 1392, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H33ClNO: 386.2245, found: 386.2246. 
[]24D = 13.7 (c 1.0, CHCl3); 90% ee from (S)-L1.
S–36 
N-Benzyl-9-bromo-3-ethyl-N-phenylnonanamide (Fig. 2, entry 14).  The title compound
was synthesized according to GP-7 from 1-bromo-6-iodohexane and zinc nucleophile Zn-1. 
The product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  
Sticky colorless oil. 
(R)-L1: 170 mg, 66% yield, 91% ee; (S)-L1: 178 mg, 69% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OD-H column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 11.7 min 
(major), 13.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.18 (m, 2H), 7.03 
– 6.92 (m, 2H), 4.93 (d, J = 14.2 Hz, 1H), 4.89 (d, J = 14.2 Hz, 1H), 3.42 (t, J = 6.7 Hz, 2H), 2.11 –
1.95 (m, 2H), 1.95 – 1.78 (m, 3H), 1.48 – 1.34 (m, 2H), 1.34 – 1.11 (m, 8H), 0.76 (t, J = 7.4 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 172.7, 142.6, 137.7, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 53.0, 
38.5, 36.5, 34.0, 33.2, 32.8, 29.0, 28.1, 26.4, 26.2, 10.8. 
FT-IR (film): 2926, 2854, 1651, 1594, 1494, 1392, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C24H33BrNO: 430.1740, found: 430.1756. 
[]24D = 13.5 (c 1.0, CHCl3); 90% ee from (S)-L1.
N-Benzyl-7-(1,3-dioxoisoindolin-2-yl)-3-ethyl-N-phenylheptanamide (Fig. 2, entry 15).
The title compound was synthesized according to GP-7 from 2-(4-iodobutyl)isoindoline-1,3-
dione and zinc nucleophile Zn-1.  The product was purified by column chromatography on 
silica gel (1:10  1:2 EtOAc/hexanes).  Sticky colorless oil. 
(R)-L1: 263 mg, 94% yield, 92% ee; (S)-L1: 266 mg, 95% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OJ-H column (5.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 43.3 min 
(minor), 47.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.90 – 7.81 (m, 2H), 7.77 – 7.68 (m, 2H), 7.36 – 7.17 (m, 8H), 7.03 
– 6.90 (m, 2H), 4.92 (d, J = 14.3 Hz, 1H), 4.87 (d, J = 14.3 Hz, 1H), 3.64 (t, J = 7.4 Hz, 2H), 2.10 –
1.94 (m, 2H), 1.93 – 1.80 (m, J = 6.0 Hz, 1H), 1.69 – 1.53 (m, 2H), 1.37 – 1.12 (m, 6H), 0.75 (t, J = 7.4
Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 172.5, 168.3, 142.5, 137.7, 133.8, 132.1, 129.4, 128.8, 128.5, 128.2, 
127.8, 127.2, 123.1, 53.0, 38.4, 37.9, 36.4, 32.9, 28.8, 26.1, 23.9, 10.8. 
S–37 
FT-IR (film): 2930, 2858, 1770, 1707, 1650, 1393, 718 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C30H33N2O3: 469.2486, found: 469.2489. 
[]24D = 12.8 (c 1.0, CHCl3); 92% ee from (S)-L1.
N-Benzyl-N-phenyl-3-((1-(thiophene-2-carbonyl)piperidin-4-yl)methyl)pentanamide (Fig.
2, entry 16).  The title compound was synthesized according to GP-7 from (4-
(iodomethyl)piperidin-1-yl)(thiophen-2-yl)methanone and zinc nucleophile Zn-1.  The product 
was purified by column chromatography on silica gel (1:10  1:2 EtOAc/hexanes).  Sticky 
colorless oil. 
(R)-L1: 252 mg, 89% yield, 90% ee; (S)-L1: 246 mg, 86% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (30.0% 
2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 12.4 min
(minor), 14.3 min (major).
1H NMR (400 MHz, CDCl3) δ 7.44 (dd, J = 5.0, 1.1 Hz, 1H), 7.39 – 7.31 (m, 3H), 7.31 – 7.24 (m, 
4H), 7.24 – 7.18 (m, 2H), 7.05 (dd, J = 5.0, 3.6 Hz, 1H), 6.97 (dd, J = 7.8, 1.8 Hz, 2H), 4.90 (s, 2H), 
4.40 (br s, 2H), 2.88 (br s, 2H), 2.14 – 1.88 (m, 3H), 1.79 – 1.58 (m, 2H), 1.55 – 1.40 (m, 1H), 1.36 – 
1.23 (m, 2H), 1.23 – 1.04 (m, 4H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.3, 163.4, 142.5, 137.61, 137.57, 129.5, 128.9, 128.5, 128.3, 
128.1, 127.9, 127.3, 126.5, 53.1, 40.6, 38.8, 33.5, 33.3, 32.6, 26.5, 10.6. 
FT-IR (film): 2918, 2849, 1647, 1612, 1594, 1436, 1394, 1269, 734 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C29H34N2O2SNa: 497.2233, found: 497.2240. 
[]24D = 33.4 (c 1.0, CHCl3); 91% ee from (S)-L1.
(3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 7-
(benzyl(phenyl)amino)-5-ethyl-7-oxoheptanoate (Fig. 2, entry 17).  The title compound was 
synthesized according to GP-7 from the alkyl iodide and zinc nucleophile Zn-1.  The product 
was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  Sticky colorless 
oil. 
S–38 
(R)-L1: 355 mg, 82% yield, 4:96 dr; (S)-L1: 370 mg, 85% yield, 95:5 dr. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 13.3 min 
(minor), 14.3 min (major). 
The 1H NMR data for the product from (S)-L1 and (R)-L1 (identical for both diastereomers): 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.17 (m, 2H), 6.97 
(dd, J = 7.8, 1.8 Hz, 2H), 5.45 – 5.32 (m, 1H), 4.90 (s, 2H), 4.68 – 4.53 (m, 1H), 2.37 – 2.28 (m, 2H), 
2.23 (t, J = 7.5 Hz, 2H), 2.09 – 1.81 (m, 8H), 1.65 – 1.44 (m, 9H), 1.43 – 1.33 (m, 3H), 1.32 – 1.06 (m, 
13H), 1.04 (s, 3H), 1.03 – 0.96 (m, 2H), 0.94 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 1.9 Hz, 3H), 0.88 (d, J = 
1.9 Hz, 3H), 0.77 (t, J = 7.4 Hz, 3H), 0.70 (s, 3H). 
The 13C NMR data for the product from (R)-L1: 
13C NMR (101 MHz, CDCl3) δ 173.1, 172.5, 142.5, 139.7, 137.7, 129.5, 128.8, 128.5, 128.3, 127.8, 
127.2, 122.6, 73.7, 56.6, 56.1, 53.0, 50.0, 42.3, 39.7, 39.5, 38.4, 38.1, 37.0, 36.6, 36.2, 36.1, 35.8, 34.8, 
32.7, 31.9, 31.8, 28.2, 28.0, 27.8, 26.0, 24.3, 23.8, 22.8, 22.5, 22.1, 21.0, 19.3, 18.7, 11.8, 10.8. 
The 13C NMR data for the product from (S)-L1: 
13C NMR (101 MHz, CDCl3) δ 173.1, 172.5, 142.5, 139.7, 137.7, 129.5, 128.9, 128.6, 128.3, 127.9, 
127.3, 122.6, 73.7, 56.7, 56.1, 53.0, 50.0, 42.3, 39.7, 39.5, 38.5, 38.2, 37.0, 36.6, 36.3, 36.2, 35.8, 34.9, 
32.7, 31.9, 31.8, 28.3, 28.0, 27.8, 26.1, 24.3, 23.8, 22.9, 22.6, 22.1, 21.0, 19.4, 18.7, 11.9, 10.8. 
FT-IR (film): 2933, 2866, 1733, 1653, 1495, 1169, 754 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C49H72NO3: 722.5507, found: 722.5511. 
[]24D = 30.5 (c 1.0, CHCl3); 95:5 dr from (S)-L1.
[]24D = 10.2 (c 1.0, CHCl3); 4:96 dr from (R)-L1.
N-Benzyl-3-cyclohexyl-N-phenylpentanamide (Fig. 2, entry 18).  The title compound was
synthesized according to GP-8 from iodocyclohexane and zinc nucleophile Zn-1.  The product 
was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  Colorless viscous 
oil. 
(R)-L1: 181 mg, 87% yield, 92% ee; (S)-L1: 180 mg, 86% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1:  13.6 min 
(minor), 16.1 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.12 (m, 8H), 7.11 – 6.76 (m, 2H), 4.89 (s, 2H), 2.19 – 1.87 
(m, 2H), 1.85 – 1.72 (m, 1H), 1.71 – 1.53 (m, 3H), 1.51 – 1.01 (m, 8H), 0.93 – 0.63 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 173.4, 142.7, 137.9, 129.5, 129.0, 128.7, 128.4, 127.9, 127.4, 53.2, 
42.3, 39.9, 35.8, 29.64, 29.60, 26.91, 26.86, 23.4, 11.9. 
FT-IR (film): 2921, 2850, 1653, 1595, 1494, 1392, 1196, 1079, 730 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C24H31NONa: 372.2298, found: 372.2302. 
[]22D = 1.9 (c 0.50, CHCl3); 92% ee from (S)-L1.
S–39 
N-Benzyl-N-phenyl-3-(tetrahydro-2H-pyran-4-yl)pentanamide (Fig. 2, entry 19).  The title
compound was synthesized according to GP-8 from 4-iodotetrahydro-2H-pyran and zinc 
nucleophile Zn-1.  The product was purified by column chromatography on silica gel (1:3 
EtOAc/hexanes).  Colorless viscous oil. 
(R)-L1: 197 mg, 93% yield, 91% ee; (S)-L1: 187 mg, 89% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (5.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 20.2 min 
(minor), 22.9 min (major). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 3H), 7.26 – 7.16 (m, 5H), 7.07 – 6.80 (m, 2H), 4.90 
(d, J = 14.2 Hz, 1H), 4.86 (d, J = 14.2 Hz, 1H), 4.00 – 3.81 (m, 2H), 3.29 (td, J = 11.4, 2.7 Hz, 2H), 
2.09 (dd, J = 15.3, 6.0 Hz, 1H), 1.95 (dd, J = 15.3, 7.0 Hz, 1H), 1.89 – 1.74 (m, 1H), 1.62 – 1.46 (m, 
1H), 1.36 – 1.15 (m, 6H), 0.78 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.6, 129.0, 128.6, 128.4, 128.0, 127.4, 68.5, 
53.2, 41.4, 37.2, 35.3, 29.8, 29.5, 23.1, 11.5. 
FT-IR (ATR) 2932, 2840, 1651, 1494, 1393, 1094, 730 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C23H29NO2Na: 374.2095, found: 374.2091. 
[]22D = 3.8 (c 0.49, CHCl3); 92% ee from (S)-L1.
tert-Butyl 4-(1-(benzyl(phenyl)amino)-1-oxopentan-3-yl)piperidine-1-carboxylate (Fig. 2, 
entry 20).  The title compound was synthesized according to GP-8 from tert-butyl 4-
iodopiperidine-1-carboxylate and zinc nucleophile Zn-1.  The product was purified by column 
chromatography on silica gel (1:3 EtOAc/hexanes).  Colorless viscous oil. 
(R)-L1: 247 mg, 91% yield, 91% ee; (S)-L1: 243 mg, 90% yield, 92% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (5.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 19.0 min 
(minor), 26.5 min (major). 
1H NMR (300 MHz, CDCl3) δ 7.42 – 7.10 (m, 8H), 6.99 – 6.84 (m, 2H), 4.87 (s, 2H), 4.05 (d, 2H), 
2.71 – 2.40 (m, 2H), 2.11 – 1.89 (m, 2H), 1.83 (q, J = 5.8 Hz, 1H), 1.43 (s, 9H), 1.37 – 1.11 (m, 5H), 
1.10 – 0.92 (m, 2H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.6, 154.7, 142.4, 137.6, 129.5, 128.8, 128.4, 128.3, 127.9, 127.3, 
79.1, 53.1, 44.24, 44.22, 41.2, 38.2, 35.4, 28.55, 28.49, 28.4, 23.2, 11.6. 
S–40 
FT-IR (film) 2930, 1688, 1652, 1392, 1234, 1166, 1141, 768 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C28H39N2O3: 451.2955, found: 451.2943. 
[]22D = 15.4 (c = 0.62, CHCl3); 92% ee from (S)-L1.
N-Benzyl-3-cyclobutyl-N-phenylpentanamide (Fig. 2, entry 21).  The title compound was
synthesized according to GP-8 from iodocyclobutane and zinc nucleophile Zn-1.  The product 
was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  Colorless viscous 
oil. 
(R)-L1: 142 mg, 88% yield, 90% ee; (S)-L1: 122 mg, 76% yield, 87% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 14.8 min 
(minor), 17.8 min (major).  
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.33 (m, 3H), 7.33 – 7.27 (m, 3H), 7.27 – 7.20 (m, 2H), 7.08 
– 6.93 (m, 2H), 4.94 (s, 2H), 2.14 – 1.90 (m, 5H), 1.90 – 1.81 (m, 1H), 1.80 – 1.64 (m, 3H), 1.64 – 1.52
(m, 1H), 1.44 – 1.31 (m, 1H), 1.31 – 1.18 (m, 1H), 0.79 (t, J = 7.5 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 172.8, 142.6, 137.7, 129.4, 128.9, 128.5, 128.2, 127.7, 127.2, 53.0, 
42.8, 40.1, 35.7, 27.5, 27.0, 24.0, 17.7, 10.6. 
FT-IR (ATR) 2958, 2929, 1652, 1494, 1393, 1260, 766, 749 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C22H28NO: 322.2165, found: 322.2166. 
[]22D = 24.2 (c 0.62, CHCl3); 87% ee from (S)-L1.
tert-Butyl 3-(1-(benzyl(phenyl)amino)-1-oxopentan-3-yl)azetidine-1-carboxylate (Fig. 2, 
entry 22).  The title compound was synthesized according to GP-8 from tert-butyl 3-
iodoazetidine-1-carboxylate (0.50 mmol) and zinc nucleophile Zn-1 (0.75 mmol).  The product 
was purified by column chromatography on silica gel (1:3 EtOAc/hexanes).  Colorless viscous 
oil. 
(R)-L1: 202 mg, 96% yield, 87% ee; (S)-L1: 190 mg, 90% yield, 89% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK AD-3 column (20.0% 2-
PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R)-L1: 
3.4 min (minor), 3.9 min (major). 
1H NMR (300 MHz, CDCl3) δ 7.34 – 7.28 (m, 3H), 7.26 – 7.16 (m, 5H), 7.30 – 7.25 (m, 3H), 7.24 
– 7.16 (m, 2H), 7.03 – 6.88 (m, 2H), 4.91 (d, J = 14.2 Hz, 1H), 4.88 (d, J = 14.1 Hz, 1H), 3.87 (t, J = 8.4
Hz, 1H), 3.82 (t, J = 8.4 Hz, 1H), 3.59 (dd, J = 8.5, 6.3 Hz, 1H), 3.51 (dd, J = 8.4, 6.4 Hz, 1H), 2.47 –
S–41 
2.32 (m, 1H), 2.19 – 2.09 (m, 1H), 2.01 (dd, J = 15.2, 7.5 Hz, 1H), 1.92 (dd, J = 15.2, 5.4 Hz, 1H), 1.44 
(s, 9H), 1.39 – 1.21 (m, 2H), 0.75 (t, J = 7.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 171.7, 156.2, 142.2, 137.4, 129.6, 128.9, 128.4, 128.3, 128.0, 127.4, 
79.1, 53.1, 40.0, 35.5, 32.7, 28.4, 24.1, 10.6. 
FT-IR (film) 2961, 2919, 1697, 1652, 1395, 1364, 1131, 767, 749 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C26H34N2O3Na: 445.2462, found: 445.2466. 
[]22D = 27.6 (c 0.66, CHCl3); 89% ee from (S)-L1.
N-Benzyl-3-(2,3-dihydro-1H-inden-2-yl)-N-phenylpentanamide (Fig. 2, entry 23). The title
compound was synthesized according to GP-8 from 2-iodo-2,3-dihydro-1H-indene (0.50 mmol) 
and zinc nuclephile Zn-1 (0.75 mmol).  The product was purified by column chromatography 
on silica gel (1:15 EtOAc/hexanes).  White solid. 
(R)-L1: 133 mg, 69% yield, 94% ee; (S)-L1 130 mg, 68% yield, 94% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK AD-3 column (25.0% 2-
PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R)-L1: 
5.1 min (minor), 6.7 min (major). 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.19 (m, 9H), 7.18 – 7.13 (m, 1H), 7.13 – 7.08 (m, 2H), 7.04 
– 6.90 (m, 2H), 4.95 (d, J = 14.2 Hz, 1H), 4.90 (d, J = 14.0 Hz, 1H), 2.90 (dd, J = 15.5, 7.9 Hz, 1H),
2.82 (dd, J = 15.3, 7.8 Hz, 1H), 2.54 (ddd, J = 34.8, 15.4, 9.5 Hz, 2H), 2.45 – 2.33 (m, 1H), 2.23 – 2.04
(m, 3H), 1.57 – 1.44 (m, 1H), 1.44 – 1.31 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 172.5, 143.4, 143.3, 142.5, 137.6, 129.5, 128.9, 128.5, 128.3, 127.9, 
127.3, 126.0, 125.9, 124.2, 124.1, 109.9, 53.1, 43.0, 40.8, 36.8, 36.7, 36.5, 24.5, 10.4. 
FT-IR (ATR) 2966, 2925, 1643, 1596, 1494, 1398, 765, 747 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C27H29NONa: 406.2141, found: 406.2145. 
[]22D = 34.8 (c = 1.0, CHCl3); 94% ee from (S)-L1.
N-Benzyl-N-phenyl-3-propylnonanamide (Fig. 2, entry 24).  The title compound was
synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-2. The product was 
purified by column chromatography on silica gel (1:15 EtOAc/hexanes). Colorless oil. 
(R)-L1: 205 mg, 94% yield, 90% ee; (S)-L1: 201 mg, 92% yield, 90% ee. 
S–42 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OD-H column (0.5% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 10.2 min 
(major), 11.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.19 (m, 2H), 6.96 
(dd, J = 7.8, 1.9 Hz, 2H), 4.94 (d, J = 14.2 Hz, 1H), 4.89 (d, J = 14.3 Hz, 1H), 2.08 – 2.00 (m, 2H), 2.00 
– 1.87 (m, 1H), 1.33 – 1.12 (m, 14H), 0.89 (t, J = 7.0 Hz, 3H), 0.87 – 0.81 (m, 3H).
13C NMR (101 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0,
39.0, 36.2, 35.0, 33.8, 31.9, 29.6, 26.5, 22.6, 19.7, 14.3, 14.1. 
FT-IR (film): 2954, 2924, 2854, 1655, 1595, 1494, 1392, 727 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H36NO: 366.2719, found: 366.2791. 
[]24D = 5.4 (c 1.0, CHCl3); 90% ee from (S)-L1.
N-Benzyl-3-pentyl-N-phenylnonanamide (Fig. 2, entry 25).  The title compound was
synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-3.  The product 
was purified by column chromatography on silica gel (1:15  1:6 EtOAc/hexanes).  Colorless 
oil. 
(R)-L1: 187 mg, 79% yield, 90% ee; (S)-L1: 203 mg, 86% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (1.0% 2-
PrOH in hexanes, 0.6 mL/min); retention times for compound obtained using (R)-L1: 17.4 min 
(major), 18.3 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.27 – 7.20 (m, 3H), 7.20 – 7.15 (m, 3H), 7.14 – 7.10 (m, 2H), 6.87 
(dd, J = 7.8, 1.9 Hz, 2H), 4.81 (s, 2H), 1.93 (d, J = 6.8 Hz, 2H), 1.89 – 1.77 (m, 1H), 1.22 – 1.03 (m, 
18H), 0.84 – 0.74 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0, 
39.0, 35.2, 33.9, 33.8, 32.1, 31.9, 29.6, 26.5, 26.2, 22.6, 14.10, 14.08. 
FT-IR (film): 2923, 2853, 1655, 1595, 1494, 1392, 725 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C27H40NO: 394.3104, found: 394.3110. 
[]24D = 1.8 (c 1.0, CHCl3); 90% ee from (S)-L1.
N-Benzyl-3-isopentyl-N-phenylnonanamide (Fig. 2, entry 26).  The title compound was
synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-4.  The product 
was purified by column chromatography on silica gel (1:15  1:6 EtOAc/hexanes).  Colorless 
oil. 
(R)-L1: 219 mg, 92% yield, 89% ee; (S)-L1: 221 mg, 93% yield, 89% ee. 
 S–43 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 18.3 min 
(major), 20.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 3H), 7.30 – 7.25 (m, 3H), 7.24 – 7.19 (m, 2H), 6.96 
(dd, J = 7.8, 1.9 Hz, 2H), 4.94 (d, J = 14.2 Hz, 1H), 4.88 (d, J = 14.3 Hz, 1H), 2.02 (d, J = 6.8 Hz, 2H), 
1.97 – 1.86 (m, 1H), 1.52 – 1.39 (m, 1H), 1.34 – 1.13 (m, 12H), 1.09 – 1.00 (m, 2H), 0.89 (t, J = 7.0 Hz, 
3H), 0.85 (dd, J = 6.6, 0.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.8, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0, 
39.0, 35.7, 35.4, 33.9, 31.9, 31.5, 29.6, 28.2, 26.5, 22.63, 22.60, 14.1. 
FT-IR (film): 2923, 2853, 1655, 1595, 1494, 1392, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C27H40NO: 394.3104, found: 394.3105. 
[]24D = 5.2 (c 1.0, CHCl3); 89% ee from (S)-L1. 
 
 
 
N-Benzyl-3-(3-((tert-butyldimethylsilyl)oxy)propyl)-N-phenylnonanamide (Fig. 2, entry 
27).  The title compound was synthesized according to GP-7 from 1-iodohexane and zinc 
nucleophile Zn-5.  The product was purified by column chromatography on silica gel (1:20 
EtOAc/hexanes).  Colorless oil. 
(R)-L1: 282 mg, 95% yield, 88% ee; (S)-L1: 274 mg, 92% yield, 87% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IE column (10.0% 2-PrOH 
in supercritical CO2, 2.5 ml/min); retention times for compound obtained using (R)-L*: 10.9 min 
(minor), 11.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 3H), 7.25 – 7.19 (m, 3H), 7.19 – 7.12 (m, 2H), 6.91 
(dd, J = 7.7, 1.9 Hz, 2H), 4.89 (d, J = 14.3 Hz, 1H), 4.82 (d, J = 14.3 Hz, 1H), 3.50 (td, J = 6.6, 1.2 Hz, 
2H), 1.97 (d, J = 7.4 Hz, 2H), 1.95 – 1.84 (m, 1H), 1.41 – 1.29 (m, 2H), 1.29 – 1.06 (m, 12H), 0.85 (s, 
12H), 0.00 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.6, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 63.5, 
53.0, 39.0, 34.9, 33.7, 31.8, 29.8, 29.7, 29.6, 26.5, 26.0, 22.6, 18.3, 14.1, -5.3. 
FT-IR (film): 2925, 2854, 1653, 1495, 1393, 1253, 1095, 833, 773 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C31H49NO2SiNa: 518.3425, found: 518.3434. 
[]24D = 0.6 (c 1.0, CHCl3); 87% ee from (S)-L1. 
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N-Benzyl-3-(4-methoxybutyl)-N-phenylnonanamide (Fig. 2, entry 28).  The title 
compound was synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-6.  
The product was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  
Colorless oil. 
(R)-L1: 182 mg, 74% yield, 90% ee; (S)-L1: 171 mg, 70% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 46.8 min 
(minor), 48.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 3H), 7.30 – 7.24 (m, 3H), 7.24 – 7.18 (m, 2H), 6.96 
(dd, J = 7.8, 1.9 Hz, 2H), 4.90 (s, 2H), 3.34 (t, J = 6.6 Hz, 2H), 3.33 (s, 3H), 2.02 (d, J = 7.8 Hz, 2H), 
1.98 – 1.86 (m, 1H), 1.60 – 1.44 (m, 2H), 1.32 – 1.10 (m, 14H), 0.89 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.7, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 72.8, 
58.5, 53.0, 38.9, 35.2, 33.8, 33.7, 31.8, 29.9, 29.6, 26.5, 23.1, 22.6, 14.1. 
FT-IR (film): 2922, 2853, 1655, 1595, 1494, 1392, 1116, 727 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C27H39NO2Na: 432.2873, found: 432.2882. 
[]24D = 1.0 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
 
N-Benzyl-3-(3-(benzyloxy)propyl)-N-phenylnonanamide (Fig. 2, entry 29).  The title 
compound was synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-7.  
The product was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  
Colorless oil. 
(R)-L1: 169 mg, 60% yield, 85% ee; (S)-L1: 168 mg, 60% yield, 84% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 22.2 min 
(major), 24.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.25 (m, 8H), 7.24 – 7.20 (m, 3H), 7.19 – 7.15 (m, 2H), 6.91 
(dd, J = 7.5, 2.2 Hz, 2H), 4.89 (d, J = 14.2 Hz, 1H), 4.83 (d, J = 14.2 Hz, 1H), 4.46 (s, 2H), 3.39 (t, J = 
6.7 Hz, 2H), 2.05 – 1.87 (m, 3H), 1.53 – 1.39 (m, 2H), 1.30 – 1.06 (m, 12H), 0.85 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.6, 142.5, 138.6, 137.7, 129.4, 128.8, 128.5, 128.29, 128.26, 
127.8, 127.6, 127.4, 127.2, 72.8, 70.7, 53.0, 38.9, 34.9, 33.8, 31.8, 30.2, 29.6, 26.8, 26.5, 22.6, 14.1. 
FT-IR (film): 2923, 2852, 1655, 1594, 1494, 1392, 733 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C32H41NO2Na: 494.3030, found: 494.3034. 
[]24D = 2.9 (c 1.0, CHCl3); 84% ee from (S)-L1. 
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N-Benzyl-3-(4-chlorobutyl)-N-phenylnonanamide (Fig. 2, entry 30).  The title compound 
was synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-8.  The 
product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  Colorless 
oil. 
(R)-L1: 232 mg, 94% yield, 90% ee; (S)-L1: 232 mg, 94% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 17.1 min 
(minor), 18.3 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.29 – 7.22 (m, 3H), 7.21 – 7.15 (m, 3H), 7.15 – 7.09 (m, 2H), 6.87 
(dd, J = 7.7, 1.9 Hz, 2H), 4.83 (d, J = 14.4 Hz, 1H), 4.79 (d, J = 14.4 Hz, 1H), 3.42 (t, J = 6.7 Hz, 2H), 
2.00 – 1.81 (m, 3H), 1.68 – 1.58 (m, 2H), 1.27 – 0.98 (m, 14H), 0.80 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.5, 142.5, 137.7, 129.5, 128.8, 128.5, 128.3, 127.8, 127.3, 53.0, 
45.1, 38.9, 34.9, 33.8, 33.0, 32.7, 31.8, 29.5, 26.5, 23.8, 22.6, 14.1. 
FT-IR (film): 2924, 2854, 1653, 1594, 1494, 1394, 727 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C26H36ClNONa: 436.2378, found: 436.2378. 
[]24D = 4.1 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
 
N-Benzyl-3-cyclohexyl-N-phenylbutanamide (Fig. 2, entry 31).  The title compound was 
synthesized according to GP-8 from iodocyclohexane and zinc nucleophile Zn-9. The product 
was purified by column chromatography on silica gel (1:20 EtOAc/hexanes). Colorless oil. 
(R)-L1: 171 mg, 86% yield, 89% ee; (S)-L1: 183 mg, 91% yield, 89% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (3.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 14.6 min 
(minor), 18.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.30 (m, 3H), 7.29 – 7.24 (m, 3H), 7.24 – 7.19 (m, 2H), 6.96 
(dd, J = 7.7, 1.9 Hz, 2H), 4.92 (d, J = 14.3 Hz, 1H), 4.90 (d, J = 14.3 Hz, 1H), 2.18 (dd, J = 14.4, 5.0 
Hz, 1H), 2.03 – 1.92 (m, 1H), 1.87 (dd, J = 14.4, 8.7 Hz, 1H), 1.73 – 1.56 (m, 3H), 1.52 (d, J = 12.7 Hz, 
1H), 1.39 (d, J = 12.4 Hz, 1H), 1.23 – 1.02 (m, 4H), 0.96 – 0.74 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 172.9, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.8, 127.2, 53.0, 
42.3, 38.7, 35.5, 30.4, 28.7, 26.7, 26.6, 26.5, 16.4. 
FT-IR (film): 2921, 2849, 1651, 1594, 1494, 1392, 732 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H30NO: 336.2322, found: 336.2322. 
[]24D = 22.6 (c 1.0, CHCl3); 89% ee from (S)-L1. 
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N-Benzyl-3-cyclohexyl-N-phenylhexanamide (Fig. 2, entry 32).  The title compound was 
synthesized according to GP-8 from iodocyclohexane and zinc nucleophile Zn-2. The product 
was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  Colorless oil. 
(R)-L1: 156 mg, 72% yield, 91% ee; (S)-L1: 153 mg, 70% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (3.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 12.1 min 
(minor), 12.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.28 – 7.21 (m, 3H), 7.21 – 7.15 (m, 3H), 7.15 – 7.10 (m, 2H), 6.87 
(dd, J = 7.9, 1.9 Hz, 2H), 4.81 (s, 2H), 2.00 (dd, J = 14.8, 6.7 Hz, 1H), 1.86 (dd, J = 14.9, 6.9 Hz, 1H), 
1.82 – 1.72 (m, 1H), 1.62 – 1.49 (m, 3H), 1.38 (d, J = 12.0 Hz, 1H), 1.27 (d, J = 12.2 Hz, 1H), 1.22 – 
0.92 (m, 8H), 0.84 – 0.67 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 173.2, 142.6, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0, 
40.3, 40.2, 36.1, 33.1, 29.5, 29.4, 26.8, 26.7, 20.5, 14.4. 
FT-IR (film): 2921, 2850, 1653, 1594, 1494, 1448, 1391, 732 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C25H34NO: 364.2635, found: 364.2634. 
[]24D = 6.9 (c 1.0, CHCl3); 90% ee from (S)-L1. 
 
 
 
N-Benzyl-3-cyclohexyl-N-phenyloctanamide (Fig. 2, entry 33).  The title compound was 
synthesized according to GP-8 from iodocyclohexane and zinc nucleophile Zn-3.  The product 
was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  Colorless oil. 
(R)-L1: 146 mg, 62% yield, 90% ee; (S)-L1: 145 mg, 62% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 13.5 min 
(minor), 14.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.29 – 7.21 (m, 3H), 7.21 – 7.15 (m, 3H), 7.15 – 7.09 (m, 2H), 6.87 
(dd, J = 7.8, 1.8 Hz, 2H), 4.83 (d, J = 14.2 Hz, 1H), 4.79 (d, J = 14.2 Hz, 1H), 2.00 (dd, J = 14.9, 6.7 
Hz, 1H), 1.87 (dd, J = 14.9, 6.9 Hz, 1H), 1.81 – 1.69 (m, 1H), 1.65 – 1.47 (m, 3H), 1.44 – 1.24 (m, 2H), 
1.23 – 0.89 (m, 12H), 0.86 – 0.66 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 173.2, 142.7, 137.8, 129.4, 128.8, 128.5, 128.3, 127.7, 127.2, 53.0, 
40.6, 40.2, 36.1, 32.2, 30.7, 29.5, 29.4, 27.0, 26.8, 26.7, 22.7, 14.1. 
FT-IR (film): 2921, 2850, 1655, 1595, 1494, 1391, 727 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C27H38NO: 392.2948, found: 392.2947. 
[]24D = 11.3 (c 1.0, CHCl3); 91% ee from (S)-L1. 
 
 
S–47 
N-Cyclohexyl-3-ethyl-N-phenylnonanamide (Fig. 2, entry 34).  The title compound was
synthesized according to GP-7 from 1-iodohexane (0.50 mmol) and zinc nucleophile Zn-10 (0.75 
mmol).  The product was purified by column chromatography on silica gel (1:15 
EtOAc/hexanes).  Colorless oil. 
(R)-L1: 151 mg, 88% yield, 90% ee; (S)-L1: 155 mg, 90% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 10.9 min 
(major), 12.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.25 (m, 3H), 7.06 – 6.93 (m, 2H), 4.56 (tt, J = 12.1, 3.6 Hz, 
1H), 1.80 – 1.70 (m, 5H), 1.64 (dt, J = 13.7, 3.5 Hz, 2H), 1.56 – 1.42 (m, 1H), 1.32 (qt, J = 13.2, 3.5 Hz, 
2H), 1.25 – 1.01 (m, 12H), 1.01 – 0.82 (m, 3H), 0.79 (t, J = 7.0 Hz, 3H), 0.65 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.1, 139.5, 130.4, 128.9, 127.9, 53.9, 39.3, 36.4, 33.3, 31.8, 31.7, 
29.5, 26.5, 26.2, 25.8, 25.4, 22.6, 14.1, 10.8. 
FT-IR (film): 2927, 2854, 1652, 1595, 1493, 1391, 1262, 1072, 705 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C23H37NONa: 366.2767, found: 366.2773. 
[]22D = 13.2 (c 1.0, CHCl3); 90% ee from (S)-L1.
3-Ethyl-1-(indolin-1-yl)nonan-1-one (Fig. 2, entry 35).  The title compound was
synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-11.  The product 
was purified by column chromatography on silica gel (1:15 EtOAc/hexanes).  White solid. 
(R)-L1: 157 mg, 91% yield, 90% ee; (S)-L1: 149 mg, 87% yield, 90% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OD-H column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 10.4 min 
(major), 13.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.0 Hz, 1H), 7.16 – 7.06 (m, 2H), 6.93 (td, J = 7.4, 1.1 
Hz, 1H), 4.00 (t, J = 8.5 Hz, 2H), 3.12 (t, J = 8.5 Hz, 2H), 2.26 (d, J = 6.8 Hz, 2H), 1.94 (hept, J = 6.5 
Hz, 1H), 1.39 – 1.31 (m, 2H), 1.29 – 1.13 (m, 10H), 0.83 (t, J = 7.4 Hz, 3H), 0.80 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.3, 143.2, 131.0, 127.5, 124.4, 123.4, 117.1, 48.1, 40.4, 35.7, 33.4, 
31.9, 29.6, 28.0, 26.7, 26.3, 22.7, 14.1, 10.9. 
FT-IR (film): 2959, 2922, 2853, 1647, 1599, 1480, 1462, 1415, 753, 745 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H30NO: 288.2322, found: 288.2320. 
[]24D = 4.4 (c 1.0, CHCl3); 90% ee from (S)-L1.
S–48 
N,N-Dibutyl-3-ethylnonanamide (Fig. 2, entry 36).  The title compound was synthesized 
according to GP-7 from 1-iodohexane and zinc nucleophile Zn-12.  The product was purified 
by column chromatography on silica gel (1:20 EtOAc/hexanes).  Colorless oil. 
(R)-L1: 175 mg, 98% yield, 85% ee; (S)-L1: 178 mg, 99% yield, 85% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OD-H column (0.5% 2-
PrOH in hexanes, 0.5 mL/min); retention times for compound obtained using (R)-L1: 13.7 min 
(major), 15.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 3.31 – 3.19 (m, 2H), 3.19 – 3.04 (m, 2H), 2.12 (d, J = 6.9 Hz, 2H), 
1.90 – 1.74 (m, J = 5.7 Hz, 1H), 1.53 – 1.37 (m, 4H), 1.32 – 1.12 (m, 16H), 0.88 (t, J = 6.9 Hz, 3H), 
0.85 (t, J = 6.9 Hz, 3H), 0.80 (t, J = 6.9 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.4, 47.8, 45.7, 37.5, 36.4, 33.5, 31.9, 31.3, 29.9, 29.7, 26.7, 26.3, 
22.6, 20.3, 20.1, 14.1, 13.9, 13.8, 10.9. 
FT-IR (film): 2956, 2925, 2872, 1640, 1456, 1419, 1377, 730 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C19H40NO: 298.3104, found: 298.3109. 
[]24D = 0.6 (c 1.0, CHCl3); 85% ee from (S)-L1.
3-Ethyl-N-methoxy-N-methylnonanamide (Fig. 2, entry 37).  The title compound was
synthesized according to GP-7 from 1-iodohexane and zinc nucleophile Zn-13.  The product 
was purified by column chromatography on silica gel (1:10  1:6 EtOAc/hexanes).  Colorless 
oil. 
(R)-L1: 124 mg, 90% yield, 88% ee; (S)-L1: 129 mg, 94% yield, 88% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (0.7% 2-
PrOH in hexanes, 0.5 mL/min); retention times for compound obtained using (R)-L1: 31.9 min 
(minor), 33.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 3.69 (s, 3H), 3.19 (s, 3H), 2.43 – 2.24 (m, 2H), 1.97 – 1.83 (m, 1H), 
1.42 – 1.20 (m, 12H), 0.93 – 0.81 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 174.6, 61.1, 36.2, 35.7, 33.5, 32.1, 31.9, 29.6, 26.6, 26.4, 22.6, 14.1, 
10.8. 
FT-IR (film): 2957, 2924, 2855, 1662, 1457, 1379, 1006, 749 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C13H28NO2: 230.2115, found: 230.2118. 
[]24D = 2.3 (c 1.0, CHCl3); 88% ee from (S)-L1.
S–49 
3-Cyclohexyl-N-methoxy-N-methylpentanamide (Fig. 2, entry 38).  The title compound
was synthesized according to GP-8 from iodocyclohexane and zinc nucleophile Zn-13.  The 
product was purified by column chromatography on silica gel (1:20 EtOAc/hexanes).  Pale-
yellow oil. 
(R)-L1: 122 mg, 90% yield, 88% ee; (S)-L1: 124 mg, 91% yield, 88% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 6.6 min 
(minor), 7.7 min (major). 
1H NMR (400 MHz, CDCl3) δ 3.70 (s, 3H), 3.20 (s, 3H), 2.42 (dd, J = 15.3, 5.9 Hz, 1H), 2.28 (dd, 
J = 15.3, 7.6 Hz, 1H), 1.85 – 1.71 (m, 3H), 1.70 – 1.58 (m, 3H), 1.47 – 1.33 (m, 2H), 1.32 – 1.15 (m, 
3H), 1.15 – 0.94 (m, 3H), 0.89 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.1, 61.1, 41.1, 40.0, 33.2, 32.2, 30.0, 29.2, 26.83, 26.79, 26.78, 
23.8, 11.8. 
FT-IR (film): 2921, 2850, 1662, 1447, 1380, 1008, 749 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C23H26NO2: 228.1958, found: 228.1961. 
[]24D = 9.1 (c 1.0, CHCl3); 88% ee from (S)-L1.
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-N-phenyloctanamide (Fig. 3, entry 
1).  The title compound was synthesized according to GP-9 from benzyl(3-bromohept-1-yn-1-
yl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 228 mg, 73% yield, 92% ee, 98:2 dr; 
(S,R)-L2: 232 mg, 74% yield, 92% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
8.8 min (major), 9.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.38 (m, 4H), 7.34 – 7.27 (m, 2H), 7.27 – 7.18 (m, 5H), 7.12 
(tt, J = 7.4, 1.3 Hz, 1H), 7.01 – 6.82 (m, 6H), 6.82 – 6.73 (m, 2H), 4.53 (tt, J = 12.1, 3.6 Hz, 1H), 2.61 – 
2.55 (m, 1H), 2.53 (d, J = 14.0 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.02 – 1.83 (m, 3H), 1.80 – 1.58 (m, 
4H), 1.52 – 1.20 (m, 10H), 1.03 – 0.74 (m, 7H), 0.68 (t, J = 7.4 Hz, 3H). 
 S–50 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.1, 137.8, 134.9, 134.8, 134.4, 134.3, 130.5, 130.1, 129.51, 
129.48, 129.2, 129.0, 128.9, 128.0, 127.8, 127.71, 127.67, 124.3, 114.6, 80.6, 54.0, 39.8, 37.5, 36.7, 32.6, 
31.7, 31.6, 30.2, 25.80, 25.78, 25.4, 24.6, 22.6, 22.3, 14.0, 11.9. 
FT-IR (film): 3024, 2931, 2858, 2162, 1651, 1596, 1395, 1111, 769, 733, 697 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C43H52NOSi: 626.3813, found: 626.3813. 
[]22D = 20.1 (c 1.0, CHCl3); 92% ee, 98:2 dr from (S,R)-L2. 
 
 
 
6-(Benzyldiphenylsilyl)-N-cyclohexyl-3-ethyl-4-phenethyl-N-phenylhex-5-ynamide (Fig. 3, 
entry 2).  The title compound was synthesized according to GP-9 from benzyl(3-bromo-5-
phenylpent-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified by 
column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  White foamy solid. 
(R,S)-L2: 252 mg, 75% yield, 89% ee, 98:2 dr; 
(S,R)-L2: 251 mg, 75% yield, 90% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
12.6 min (major), 18.5 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.41 (m, 4H), 7.36 – 7.29 (m, 2H), 7.28 – 7.16 (m, 7H), 7.15 
– 7.05 (m, 4H), 7.01 – 6.88 (m, 5H), 6.87 – 6.75 (m, 3H), 4.50 (tt, J = 12.1, 3.5 Hz, 1H), 2.77 (ddd, J = 
13.7, 10.1, 5.0 Hz, 1H), 2.68 – 2.40 (m, 4H), 2.01 – 1.86 (m, 3H), 1.76 – 1.59 (m, 6H), 1.52 – 1.43 (m, 
1H), 1.41 – 1.23 (m, 3H), 1.02 – 0.77 (m, 4H), 0.66 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 142.1, 139.0, 137.8, 134.9, 134.8, 134.3, 134.2, 130.4, 130.0, 
129.60, 129.57, 129.3, 129.0, 128.9, 128.5, 128.3, 128.0, 127.83, 127.78, 127.7, 125.7, 124.4, 113.9, 81.4, 
54.1, 40.1, 37.5, 36.5, 35.0, 34.3, 31.65, 31.55, 25.8, 25.4, 24.6, 22.5, 11.9. 
FT-IR (film): 3061, 3026, 2927, 2856, 2164, 1651, 1596, 1493, 1395, 1113, 745 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C47H52NOSi: 674.3813, found: 674.3822. 
[]22D = 9.4 (c 1.0, CHCl3); 90% ee, 98:2 dr from (S,R)-L2. 
 
 
 
6-(Benzyldiphenylsilyl)-N-cyclohexyl-3-ethyl-4-methyl-N-phenylhex-5-ynamide (Fig. 3, 
entry 3).  The title compound was synthesized according to GP-9 from benzyl(3-bromobut-1-
yn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 223 mg, 77% yield, 90% ee, 98:2 dr; 
 S–51 
(S,R)-L2: 228 mg, 78% yield, 90% ee, 98:2 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK AD-3 column (15.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 8.1 min (major), 9.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.60 – 7.48 (m, 4H), 7.46 – 7.30 (m, 7H), 7.25 (tt, J = 7.4, 1.1 Hz, 
1H), 7.13 – 6.94 (m, 6H), 6.93 – 6.84 (m, 2H), 4.64 (tt, J = 12.1, 3.6 Hz, 1H), 2.82 (qd, J = 7.1, 3.6 Hz, 
1H), 2.64 (d, J = 13.9 Hz, 1H), 2.60 (d, J = 13.9 Hz, 1H), 2.17 – 1.91 (m, 3H), 1.91 – 1.70 (m, 4H), 
1.65 – 1.54 (m, 1H), 1.53 – 1.34 (m, 3H), 1.19 (d, J = 7.1 Hz, 3H), 1.15 – 0.86 (m, 4H), 0.80 (t, J = 7.4 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.1, 137.8, 134.89, 134.85, 134.24, 134.21, 130.5, 130.1, 
129.54, 129.51, 129.2, 129.0, 128.9, 128.0, 127.8, 127.73, 127.69, 124.3, 115.4, 79.8, 54.1, 41.1, 37.4, 
31.7, 31.6, 30.3, 25.81, 25.79, 25.4, 24.6, 22.1, 18.6, 11.9. 
FT-IR (film): 3050, 3024, 2932, 2344, 2166, 1646, 1394, 1110, 737, 702 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C40H46NOSi: 584.3343, found: 584.3343. 
[]22D = 33.1 (c 1.0, CHCl3); 90% ee, 98:2 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-6-methyl-N-phenylheptanamide 
(Fig. 3, entry 4).  The title compound was synthesized according to GP-9 from benzyl(3-bromo-
5-methylhex-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified 
by column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 190 mg, 61% yield, 95% ee, 99:1 dr; 
(S,R)-L2: 197 mg, 63% yield, 95% ee, 99:1 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK IC-3 column (15.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 5.2 min (major), 5.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.48 – 7.37 (m, 4H), 7.35 – 7.19 (m, 7H), 7.12 (tt, J = 7.4, 1.3 Hz, 
1H), 7.02 – 6.82 (m, 6H), 6.83 – 6.72 (m, 2H), 4.53 (tt, J = 12.1, 3.6 Hz, 1H), 2.67 (ddd, J = 10.1, 5.4, 
3.4 Hz, 1H), 2.53 (d, J = 13.9 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.04 – 1.80 (m, 3H), 1.80 – 1.58 (m, 
5H), 1.53 – 1.43 (m, 1H), 1.43 – 1.23 (m, 4H), 1.11 (ddd, J = 13.1, 8.7, 5.4 Hz, 1H), 1.03 – 0.74 (m, 
10H), 0.68 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.1, 137.8, 134.9, 134.8, 134.4, 134.3, 130.5, 130.1, 129.51, 
129.48, 129.2, 129.0, 128.9, 128.0, 127.8, 127.72, 127.68, 124.3, 114.6, 80.5, 53.9, 41.7, 39.9, 37.6, 34.5, 
31.7, 31.6, 26.1, 25.79, 25.77, 25.4, 24.6, 23.2, 22.3, 21.9, 12.0. 
FT-IR (film): 3067, 2929, 2857, 2163, 1651, 1393, 1112, 769, 734, 703 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C43H52NOSi: 626.3813, found: 626.3848. 
 S–52 
[]22D = 24.8 (c 1.0, CHCl3); 95% ee, 99:1 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-7-((tert-butyldimethylsilyl)oxy)-N-cyclohexyl-3-ethyl-N-
phenylheptanamide (Fig. 3, entry 5).  The title compound was synthesized according to GP-9 
from benzyl(3-bromo-6-((tert-butyldimethylsilyl)oxy)hex-1-yn-1-yl)diphenylsilane and zinc 
nucleophile Zn-10.  The product was purified by column chromatography on silica gel (1:30  
1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 248 mg, 67% yield, 90% ee, 99:1 dr; 
(S,R)-L2: 248 mg, 67% yield, 91% ee, 99:1 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK IF-3 column (15.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 9.8 min (major), 11.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.43 (m, 4H), 7.38 – 7.23 (m, 7H), 7.17 (tt, J = 7.4, 1.0 Hz, 
1H), 7.05 – 6.92 (m, 5H), 6.92 – 6.85 (m, 1H), 6.85 – 6.78 (m, 2H), 4.56 (tt, J = 12.1, 3.6 Hz, 1H), 3.64 
– 3.51 (m, 2H), 2.62 (td, J = 7.6, 2.9 Hz, 1H), 2.57 (d, J = 13.9 Hz, 1H), 2.52 (d, J = 13.9 Hz, 1H), 2.07 
– 1.86 (m, 3H), 1.83 – 1.63 (m, 5H), 1.60 – 1.43 (m, 4H), 1.43 – 1.25 (m, 3H), 1.09 – 0.90 (m, 3H), 
0.89 – 0.81 (m, 10H), 0.72 (t, J = 7.4 Hz, 3H), 0.00 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 139.1, 137.8, 134.9, 134.8, 134.3, 134.2, 130.5, 130.1, 129.52, 
129.48, 129.2, 129.0, 128.9, 128.0, 127.8, 127.72, 127.68, 124.3, 114.3, 80.8, 63.0, 54.0, 39.8, 37.5, 36.4, 
31.7, 31.6, 31.2, 29.1, 26.0, 25.80, 25.78, 25.4, 24.6, 22.3, 18.3, 11.9, -5.3. 
FT-IR (film): 3050, 3024, 2932, 2857, 2164, 1651, 1394, 1253, 1110, 767, 704 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C48H63NO2Si2Na: 764.4290, found: 764.4287. 
[]22D = 15.4 (c 1.0, CHCl3); 91% ee, 99:1 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-8-(benzyloxy)-N-cyclohexyl-3-ethyl-N-
phenyloctanamide (Fig. 3, entry 6).  The title compound was synthesized according to GP-9 
from benzyl(7-(benzyloxy)-3-bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  
The product was purified by column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  
Pale-yellow oil. 
(R,S)-L2: 285 mg, 78% yield, 92% ee, 98:2 dr; 
(S,R)-L2: 265 mg, 73% yield, 92% ee, 99:1 dr. 
 S–53 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
15.1 min (major), 16.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.48 – 7.36 (m, 4H), 7.34 – 7.16 (m, 12H), 7.12 (t, J = 7.4 Hz, 1H), 
7.01 – 6.81 (m, 6H), 6.81 – 6.71 (m, 2H), 4.52 (tt, J = 12.1, 3.6 Hz, 1H), 4.41 (s, 2H), 3.37 (t, J = 6.5 Hz, 
2H), 2.58 (dt, J = 9.0, 4.1 Hz, 1H), 2.52 (d, J = 13.9 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.03 – 1.82 (m, 
3H), 1.78 – 1.60 (m, 4H), 1.58 – 1.27 (m, 10H), 1.01 – 0.73 (m, 4H), 0.67 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 139.0, 138.6, 137.8, 134.9, 134.8, 134.32, 134.26, 130.5, 
130.1, 129.53, 129.50, 129.2, 129.0, 128.9, 128.3, 128.0, 127.8, 127.72, 127.68, 127.59, 127.4, 124.3, 
114.3, 80.8, 72.8, 70.4, 54.0, 39.8, 37.5, 36.7, 32.7, 31.7, 31.6, 29.6, 25.79, 25.78, 25.4, 24.62, 24.61, 22.3, 
11.9. 
FT-IR (film): 3062, 3025, 2933, 2857, 2163, 1651, 1594, 1395, 1111, 735, 700 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C50H57NO2SiNa: 754.4051, found: 754.4059. 
[]22D = 13.6 (c 1.0, CHCl3); 92% ee, 99:1 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-7-(naphthalen-2-yloxy)-N-
phenylheptanamide (Fig. 3, entry 7).  The title compound was synthesized according to GP-9 
from benzyl(3-bromo-6-(naphthalen-2-yloxy)hex-1-yn-1-yl)diphenylsilane and zinc nucleophile 
Zn-10.  The product was purified by column chromatography on silica gel (1:30  1:10 
EtOAc/hexanes).  White foamy solid. 
(R,S)-L2: 298 mg, 79% yield, 91% ee, 99:1 dr; 
(S,R)-L2: 314 mg, 83% yield, 91% ee, 99:1 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(4.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
17.8 min (major), 19.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.76 – 7.63 (m, 3H), 7.58 – 7.47 (m, 4H), 7.42 – 7.24 (m, 9H), 7.20 
– 7.07 (m, 3H), 7.07 – 6.89 (m, 6H), 6.86 (d, J = 7.2 Hz, 2H), 4.57 (tt, J = 12.1, 3.7 Hz, 1H), 4.12 – 
3.97 (m, 2H), 2.83 – 2.66 (m, 1H), 2.59 (d, J = 13.9 Hz, 1H), 2.55 (d, J = 13.9 Hz, 1H), 2.16 – 1.83 (m, 
5H), 1.83 – 1.61 (m, 6H), 1.57 – 1.28 (m, 4H), 1.11 – 0.82 (m, 4H), 0.75 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 157.0, 139.0, 137.8, 134.83, 134.79, 134.6, 134.19, 134.16, 
130.4, 130.0, 129.55, 129.53, 129.24, 129.21, 128.93, 128.87, 128.83, 128.0, 127.8, 127.74, 127.71, 127.5, 
126.7, 126.2, 124.4, 123.4, 119.0, 113.9, 106.5, 81.2, 67.6, 54.0, 39.9, 37.4, 36.5, 31.6, 31.5, 29.5, 27.7, 
25.7, 25.3, 24.5, 22.3, 11.9. 
FT-IR (film): 3056, 3023, 2931, 2858, 2165, 1649, 1633, 1598, 1391, 1112, 733, 702 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C52H56NO2Si: 754.4075, found: 754.4079. 
[]22D = 11.4 (c 1.0, CHCl3); 91% ee, 99:1 dr from (S,R)-L2. 
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4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-7-(5,5-dimethyl-1,3-dioxan-2-yl)-3-ethyl-N-
phenylheptanamide (Fig. 3, entry 8).  The title compound was synthesized according to GP-9 
from benzyl(3-bromo-6-(5,5-dimethyl-1,3-dioxan-2-yl)hex-1-yn-1-yl)diphenylsilane and zinc 
nucleophile Zn-10.  The product was purified by column chromatography on silica gel (1:30  
1:10 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 266 mg, 73% yield, 88% ee, 98:2 dr; 
(S,R)-L2: 265 mg, 73% yield, 89% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(4.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
9.0 min (minor), 10.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.35 (m, 4H), 7.34 – 7.20 (m, 7H), 7.12 (t, J = 7.4 Hz, 1H), 
7.03 – 6.87 (m, 5H), 6.87 – 6.81 (m, 1H), 6.79 (d, J = 6.9 Hz, 2H), 4.51 (tt, J = 12.1, 3.6 Hz, 1H), 4.30 
(t, J = 4.7 Hz, 1H), 3.51 (dt, J = 11.1, 2.6 Hz, 2H), 3.32 (dd, J = 11.1, 5.3 Hz, 2H), 2.61 – 2.55 (m, 1H), 
2.53 (d, J = 13.9 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.01 – 1.85 (m, 3H), 1.77 – 1.56 (m, 6H), 1.55 – 
1.44 (m, 2H), 1.44 – 1.24 (m, 6H), 1.11 (s, 3H), 1.00 – 0.77 (m, 4H), 0.67 (t, J = 7.4 Hz, 3H), 0.63 (s, 
3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 139.0, 137.8, 134.9, 134.8, 134.32, 134.26, 130.5, 130.0, 
129.49, 129.45, 129.2, 128.9, 128.8, 128.0, 127.8, 127.70, 127.66, 124.3, 114.2, 102.1, 80.8, 77.2, 54.0, 
39.7, 37.5, 36.7, 34.7, 32.6, 31.64, 31.57, 30.1, 25.8, 25.4, 24.6, 23.0, 22.6, 22.3, 21.8, 11.9. 
FT-IR (film): 3049, 2935, 2858, 2162, 1651, 1392, 1116, 749 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C48H60NO3Si: 726.4337, found: 726.4339. 
[]22D = 8.3 (c 1.0, CHCl3); 89% ee, 98:2 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-N-phenylpentadec-12-ynamide 
(Fig. 3, entry 9).  The title compound was synthesized according to GP-9 from benzyl(3-
bromotetradeca-1,11-diyn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  The product was 
purified by column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 283 mg, 79% yield, 90% ee, 99:1 dr; 
(S,R)-L2: 273 mg, 76% yield, 91% ee, 98:2 dr. 
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HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
7.8 min (major), 8.9 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.35 (m, 4H), 7.35 – 7.20 (m, 7H), 7.13 (t, J = 7.4 Hz, 1H), 
7.02 – 6.82 (m, 6H), 6.82 – 6.73 (m, 2H), 4.53 (tt, J = 12.1, 3.6 Hz, 1H), 2.65 – 2.37 (m, 3H), 2.16 – 
2.01 (m, 4H), 2.01 – 1.81 (m, 3H), 1.79 – 1.57 (m, 4H), 1.52 – 1.17 (m, 16H), 1.04 (t, J = 7.3 Hz, 3H), 
1.01 – 0.75 (m, 4H), 0.68 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.1, 137.8, 134.9, 134.8, 134.4, 134.3, 130.5, 130.1, 129.52, 
129.49, 129.2, 129.0, 128.9, 128.0, 127.8, 127.72, 127.67, 124.3, 114.6, 81.6, 80.6, 79.6, 54.0, 39.9, 37.5, 
36.8, 32.9, 31.7, 31.6, 29.4, 29.2, 29.1, 28.9, 28.0, 25.8, 25.4, 24.6, 22.3, 18.7, 14.4, 12.4, 11.9. 
FT-IR (film): 3049, 2932, 2857, 2163, 1651, 1394, 1112, 765, 733, 702 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C50H61NOSiNa: 742.4415, found: 742.4415. 
[]22D = 12.9 (c 1.0, CHCl3); 91% ee, 98:2 dr from (S,R)-L2. 
 
 
 
(Z)-4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-N-phenyltridec-10-enamide 
(Fig. 3, entry 10).  The title compound was synthesized according to GP-9 from (Z)-benzyl(3-
bromododec-9-en-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  The product was 
purified by column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 260 mg, 75% yield, 90% ee, 98:2 dr; 
(S,R)-L2: 266 mg, 77% yield, 92% ee, 98:2 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK IE-3 column (20.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 5.8 min (major), 6.4 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.37 (m, 4H), 7.35 – 7.18 (m, 7H), 7.13 (tt, J = 7.4, 1.3 Hz, 
1H), 7.03 – 6.83 (m, 6H), 6.83 – 6.72 (m, 2H), 5.38 – 5.17 (m, 2H), 4.52 (tt, J = 12.1, 3.6 Hz, 1H), 2.63 
– 2.42 (m, 3H), 2.07 – 1.83 (m, 7H), 1.83 – 1.56 (m, 4H), 1.52 – 1.19 (m, 12H), 1.02 – 0.75 (m, 7H), 
0.68 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.1, 137.8, 134.9, 134.8, 134.4, 134.3, 131.5, 130.5, 130.1, 
129.52, 129.48, 129.2, 129.0, 128.9, 128.0, 127.8, 127.72, 127.67, 124.3, 114.6, 80.6, 54.0, 39.8, 37.5, 
36.8, 32.9, 31.7, 31.6, 29.7, 29.2, 27.9, 27.1, 25.80, 25.79, 25.4, 24.6, 22.3, 20.5, 14.4, 11.9. 
FT-IR (film): 3001, 2926, 2858, 2163, 1651, 1595, 1393, 1110, 768, 734, 704 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C48H60NOSi: 694.4439, found: 694.4441. 
[]22D = 13.8 (c 1.0, CHCl3); 92% ee, 98:2 dr from (S,R)-L2. 
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Methyl 6-((benzyldiphenylsilyl)ethynyl)-9-(cyclohexyl(phenyl)amino)-7-ethyl-9-
oxononanoate (Fig. 3, entry 11).  The title compound was synthesized according to GP-9 from 
methyl 8-(benzyldiphenylsilyl)-6-bromooct-7-ynoate and zinc nucleophile Zn-10.  The product 
was purified by column chromatography on silica gel (1:10  1:5 EtOAc/hexanes).  Colorless 
oil. 
(R,S)-L2: 249 mg, 73% yield, 93% ee, 99:1 dr; 
(S,R)-L2: 250 mg, 73% yield, 93% ee, 99:1 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
22.2 min (major), 25.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.40 (m, 4H), 7.34 – 7.21 (m, 7H), 7.16 – 7.10 (m, 1H), 7.00 
– 6.89 (m, 5H), 6.88 – 6.81 (m, 1H), 6.81 – 6.73 (m, 2H), 4.52 (tt, J = 12.1, 3.6 Hz, 1H), 3.56 (s, 3H), 
2.63 – 2.55 (m, 1H), 2.53 (d, J = 13.9 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.27 – 2.13 (m, 2H), 2.01 – 
1.84 (m, 3H), 1.79 – 1.60 (m, 4H), 1.57 – 1.25 (m, 10H), 1.01 – 0.74 (m, 4H), 0.67 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 174.1, 171.5, 139.0, 137.8, 134.84, 134.80, 134.3, 134.2, 130.5, 
130.0, 129.6, 129.5, 129.3, 128.94, 128.88, 128.0, 127.8, 127.74, 127.70, 124.4, 114.1, 80.9, 54.0, 51.4, 
39.8, 37.4, 36.6, 34.0, 32.5, 31.7, 31.6, 27.6, 25.79, 25.77, 25.4, 24.8, 24.6, 22.2, 11.9. 
FT-IR (film): 3024, 2929, 2857, 2163, 1732, 1651, 1595, 1395, 1110, 769, 735, 708 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C45H54NO3Si: 684.3867, found: 684.3859. 
[]22D = 13.4 (c 1.0, CHCl3); 93% ee, 99:1 dr from (S,R)-L2. 
 
 
 
5-((Benzyldiphenylsilyl)ethynyl)-8-(cyclohexyl(phenyl)amino)-6-ethyl-8-oxooctyl acetate 
(Fig. 3, entry 12).  The title compound was synthesized according to GP-9 from 7-
(benzyldiphenylsilyl)-5-bromohept-6-yn-1-yl acetate and zinc nucleophile Zn-10.  The product 
was purified by column chromatography on silica gel (1:15  1:5 EtOAc/hexanes).  Colorless 
oil. 
(R,S)-L2: 265 mg, 78% yield, 92% ee, 99:1 dr; 
(S,R)-L2: 246 mg, 72% yield, 92% ee, 99:1 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(4.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
15.4 min (major), 19.1 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.46 – 7.38 (m, 4H), 7.32 – 7.27 (m, 2H), 7.27 – 7.19 (m, 5H), 7.13 
(t, J = 7.3 Hz, 1H), 6.98 – 6.83 (m, 6H), 6.83 – 6.72 (m, 2H), 4.52 (tt, J = 12.1, 3.6 Hz, 1H), 3.96 (t, J = 
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6.3 Hz, 2H), 2.60 (td, J = 8.4, 4.1 Hz, 1H), 2.53 (d, J = 13.8 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.00 – 
1.84 (m, 6H), 1.78 – 1.60 (m, 4H), 1.59 – 1.42 (m, 5H), 1.40 – 1.25 (m, 5H), 0.99 – 0.74 (m, 4H), 0.67 
(t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 171.1, 139.0, 137.7, 134.80, 134.76, 134.22, 134.16, 130.4, 
130.0, 129.55, 129.52, 129.2, 128.91, 128.86, 128.0, 127.74, 127.72, 127.68, 124.3, 114.0, 81.0, 64.4, 
54.0, 39.8, 37.4, 36.6, 32.5, 31.6, 31.5, 28.4, 25.8, 25.7, 25.3, 24.5, 24.4, 22.2, 20.9, 11.9. 
FT-IR (film): 3048, 3024, 2931, 2858, 2165, 1737, 1651, 1240, 1112, 706, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C45H54NO3Si: 684.3867, found: 684.3871. 
[]22D = 14.3 (c 1.0, CHCl3); 92% ee, 99:1 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-8-chloro-N-cyclohexyl-3-ethyl-N-phenyloctanamide (Fig. 
3, entry 13).  The title compound was synthesized according to GP-9 from benzyl(3-bromo-7-
chlorohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified by 
column chromatography on silica gel (1:30  1:10 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 230 mg, 70% yield, 92% ee, 99:1 dr; 
(S,R)-L2: 234 mg, 71% yield, 93% ee, 99:1 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK AD-3 column (20.0% 
2-PrOH in supercritical CO2, 2.5 ml/min); retention times for compound obtained using (R, S)-L*: 
5.4 min (major), 5.8 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.61 – 7.47 (m, 4H), 7.45 – 7.29 (m, 7H), 7.24 (t, J = 7.3 Hz, 1H), 
7.12 – 6.99 (m, 5H), 6.95 (d, J = 8.0 Hz, 1H), 6.92 – 6.84 (m, 2H), 4.62 (tt, J = 12.1, 3.6 Hz, 1H), 3.51 
(t, J = 6.7 Hz, 2H), 2.74 – 2.67 (m, 1H), 2.64 (d, J = 13.9 Hz, 1H), 2.59 (d, J = 13.9 Hz, 1H), 2.13 – 
1.91 (m, 3H), 1.87 – 1.70 (m, 6H), 1.65 – 1.34 (m, 8H), 1.11 – 0.88 (m, 4H), 0.78 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 139.0, 137.8, 134.82, 134.78, 134.2, 134.1, 130.4, 130.0, 
129.55, 129.52, 129.2, 128.92, 128.87, 128.0, 127.74, 127.72, 127.68, 124.3, 113.9, 81.1, 54.0, 44.8, 39.8, 
37.4, 36.5, 32.4, 32.1, 31.6, 31.5, 25.8, 25.3, 24.5, 22.2, 11.9. 
FT-IR (film): 3049, 2929, 2857, 2164, 1645, 1595, 1394, 1111, 760, 734, 707 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C43H51ClNOSi: 660.3423, found: 660.3418. 
[]22D = 13.8 (c 1.0, CHCl3); 93% ee, 99:1 dr from (S,R)-L2. 
 
 
 
6-(Benzyldiphenylsilyl)-N-cyclohexyl-3-ethyl-4-(2-(5-methylfuran-2-yl)ethyl)-N-
phenylhex-5-ynamide (Fig. 3, entry 14).  The title compound was synthesized according to 
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GP-9 from benzyl(3-bromo-5-(5-methylfuran-2-yl)pent-1-yn-1-yl)diphenylsilane and zinc 
nucleophile Zn-10.  The product was purified by column chromatography on silica gel (1:30  
1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 286 mg, 84% yield, 88% ee, 98:2 dr; 
(S,R)-L2: 272 mg, 80% yield, 90% ee, 98:2 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK IE-3 column (20.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 6.4 min (major), 7.5 min (minor).  
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.40 (m, 4H), 7.35 – 7.28 (m, 2H), 7.28 – 7.19 (m, 5H), 7.12 
(t, J = 7.4 Hz, 1H), 7.01 – 6.88 (m, 5H), 6.88 – 6.75 (m, 3H), 5.80 – 5.71 (m, 2H), 4.51 (tt, J = 12.1, 3.5 
Hz, 1H), 2.79 – 2.66 (m, 1H), 2.66 – 2.42 (m, 4H), 2.18 (s, 3H), 2.03 – 1.85 (m, 3H), 1.78 – 1.59 (m, 
6H), 1.53 – 1.43 (m, 1H), 1.39 – 1.23 (m, 3H), 1.06 – 0.79 (m, 4H), 0.68 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 153.8, 150.2, 139.0, 137.8, 134.9, 134.8, 134.22, 134.17, 
130.4, 130.1, 129.6, 129.5, 129.2, 128.94, 128.87, 128.0, 127.82, 127.75, 127.7, 124.4, 113.6, 105.7, 
105.5, 81.4, 54.1, 40.0, 37.5, 36.3, 31.65, 31.57, 31.4, 26.6, 25.80, 25.78, 25.4, 24.6, 22.5, 13.5, 11.9. 
FT-IR (film): 3048, 3025, 2933, 2857, 2164, 1650, 1394, 1112, 759, 741, 710 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C46H51NO2SiNa: 700.3581, found: 700.3582. 
[]22D = 7.4 (c 1.0, CHCl3); 90% ee, 98:2 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-7-(((8R,9S,13S,14S)-13-methyl-
6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-
yl)oxy)-N-phenylheptanamide (Fig. 3, entry 15).  The title compound was synthesized 
according to GP-9 from benzyl(3-bromo-6-(((8R,9S,13S,14S)-13-methyl-6,7,8,9,11,12,13,14,15,16-
decahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3-yl)oxy)hex-1-yn-1-
yl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified by column 
chromatography on silica gel (1:30  1:10 EtOAc/hexanes).  White solid. 
(R,S)-L2: 345 mg, 75% yield, 6:94 dr; 
(S,R)-L2: 321 mg, 69% yield, 94:6 dr. 
SFC analysis: The dr was determined via SFC on a CHIRALPAK AD-3 column (30.0% 2-
PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-L2: 
7.8 min (major), 10.0 min (minor). 
NMR data for the product from (R,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.39 (m, 4H), 7.33 – 7.27 (m, 2H), 7.27 – 7.20 (m, 5H), 7.15 
– 7.06 (m, 2H), 7.00 – 6.88 (m, 5H), 6.85 (d, J = 7.9 Hz, 1H), 6.81 – 6.73 (m, 2H), 6.61 (dd, J = 8.6, 2.8 
Hz, 1H), 6.54 (d, J = 2.7 Hz, 1H), 4.51 (tt, J = 12.1, 3.6 Hz, 1H), 3.90 – 3.79 (m, 6H), 2.84 – 2.67 (m, 
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2H), 2.67 – 2.57 (m, 1H), 2.53 (d, J = 13.8 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.23 (dq, J = 12.6, 3.6 
Hz, 1H), 2.15 (td, J = 10.6, 4.1 Hz, 1H), 2.02 – 1.84 (m, 5H), 1.84 – 1.66 (m, 7H), 1.62 – 1.43 (m, 7H), 
1.41 – 1.23 (m, 7H), 1.03 – 0.84 (m, 3H), 0.80 (s, 4H), 0.67 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 156.9, 139.0, 137.9, 137.8, 134.84, 134.80, 134.23, 134.19, 
132.5, 130.4, 130.0, 129.53, 129.51, 129.2, 128.94, 128.87, 128.0, 127.8, 127.74, 127.71, 126.2, 124.3, 
119.4, 114.4, 113.9, 112.0, 81.1, 67.5, 65.2, 64.5, 54.0, 49.3, 46.1, 43.6, 39.9, 39.0, 37.4, 36.5, 34.2, 31.64, 
31.56, 30.7, 29.8, 29.4, 27.8, 27.0, 26.1, 25.78, 25.77, 25.3, 24.6, 22.3, 14.3, 11.9. 
NMR data for the product from (S,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.39 (m, 4H), 7.35 – 7.18 (m, 7H), 7.16 – 7.07 (m, 2H), 7.03 
– 6.82 (m, 6H), 6.82 – 6.73 (m, 2H), 6.61 (dd, J = 8.6, 2.7 Hz, 1H), 6.54 (d, J = 2.7 Hz, 1H), 4.51 (tt, J 
= 12.1, 3.6 Hz, 1H), 3.96 – 3.73 (m, 6H), 2.85 – 2.67 (m, 2H), 2.67 – 2.58 (m, 1H), 2.53 (d, J = 13.9 Hz, 
1H), 2.48 (d, J = 13.9 Hz, 1H), 2.29 – 2.10 (m, 2H), 2.03 – 1.84 (m, 5H), 1.82 – 1.59 (m, 9H), 1.58 – 
1.43 (m, 5H), 1.41 – 1.24 (m, 7H), 1.03 – 0.85 (m, 3H), 0.80 (s, 4H), 0.67 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 156.9, 139.0, 137.9, 137.8, 134.85, 134.81, 134.24, 134.19, 
132.5, 130.4, 130.0, 129.54, 129.52, 129.2, 128.95, 128.88, 128.0, 127.80, 127.75, 127.71, 126.2, 124.4, 
119.4, 114.5, 113.9, 112.0, 81.1, 67.5, 65.2, 64.5, 54.0, 49.3, 46.1, 43.6, 39.9, 39.1, 37.4, 36.5, 34.2, 31.65, 
31.57, 30.7, 29.8, 29.5, 27.8, 27.0, 26.1, 25.79, 25.78, 25.4, 24.6, 22.3, 14.3, 11.9. 
FT-IR (film): 2927, 2165, 1644, 1493, 1241, 1110, 732, 703 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C62H74NO4Si: 924.5382, found: 924.5379. 
[]22D = 0.8 (c 1.0, CHCl3); 94:6 dr from (R,S)-L2. 
[]22D = 20.3 (c 1.0, CHCl3); 6:94 dr from (S,R)-L2. 
 
 
 
N-Cyclohexyl-3-ethyl-4-((ethyldiphenylsilyl)ethynyl)-N-phenyloctanamide (Fig. 3, entry 
16).  The title compound was synthesized according to GP-9 from (3-bromohept-1-yn-1-
yl)(ethyl)diphenylsilane and zinc nucleophile Zn-10.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 180 mg, 64% yield, 91% ee, 99:1 dr; 
(S,R)-L2: 176 mg, 63% yield, 91% ee, 99:1 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
6.1 min (major), 6.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.56 – 7.46 (m, 4H), 7.37 – 7.18 (m, 7H), 7.18 – 7.11 (m, 1H), 7.03 
– 6.82 (m, 3H), 4.53 (tt, J = 12.1, 3.6 Hz, 1H), 2.69 – 2.55 (m, 1H), 2.08 – 1.86 (m, 3H), 1.80 – 1.68 (m, 
2H), 1.68 – 1.55 (m, 2H), 1.53 – 1.21 (m, 10H), 1.17 – 1.06 (m, 1H), 1.01 – 0.87 (m, 7H), 0.87 – 0.77 
(m, 4H), 0.72 (t, J = 7.4 Hz, 3H). 
S–60 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.0, 135.3, 135.1, 134.7, 134.6, 130.5, 130.1, 129.31, 
129.28, 129.2, 128.9, 127.9, 127.7, 113.5, 81.0, 54.0, 39.7, 37.7, 36.7, 32.7, 31.63, 31.59, 30.2, 25.8, 25.4, 
22.6, 22.5, 14.0, 12.0, 7.5, 6.4. 
FT-IR (film): 3067, 3048, 2929, 2858, 2162, 1658, 1651, 1595, 1393, 1111, 704, 696 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C38H49NOSiNa: 586.3476, found: 586.3480. 
[]22D = 18.7 (c 1.0, CHCl3); 91% ee, 99:1 dr from (S,R)-L2.
N-Cyclohexyl-3-ethyl-N-phenyl-4-((triphenylsilyl)ethynyl)octanamide (Fig. 3, entry 17).
The title compound was synthesized according to GP-9 from (3-bromohept-1-yn-1-
yl)triphenylsilane and zinc nucleophile Zn-10.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 221 mg, 72% yield, 91% ee, 99:1 dr; 
(S,R)-L2: 221 mg, 72% yield, 90% ee, 99:1 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
6.1 min (major), 7.4 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.42 (m, 6H), 7.37 – 7.29 (m, 3H), 7.29 – 7.17 (m, 7H), 7.13 
– 7.04 (m, 1H), 6.93 (d, J = 7.9 Hz, 1H), 6.89 – 6.74 (m, 2H), 4.52 (tt, J = 12.1, 3.6 Hz, 1H), 2.73 –
2.61 (m, 1H), 2.08 – 1.85 (m, 3H), 1.80 – 1.57 (m, 4H), 1.55 – 1.21 (m, 10H), 1.19 – 1.03 (m, 1H),
0.98 – 0.85 (m, 2H), 0.85 – 0.76 (m, 4H), 0.70 (t, J = 7.4 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 171.6, 139.0, 135.4, 134.3, 130.5, 130.0, 129.6, 129.2, 128.8, 127.9, 
127.7, 114.6, 81.0, 54.0, 39.7, 37.6, 36.6, 32.6, 31.63, 31.58, 30.2, 25.78, 25.77, 25.4, 22.6, 22.5, 14.0, 
11.9. 
FT-IR (film): 3067, 3048, 2932, 2857, 2162, 1651, 1594, 1394, 1112, 704 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C42H50NOSi: 612.3656, found: 612.3660. 
[]22D = 12.0 (c 1.0, CHCl3); 90% ee, 99:1 dr from (S,R)-L2.
N-Cyclohexyl-3-ethyl-N-phenyl-4-((triisopropylsilyl)ethynyl)octanamide (Fig. 3, entry 18).
The title compound was synthesized according to GP-9 from (3-bromohept-1-yn-1-
yl)triisopropylsilane and zinc nucleophile Zn-10.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 105 mg, 41% yield, 91% ee, 99:1 dr; 
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(S,R)-L2: 105 mg, 41% yield, 90% ee, 99:1 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK AD-3 column (5.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 5.1 min (major), 5.6 min (minor).
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.22 (m, 3H), 7.08 – 6.92 (m, 2H), 4.54 (tt, J = 12.1, 3.7 Hz, 
1H), 2.50 – 2.37 (m, 1H), 2.05 – 1.80 (m, 3H), 1.74 (t, J = 12.4 Hz, 2H), 1.64 (d, J = 13.4 Hz, 2H), 1.49 
(d, J = 13.4 Hz, 1H), 1.44 – 1.17 (m, 9H), 1.14 – 1.04 (m, 1H), 0.98 – 0.84 (m, 23H), 0.84 – 0.76 (m, 
4H), 0.71 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.7, 139.2, 130.5, 130.2, 129.2, 129.0, 128.0, 110.8, 81.5, 54.0, 
39.7, 38.1, 36.8, 33.0, 31.6, 30.2, 25.8, 25.4, 22.6, 22.5, 18.7, 18.6, 14.0, 12.0, 11.2. 
FT-IR (film): 2931, 2663, 2161, 1652, 1595, 1461, 1393, 1072, 883, 703, 681 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C33H55NOSiNa: 532.3945, found: 532.3950. 
[]22D = 13.9 (c 1.0, CHCl3); 91% ee, 99:1 dr from (S,R)-L2.
4-((Benzyldiphenylsilyl)ethynyl)-N-butyl-3-ethyl-N-phenyloctanamide (Fig. 3, entry 19).  
The title compound was synthesized according to GP-9 from benzyl(3-bromohept-1-yn-1-
yl)diphenylsilane and zinc nucleophile Zn-14.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 218 mg, 73% yield, 90% ee, 98:2 dr; 
(S,R)-L2: 226 mg, 76% yield, 90% ee, 98:2 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK AD-3 column (15.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 4.1 min (major), 4.4 min (minor).
1H NMR (400 MHz, CDCl3) δ 7.61 – 7.48 (m, 4H), 7.45 – 7.38 (m, 2H), 7.38 – 7.30 (m, 4H), 7.25 
– 7.14 (m, 3H), 7.12 – 6.99 (m, 5H), 6.96 – 6.83 (m, 2H), 3.81 – 3.60 (m, 2H), 2.77 – 2.50 (m, 3H),
2.20 (dd, J = 16.1, 8.8 Hz, 1H), 2.12 (dd, J = 16.1, 4.7 Hz, 1H), 2.08 – 1.92 (m, 1H), 1.60 – 1.28 (m,
11H), 1.09 (ddq, J = 14.3, 9.3, 7.3 Hz, 1H), 1.00 – 0.86 (m, 6H), 0.80 (t, J = 7.4 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 171.9, 142.6, 137.8, 134.9, 134.8, 134.4, 134.3, 129.6, 129.52, 
129.49, 129.0, 128.3, 127.8, 127.72, 127.68, 127.65, 124.3, 114.5, 80.7, 49.1, 39.9, 36.9, 36.6, 32.6, 30.2, 
29.9, 24.6, 22.5, 22.3, 20.1, 14.0, 13.8, 11.9. 
FT-IR (film): 3023, 2957, 2932, 2343, 2163, 1653, 1595, 1494, 1402, 1112, 767, 733, 695 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C41H49NOSiNa: 622.3476, found: 622.3484. 
[]22D = 22.3 (c 1.0, CHCl3); 90% ee, 98:2 dr from (S,R)-L2.
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4-((Benzyldiphenylsilyl)ethynyl)-3-ethyl-N-methoxy-N,6-dimethylheptanamide (Fig. 3, 
entry 20).  The title compound was synthesized according to GP-9 from benzyl(3-bromo-5-
methylhex-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-13.  The product was purified by 
column chromatography on silica gel (1:20  1:10 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 146 mg, 58% yield, 85% ee, 95:5 dr; 
(S,R)-L2: 147 mg, 57% yield, 85% ee, 95:5 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK OD-H column 
(0.5% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
14.1 min (minor), 15.3 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.46 (m, 4H), 7.32 – 7.21 (m, 6H), 7.02 (t, J = 7.3 Hz, 2H), 
6.99 – 6.93 (m, 1H), 6.93 – 6.85 (m, 2H), 3.34 (s, 3H), 3.05 (s, 3H), 2.70 (ddd, J = 10.5, 5.2, 3.4 Hz, 
1H), 2.57 (s, 3H), 2.43 – 2.24 (m, 1H), 1.98 – 1.83 (m, 1H), 1.82 – 1.66 (m, 1H), 1.55 – 1.42 (m, 2H), 
1.33 – 1.13 (m, 2H), 0.89 – 0.81 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ 173.9, 137.8, 135.89, 135.86, 134.85, 134.84, 134.2, 129.6, 129.2, 
129.0, 127.8, 127.72, 127.70, 124.4, 114.6, 80.9, 61.0, 41.3, 39.0, 34.4, 34.2, 32.2, 26.1, 24.5, 23.2, 22.5, 
21.8, 12.0. 
FT-IR (film): 3024, 2954, 2934, 2163, 1667, 1456, 1428, 1385, 1113, 769, 733, 703 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C33H42NO2Si: 512.2979, found: 512.2984. 
[]22D = 24.2 (c 1.0, CHCl3); 85% ee, 95:5 dr from (S,R)-L2. 
 
 
 
3-(1-(Benzyldiphenylsilyl)hept-1-yn-3-yl)-N-cyclohexyl-N-phenylnonanamide (Fig. 3, 
entry 21).  The title compound was synthesized according to GP-9 from benzyl(3-bromohept-1-
yn-1-yl)diphenylsilane and zinc nucleophile Zn-15.  The product was purified by column 
chromatography on silica gel (1:50  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 245 mg, 72% yield, 92% ee, 98:2 dr; 
(S,R)-L2: 244 mg, 72% yield, 91% ee, 98:2 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK AD-3 column (30.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 8.0 min (minor), 9.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.60 – 7.49 (m, 4H), 7.46 – 7.39 (m, 2H), 7.39 – 7.29 (m, 5H), 7.23 
(tt, J = 7.4, 1.1 Hz, 1H), 7.13 – 6.94 (m, 6H), 6.94 – 6.86 (m, 2H), 4.64 (tt, J = 12.1, 3.6 Hz, 1H), 2.73 – 
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2.66 (m, 1H), 2.64 (d, J = 13.7 Hz, 1H), 2.59 (d, J = 13.9 Hz, 1H), 2.17 – 1.92 (m, 3H), 1.91 – 1.67 (m, 
4H), 1.66 – 1.33 (m, 10H), 1.33 – 0.98 (m, 11H), 0.91 (dt, J = 16.9, 7.1 Hz, 7H). 
13C NMR (101 MHz, CDCl3) δ 171.6, 139.1, 137.8, 134.89, 134.85, 134.4, 134.3, 130.5, 130.1, 
129.51, 129.48, 129.2, 129.0, 128.9, 128.0, 127.8, 127.7, 127.6, 124.4, 114.7, 80.6, 54.0, 38.2, 38.1, 36.9, 
32.7, 31.8, 31.7, 31.6, 30.2, 29.6, 29.5, 27.3, 25.80, 25.79, 25.4, 24.7, 22.64, 22.58, 14.09, 14.06. 
FT-IR (film): 3049, 3024, 2929, 2857, 2162, 1651, 1595, 1393, 1112, 701 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C47H60NOSi: 682.4439, found: 682.4453. 
[]22D = 17.9 (c 1.0, CHCl3); 91% ee, 98:2 dr from (S,R)-L2. 
 
 
 
3-Benzyl-4-((benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-N-phenyloctanamide (Fig. 3, 
entry 22).  The title compound was synthesized according to GP-9 from benzyl(3-bromohept-1-
yn-1-yl)diphenylsilane and zinc nucleophile Zn-16.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 207 mg, 60% yield, 95% ee, 97:3 dr; 
(S,R)-L2: 203 mg, 59% yield, 95% ee, 99:1 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK OJ-3 column (10.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 4.0 min (minor), 5.4 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.40 (m, 4H), 7.35 – 7.29 (m, 2H), 7.29 – 7.21 (m, 4H), 7.21 
– 7.04 (m, 5H), 7.01 – 6.92 (m, 3H), 6.92 – 6.82 (m, 5H), 6.82 – 6.64 (m, 2H), 4.45 (tt, J = 12.1, 3.5 Hz, 
1H), 2.76 – 2.70 (m, 1H), 2.67 (dd, J = 13.7, 4.6 Hz, 1H), 2.55 (s, 2H), 2.43 – 2.26 (m, 1H), 2.16 (dd, J 
= 13.8, 10.3 Hz, 1H), 1.96 (dd, J = 16.6, 9.2 Hz, 1H), 1.75 (dd, J = 16.6, 3.9 Hz, 1H), 1.72 – 1.54 (m, 
4H), 1.50 – 1.38 (m, 4H), 1.36 – 1.20 (m, 5H), 0.95 – 0.71 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.2, 140.5, 138.8, 137.8, 134.90, 134.86, 134.3, 134.2, 130.3, 
130.1, 129.59, 129.56, 129.23, 129.16, 129.0, 128.8, 128.1, 127.9, 127.85, 127.75, 127.72, 125.7, 124.4, 
114.3, 81.3, 53.9, 39.8, 37.2, 36.5, 35.8, 32.7, 31.6, 31.5, 30.2, 25.8, 25.7, 25.3, 24.6, 22.6, 14.1. 
FT-IR (film): 3059, 3024, 2930, 2858, 2163, 1651, 1595, 1394, 1111, 763, 694 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C48H54NOSi: 688.3969, found: 688.3987. 
[]22D = 60.6 (c 1.0, CHCl3); 95% ee, 99:1 dr from (S,R)-L2. 
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4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-isobutyl-N-phenyloctanamide (Fig. 3, 
entry 23).  The title compound was synthesized according to GP-9 from benzyl(3-bromohept-1-
yn-1-yl)diphenylsilane and zinc nucleophile Zn-17.  The product was purified by column 
chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 207 mg, 63% yield, 92% ee, 98:2 dr; 
(S,R)-L2: 217 mg, 66% yield, 92% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
5.6 min (major), 6.3 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.61 – 7.50 (m, 4H), 7.46 – 7.39 (m, 2H), 7.39 – 7.30 (m, 5H), 7.26 
– 7.17 (m, 1H), 7.12 – 6.93 (m, 6H), 6.93 – 6.86 (m, 2H), 4.64 (tt, J = 12.1, 3.6 Hz, 1H), 2.75 – 2.67 (m, 
1H), 2.64 (d, J = 13.8 Hz, 1H), 2.60 (d, J = 13.8 Hz, 1H), 2.23 – 2.04 (m, 2H), 1.96 (dd, J = 15.8, 3.4 
Hz, 1H), 1.89 – 1.68 (m, 4H), 1.66 – 1.49 (m, 3H), 1.49 – 1.32 (m, 7H), 1.13 (ddd, J = 13.3, 9.5, 3.5 
Hz, 1H), 1.09 – 0.97 (m, 3H), 0.97 – 0.89 (m, 4H), 0.84 (t, J = 6.3 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 139.0, 137.8, 134.90, 134.86, 134.4, 134.3, 130.5, 130.0, 
129.51, 129.47, 129.2, 129.0, 128.8, 128.0, 127.8, 127.7, 127.6, 124.4, 114.7, 80.6, 54.0, 38.9, 38.3, 36.9, 
35.8, 32.7, 31.7, 31.6, 30.2, 25.80, 25.78, 25.4, 25.3, 24.7, 23.8, 22.6, 21.9, 14.1. 
FT-IR (film): 3049, 2999, 2930, 2858, 2161, 1651, 1596, 1392, 1108, 702 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C45H56NOSi: 654.4126, found: 654.4142. 
[]22D = 18.4 (c 1.0, CHCl3); 92% ee, 98:2 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-3-(4-(benzyloxy)butyl)-N-cyclohexyl-N-
phenyloctanamide (Fig. 3, entry 24).  The title compound was synthesized according to GP-9 
from benzyl(3-bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-18.  The product 
was purified by column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless 
oil. 
(R,S)-L2: 239 mg, 63% yield, 90% ee, 99:1 dr; 
(S,R)-L2: 231 mg, 61% yield, 91% ee, 99:1 dr. 
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SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK IF-3 column (25.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 9.2 min (major), 11.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.35 (m, 4H), 7.33 – 7.15 (m, 12H), 7.09 (t, J = 7.3 Hz, 1H), 
6.99 – 6.81 (m, 6H), 6.78 (d, J = 7.0 Hz, 2H), 4.51 (tt, J = 12.1, 3.7 Hz, 1H), 4.37 (s, 2H), 3.30 (t, J = 
6.5 Hz, 2H), 2.61 – 2.54 (m, 1H), 2.52 (d, J = 13.9 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.08 – 1.81 (m, 
3H), 1.79 – 1.57 (m, 4H), 1.50 – 1.11 (m, 14H), 1.00 – 0.77 (m, 7H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 139.0, 138.6, 137.8, 134.84, 134.80, 134.28, 130.2, 130.0, 
129.50, 129.46, 129.2, 128.92, 128.85, 128.3, 128.0, 127.73, 127.68, 127.6, 127.5, 127.4, 124.3, 114.5, 
80.7, 72.8, 70.3, 54.0, 38.1, 38.0, 36.8, 32.7, 31.6, 31.5, 30.1, 29.9, 29.4, 25.8, 25.7, 25.3, 24.6, 24.0, 22.5, 
14.0. 
FT-IR (film): 3059, 3049, 2923, 2860, 2162, 1651, 1644, 1595, 1492, 1451, 1110, 767, 735 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C52H62NO2Si: 760.4544, found: 760.4550. 
[]22D = 19.4 (c 1.0, CHCl3); 91% ee, 99:1 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-(3-(5,5-dimethyl-1,3-dioxan-2-yl)propyl)-
N-phenyloctanamide (Fig. 3, entry 25).  The title compound was synthesized according to GP-
9 from benzyl(3-bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-19.  The product 
was purified by column chromatography on silica gel (1:30  1:10 EtOAc/hexanes).  Colorless 
oil. 
(R,S)-L2: 241 mg, 64% yield, 91% ee, 99:1 dr; 
(S,R)-L2: 234 mg, 62% yield, 91% ee, 99:1 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
10.6 min (minor), 20.0 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.37 (m, 4H), 7.33 – 7.27 (m, 2H), 7.26 – 7.18 (m, 5H), 7.10 
(t, J = 7.2 Hz, 1H), 7.00 – 6.82 (m, 6H), 6.78 (d, J = 6.9 Hz, 2H), 4.51 (tt, J = 12.1, 3.6 Hz, 1H), 4.23 (t, 
J = 5.0 Hz, 1H), 3.48 (d, J = 11.0 Hz, 2H), 3.27 (dd, J = 11.2, 3.2 Hz, 2H), 2.62 – 2.54 (m, 1H), 2.52 (d, 
J = 13.7 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.05 – 1.82 (m, 3H), 1.80 – 1.57 (m, 4H), 1.54 – 1.36 (m, 
5H), 1.36 – 1.13 (m, 9H), 1.09 (s, 3H), 1.01 – 0.85 (m, 3H), 0.82 (t, J = 7.0 Hz, 4H), 0.61 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 139.0, 137.8, 134.84, 134.80, 134.29, 134.26, 130.4, 130.1, 
129.49, 129.46, 129.2, 128.91, 128.85, 127.9, 127.8, 127.7, 127.6, 124.4, 114.5, 102.0, 80.7, 77.1, 54.0, 
38.2, 38.1, 36.8, 35.0, 32.7, 31.6, 31.5, 30.12, 30.06, 29.4, 25.8, 25.3, 24.6, 23.0, 22.5, 21.84, 21.79, 14.0. 
FT-IR (film): 3053, 2936, 2855, 2163, 1650, 1594, 1395, 1112, 760, 701 cm-1. 
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HRMS (ESI-MS) m/z [M+H]+ calcd for C50H64NO3Si: 754.4650, found: 754.4650. 
[]22D = 24.5 (c 1.0, CHCl3); 91% ee, 99:1 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-(2-(5-methylfuran-2-yl)ethyl)-N-
phenyloctanamide (Fig. 3, entry 26).  The title compound was synthesized according to GP-9 
from benzyl(3-bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-20.  The product 
was purified by column chromatography on silica gel (1:30  1:15 EtOAc/hexanes).  Colorless 
oil. 
(R,S)-L2: 216 mg, 61% yield, 90% ee, 98:2 dr; 
(S,R)-L2: 210 mg, 60% yield, 92% ee, 98:2 dr. 
SFC analysis: The ee and dr were determined via SFC on a CHIRALPAK IE-3 column (20.0% 
2-PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-
L2: 6.4 min (major), 7.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.37 (m, 4H), 7.35 – 7.27 (m, 2H), 7.27 – 7.18 (m, 5H), 7.12 
(t, J = 7.4 Hz, 1H), 7.02 – 6.81 (m, 6H), 6.79 (d, J = 7.0 Hz, 2H), 5.73 (d, J = 3.2 Hz, 1H), 5.68 (d, J = 
3.0 Hz, 1H), 4.52 (tt, J = 12.1, 3.6 Hz, 1H), 2.66 – 2.56 (m, 1H), 2.53 (d, J = 13.8 Hz, 1H), 2.48 (d, J = 
13.8 Hz, 1H), 2.41 (ddd, J = 15.3, 9.9, 5.3 Hz, 1H), 2.30 (ddd, J = 15.6, 9.7, 6.6 Hz, 1H), 2.14 (s, 3H), 
2.09 – 1.96 (m, 2H), 1.96 – 1.84 (m, 1H), 1.80 – 1.57 (m, 5H), 1.51 – 1.20 (m, 10H), 0.98 – 0.76 (m, 
6H). 
13C NMR (101 MHz, CDCl3) δ 171.2, 154.1, 150.0, 138.9, 137.8, 134.9, 134.8, 134.3, 134.2, 130.4, 
130.1, 129.53, 129.50, 129.2, 128.9, 128.0, 127.8, 127.72, 127.67, 124.4, 114.2, 105.8, 105.3, 80.9, 54.0, 
38.0, 37.6, 36.8, 32.7, 31.65, 31.57, 30.1, 28.0, 26.0, 25.78, 25.77, 25.4, 24.6, 22.6, 14.0, 13.5. 
FT-IR (film): 3048, 2923, 2859, 2162, 1651, 1397, 1110, 760, 736 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C48H55NO2SiNa: 728.3894, found: 728.3896. 
[]22D = 14.5 (c 1.0, CHCl3); 92% ee, 98:2 dr from (S,R)-L2. 
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(5S)-3-(1-(Benzyldiphenylsilyl)hept-1-yn-3-yl)-N-cyclohexyl-5,9-dimethyl-N-phenyldec-8-
enamide (Fig. 3, entry 27).  The title compound was synthesized according to GP-9 from 
benzyl(3-bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-21.  The product was 
purified by column chromatography on silica gel (1:25 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 203 mg, 56% yield, 96:4 dr; 
(S,R)-L2: 199 mg, 55% yield, 3:97 dr. 
HPLC analysis: The dr was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 0.6 mL/min); retention times for compound obtained using (R,S)-L2: 8.2 min 
(major), 9.2 min (minor). 
NMR data for the product from (R,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.36 (m, 4H), 7.34 – 7.27 (m, 2H), 7.27 – 7.18 (m, 5H), 7.10 
(t, J = 7.3 Hz, 1H), 7.00 – 6.74 (m, 8H), 5.00 (t, J = 7.1 Hz, 1H), 4.53 (tt, J = 12.1, 3.6 Hz, 1H), 2.65 – 
2.56 (m, 1H), 2.53 (d, J = 13.9 Hz, 1H), 2.49 (d, J = 13.9 Hz, 1H), 2.14 – 1.96 (m, 2H), 1.96 – 1.64 (m, 
6H), 1.64 – 1.58 (m, 4H), 1.51 (s, 3H), 1.49 – 1.10 (m, 12H), 1.01 – 0.77 (m, 8H), 0.72 (d, J = 5.8 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 139.0, 137.8, 134.90, 134.86, 134.34, 134.30, 130.9, 130.5, 
130.0, 129.51, 129.48, 129.2, 129.0, 128.8, 128.0, 127.8, 127.7, 127.6, 124.9, 124.4, 114.7, 80.7, 53.9, 
38.4, 37.3, 36.7, 36.1, 35.7, 32.4, 31.7, 31.6, 30.2, 30.0, 25.8, 25.7, 25.4, 25.2, 24.7, 22.6, 20.5, 17.7, 14.1. 
NMR data for the product from (S,R)-L2: 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.37 (m, 4H), 7.34 – 7.27 (m, 2H), 7.27 – 7.18 (m, 5H), 7.15 
– 7.04 (m, 1H), 7.02 – 6.90 (m, 4H), 6.90 – 6.73 (m, 4H), 4.93 (tt, J = 7.1, 1.3 Hz, 1H), 4.52 (tt, J = 12.1, 
3.6 Hz, 1H), 2.68 – 2.56 (m, 1H), 2.52 (d, J = 13.9 Hz, 1H), 2.49 (d, J = 13.9 Hz, 1H), 2.13 – 1.92 (m, 
2H), 1.90 – 1.60 (m, 7H), 1.58 (s, 3H), 1.55 – 1.42 (m, 3H), 1.41 (s, 3H), 1.38 – 1.21 (m, 6H), 1.14 – 
0.94 (m, 5H), 0.94 – 0.78 (m, 6H), 0.73 (d, J = 5.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 139.0, 137.8, 134.9, 134.8, 134.3, 130.9, 130.5, 130.0, 129.50, 
129.47, 129.3, 129.0, 128.8, 128.0, 127.8, 127.7, 127.6, 124.8, 124.4, 114.6, 80.7, 54.0, 38.2, 38.1, 36.94, 
36.90, 35.6, 32.8, 31.7, 31.6, 30.2, 29.6, 25.80, 25.78, 25.7, 25.5, 25.4, 24.7, 22.6, 19.4, 17.6, 14.1. 
FT-IR (film): 3058, 3024, 2927, 2857, 2163, 1651, 1595, 1394, 1113, 706, 700 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C50H63NOSiNa: 744.4571, found: 744.4573. 
[]22D = 18.7 (c 1.0, CHCl3); 96:4 dr from (R,S)-L2. 
[]22D = 38.8 (c 1.0, CHCl3); 3:97 dr from (S,R)-L2. 
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(Z)-3-(1-(Benzyldiphenylsilyl)hept-1-yn-3-yl)-N-cyclohexyl-N-phenyldodec-9-enamide 
(Fig. 3, entry 28).  The title compound was synthesized according to GP-9 from benzyl(3-
bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-22.  The product was purified by 
column chromatography on silica gel (1:30  1:10 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 232 mg, 65% yield, 94% ee, 98:2 dr; 
(S,R)-L2: 233 mg, 64% yield, 93% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 0.6 mL/min); retention times for compound obtained using (R,S)-L2: 
16.5 min (major), 18.6 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.48 – 7.38 (m, 4H), 7.34 – 7.27 (m, 2H), 7.27 – 7.19 (m, 5H), 7.12 
(t, J = 7.4 Hz, 1H), 7.00 – 6.82 (m, 6H), 6.82 – 6.74 (m, 2H), 5.40 – 5.11 (m, 2H), 4.52 (tt, J = 12.1, 3.6 
Hz, 1H), 2.61 – 2.54 (m, 1H), 2.53 (d, J = 13.8 Hz, 1H), 2.48 (d, J = 13.9 Hz, 1H), 2.07 – 1.79 (m, 7H), 
1.78 – 1.59 (m, 4H), 1.53 – 1.02 (m, 16H), 1.00 – 0.77 (m, 10H). 
13C NMR (101 MHz, CDCl3) δ 171.5, 139.0, 137.8, 134.9, 134.8, 134.34, 134.31, 131.5, 130.5, 
130.0, 129.51, 129.47, 129.25, 129.21, 129.0, 128.8, 128.0, 127.8, 127.7, 127.6, 124.3, 114.6, 80.6, 54.0, 
38.2, 38.1, 36.8, 32.7, 31.7, 31.6, 30.2, 29.7, 29.6, 29.5, 27.3, 27.0, 25.8, 25.4, 24.7, 22.6, 20.5, 14.4, 14.1. 
FT-IR (film): 3023, 3001, 2932, 2857, 2162, 1659, 1650, 1393, 1113, 707, 699 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C50H64NOSi: 722.4752, found: 722.4748. 
[]22D = 21.4 (c 1.0, CHCl3); 93% ee, 98:2 dr from (S,R)-L2. 
 
 
 
Methyl 7-((benzyldiphenylsilyl)ethynyl)-6-(2-(cyclohexyl(phenyl)amino)-2-
oxoethyl)undecanoate (Fig. 3, entry 29).  The title compound was synthesized according to 
GP-9 from benzyl(3-bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-23.  The 
product was purified by column chromatography on silica gel (1:30  1:5 EtOAc/hexanes).  
Colorless oil. 
(R,S)-L2: 227 mg, 64% yield, 90% ee, 98:2 dr; 
(S,R)-L2: 228 mg, 64% yield, 90% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(5.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
10.0 min (minor), 13.0 min (major). 
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1H NMR (400 MHz, CDCl3) δ 7.48 – 7.35 (m, 4H), 7.34 – 7.28 (m, 2H), 7.28 – 7.19 (m, 5H), 7.12 
(t, J = 7.4 Hz, 1H), 7.01 – 6.82 (m, 6H), 6.81 – 6.71 (m, 2H), 4.51 (tt, J = 12.1, 3.6 Hz, 1H), 3.56 (s, 
3H), 2.62 – 2.43 (m, 3H), 2.13 (t, J = 7.5 Hz, 2H), 2.05 – 1.78 (m, 3H), 1.77 – 1.57 (m, 4H), 1.53 – 1.20 
(m, 12H), 1.14 – 0.74 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ 174.0, 171.3, 139.0, 137.8, 134.84, 134.80, 134.3, 134.2, 130.4, 
130.0, 129.52, 129.49, 129.2, 128.93, 128.88, 128.0, 127.74, 127.69, 127.65, 124.3, 114.4, 80.8, 54.0, 
51.4, 38.0, 36.8, 34.0, 32.6, 31.62, 31.55, 30.1, 29.3, 26.9, 25.8, 25.7, 25.3, 25.1, 24.6, 22.5, 14.0. 
FT-IR (film): 3066, 3052, 2926, 2858, 2162, 1738, 1651, 1594, 1493, 1393, 1112, 740, 704 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C47H58NO3Si: 712.4180, found: 712.4181. 
[]22D = 19.9 (c 1.0, CHCl3); 90% ee, 98:2 dr from (S,R)-L2. 
 
 
 
4-((Benzyldiphenylsilyl)ethynyl)-3-(4-chlorobutyl)-N-cyclohexyl-N-phenyloctanamide 
(Fig. 3, entry 30).  The title compound was synthesized according to GP-9 from benzyl(3-
bromohept-1-yn-1-yl)diphenylsilane and zinc nucleophile Zn-24.  The product was purified by 
column chromatography on silica gel (1:30  1:10 EtOAc/hexanes).  Colorless oil. 
(R,S)-L2: 230 mg, 67% yield, 92% ee, 98:2 dr; 
(S,R)-L2: 233 mg, 68% yield, 92% ee, 98:2 dr. 
HPLC analysis: The ee and dr were determined via HPLC on a CHIRALPAK AD-H column 
(2.0% 2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 
12.9 min (minor), 17.5 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.59 – 7.48 (m, 4H), 7.46 – 7.30 (m, 7H), 7.28 – 7.21 (m, 1H), 7.12 
– 7.00 (m, 5H), 6.97 (d, J = 8.0 Hz, 1H), 6.93 – 6.83 (m, 2H), 4.63 (tt, J = 12.1, 3.6 Hz, 1H), 3.45 (t, J = 
6.7 Hz, 2H), 2.70 – 2.56 (m, 3H), 2.19 – 1.92 (m, 3H), 1.90 – 1.27 (m, 18H), 1.15 – 0.98 (m, 3H), 0.98 
– 0.84 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 171.3, 139.0, 137.8, 134.9, 134.8, 134.3, 134.2, 130.4, 130.1, 129.6, 
129.5, 129.3, 129.0, 128.1, 127.8, 127.72, 127.68, 124.4, 114.3, 80.9, 54.1, 44.9, 38.03, 37.99, 36.9, 32.69, 
32.65, 31.64, 31.58, 30.1, 28.9, 25.78, 25.77, 25.4, 24.6, 24.5, 22.5, 14.0. 
FT-IR (film): 3048, 3024, 2920, 2858, 2163, 1651, 1595, 1394, 1111, 762, 733, 706 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C45H55ClNOSi: 688.3736, found: 688.3758. 
[]22D = 21.8 (c 1.0, CHCl3); 92% ee, 98:2 dr from (S,R)-L2. 
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 VI.  Effect of Reaction Parameters 
 
General Procedure 10 (GP-10): In a glovebox, NiCl2glyme (2.2 mg, 0.010 mmol), chiral 
ligand L1 (3.2 mg, 0.012 mmol), 1,5-bis(diphenylphosphino)pentane (4.4 mg, 0.010 mmol), and 
THF (1.0 mL) were added sequentially to a 4-mL vial equipped with a stir bar.  The mixture 
was stirred at room temperature for 30 min (pink suspension), and then a solution of the 
alkylzinc nucleophile (0.15 mmol) was added dropwise via a 0.25 mL syringe (for the additive 
studies, the additive was added before the alkylzinc reagent).  The vial was sealed with a 
septum cap and wrapped with electrical tape.  The reaction mixture was stirred at room 
temperature for 10 min, at which time it had become a dark-red homogeneous solution.  Next, 
the vial was transferred out of the glovebox and cooled to 5 C.  After the reaction mixture 
had stirred at 5 C for 10 min, 1-iodohexane (0.10 mmol, 0.015 mL) was added via a 
microsyringe in one portion.  The punctures in the septum cap were covered with grease, and 
then the reaction mixture was stirred at 5 C for 72 h.  Next, the reaction was quenched by the 
addition of MeOH (0.1 mL).  The resulting mixture was allowed to warm to room temperature, 
and then dodecane (22 L, 0.10 mmol) was added as an internal standard.  The mixture was 
filtered through a small plug of silica gel, which was flushed with Et2O (20 mL).  A portion of 
the filtrate (0.1 mL) was diluted with acetone (total volume: 1 mL) and analyzed via GC, and the 
remainder of the filtrate was concentrated via rotary evaporation, and the pure product was 
isolated by preparative TLC on silica gel (1:5 EtOAc/hexanes). 
 
GP-10 was followed, using 1-iodohexane (0.10 mmol) and Zn-1 (0.15 mmol).  The yield and 
conversion were determined via GC analysis with dodecane as an internal standard.  The ee 
values were determined via HPLC analysis after purification by preparative thin-layer 
chromatography. 
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Table S-1. 
 
 
The role of the phosphine has not yet been elucidated.  The presence of the phosphine leads 
to a homogeneous, rather than a heterogeneous, reaction mixture.  31P NMR spectroscopic 
studies establish that the resonance for the free phosphine is altered in the presence of the 
alkylzinc nucleophile, as well as under the coupling conditions. 
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General Procedure 11 (GP-11):  In a glovebox, NiBr2glyme (3.1 mg, 0.010 mmol, 10%), 
chiral ligand L2 (3.7 mg, 0.013 mmol, 13%), anhydrous LiCl (5.1 mg, 0.12 mmol), and THF (1.0 
mL) were added sequentially to a 4-mL vial equipped with a stir bar.  The mixture was 
allowed to stir for 40 min, after which it was a cloudy, yellow suspension.  Then, a solution of 
the propargylic bromide (100 L, 0.10 mmol, 1.0 M in THF) was added via microsyringe.  Next, 
a solution of the alkylzinc nucleophile (0.10 mmol) was added in one portion, leading to a dark-
red reaction mixture.  The reaction mixture was transferred out of the glovebox and stirred 
(~800 rpm) at room temperature for 20 h.  The reaction mixture was then passed through a 
short pad of silica gel, with Et2O as the eluent (~10 mL).  The resulting mixture was 
concentrated, and the residue was purified by preparative TLC on silica gel (1:5 EtOAc/hexanes). 
Benzyl(3-bromohept-1-yn-1-yl)diphenylsilane (0.10 mmol) was reacted with zinc nuclephile 
Zn-10 (0.10 mmol) according to GP-11.  The yield was determined after purification by 
preparative thin-layer chromatography.  The ee and dr values were determined via HPLC 
analysis. 
Table S-2. 
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VII.  Functional-Group Compatibility 
 
GP-10 was followed, using 1-iodohexane (0.10 mmol) and Zn-1 (0.15 mmol), in the presence 
of 1.0 equiv of the additives shown below.  The yield and conversion were determined via GC 
analysis with dodecane as an internal standard.  The ee values were determined via HPLC 
analysis after purification by preparative thin-layer chromatography. 
 
Table S-3. 
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VIII. Derivatization of Coupling Products
N-Benzyl-N-(3-ethyl-6-phenylhexyl)aniline (top of Fig. 4).  Borane-SMe2 (0.24 mL, 2.0 M in
THF, 1.2 equiv) was added dropwise to a solution of N-benzyl-3-ethyl-N,6-diphenylhexanamide 
(154 mg, 0.40 mmol, 1.0 equiv) in THF (4.0 mL) at 0 C in a 25-mL Schlenk tube.  Next, the 
reaction mixture was allowed to warm to room temperature, and then it was heated to 85 °C.  
After being stirred at 85 C in the sealed Schlenk tube for 8 h, the reaction was quenched with 
aqueous NaOH (1 M, 1.0 mL), and the reaction mixture was extracted with Et2O (3  20 mL).  
The combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced 
pressure.  The residue was purified by flash chromatography on silica gel (1:20 EtOAc/hexanes) 
to afford the pure product.  Colorless oil. 
(R)-L1: 133 mg, 90% yield, 90% ee; (S)-L1: 126 mg, 85% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK OD-H column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 12.7 min 
(minor), 13.6 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.31 (m, 3H), 7.31 – 7.25 (m, 4H), 7.25 – 7.17 (m, 5H), 6.75 
– 6.65 (m, 3H), 4.54 (s, 2H), 3.48 – 3.33 (m, 2H), 2.63 (t, J = 7.3 Hz, 2H), 1.71 – 1.58 (m, 4H), 1.45 –
1.28 (m, 5H), 0.89 (t, J = 7.2 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 148.5, 142.6, 139.1, 129.2, 128.5, 128.3, 128.2, 126.7, 126.5, 125.6, 
115.9, 112.0, 54.3, 49.2, 37.1, 36.3, 32.8, 30.0, 28.6, 25.9, 10.9. 
FT-IR (film): 3024, 2928, 2856, 1596, 1504, 1451, 1354, 744, 726 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C27H34N: 372.2686, found: 372.2678. 
[]24D = 4.2 (c 1.0, CHCl3); 91% ee from (S)-L1.
3-Ethyl-6-phenylhexan-1-ol (top of Fig. 4).  Lithium aluminum hydride (0.98 mL, 1.0 M in
Et2O, 2.0 equiv) was added dropwise to a solution of N-benzyl-3-ethyl-N,6-diphenylhexanamide 
(188 mg, 0.49 mmol, 1.0 equiv) in THF (5.0 mL) at 0 C in a 25-mL Schlenk tube.  Next, the 
reaction mixture was allowed to warm to room temperature, and then it was heated to 85 °C.  
After being stirred at 85 C in the sealed Schlenk tube overnight, the reaction mixture was 
diluted with Et2O (20 mL) and cooled to 0 °C.  The reaction was then quenched in turn with 
H2O (38 L), 15% aqueous NaOH (38 L), and H2O (114 L).  Next, the suspension was filtered 
through a sintered funnel to remove the white solid.  The combined organic layers were dried 
(Na2SO4), filtered, and concentrated under reduced pressure.  The residue was purified by 
S–75 
flash chromatography on silica gel (1:10 EtOAc/hexanes) to afford the pure product.  Colorless 
oil. 
(R)-L1: 88 mg, 87% yield, 90% ee; (S)-L1: 86 mg, 85% yield, 91% ee. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (1.0% 
EtOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R)-L1: 17.5 min 
(minor), 18.9 min (major). 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.27 (m, 2H), 7.26 – 7.16 (m, 3H), 3.67 (t, J = 7.0 Hz, 2H), 
2.63 (t, J = 7.8 Hz, 2H), 1.70 – 1.60 (m, 2H), 1.59 – 1.52 (m, 2H), 1.52 – 1.40 (m, 1H), 1.40 – 1.26 (m, 
5H), 0.88 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 142.7, 128.3, 128.2, 125.6, 61.2, 36.4, 36.3, 35.4, 32.8, 28.5, 25.9, 
10.7. 
FT-IR (film): 3336, 2958, 2928, 2857, 1495, 1452, 1057, 1029, 745 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C14H23O: 207.1743, found: 207.1737. 
[]24D = 2.2 (c 1.0, CHCl3); 91% ee from (S)-L1.
5-Ethyl-1,8-diphenyloctan-3-one (top of Fig. 4).  Trifluoromethanesulfonic anhydride (40
L, 0.24 mmol, 1.2 equiv) was added dropwise to a mixture of N-benzyl-3-ethyl-N,6-
diphenylhexanamide (77.0 mg, 0.20 mmol, 1.0 equiv) and DTBMP (49.2 mg, 0.24 mmol, 1.2
equiv) in CH2Cl2 (2.0 mL) at 78 C in a 40-mL vial.  The reaction mixture was allowed to stir at
78 C for 3 h.  Next, phenethylmagnesium chloride (0.22 mL, 1.0 M in THF, 1.2 equiv) was
added dropwise to this mixture at 78 C, and the mixture was stirred at 78 C for 5 h.  Next,
the reaction was quenched with aqueous saturated NH4Cl (2.0 mL), and the reaction mixture
was extracted with Et2O (3  20 mL).  The combined organic layers were dried (Na2SO4),
filtered, and concentrated under reduced pressure.  The residue was purified by preparative
TLC on silica gel (1:30 EtOAc/hexanes) to afford the pure product.  Colorless oil.
(R)-L1: 43 mg, 69% yield, 90% ee; (S)-L1: 45 mg, 73% yield, 90% ee. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK IC-3 column (5.0% 2-PrOH 
in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-L1: 8.5 
min (major), 9.2 min (minor).
1H NMR (400 MHz, ) δ 7.23 – 7.15 (m, 4H), 7.13 – 7.06 (m, 6H), 2.80 (t, J = 7.4 Hz, 2H), 2.61 (t, J 
= 7.4 Hz, 2H), 2.48 (t, J = 7.9 Hz, 2H), 2.23 (dd, J = 16.1, 6.8 Hz, 1H), 2.20 (dd, J = 16.1, 6.6 Hz, 1H), 
1.87 – 1.74 (m, 1H), 1.54 – 1.41 (m, 2H), 1.31 – 1.07 (m, 4H), 0.73 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 210.2, 142.5, 141.1, 128.4, 128.31, 128.30, 128.2, 126.0, 125.6, 47.5, 
44.8, 36.1, 35.0, 33.1, 29.7, 28.5, 26.3, 10.8. 
FT-IR (film): 3061, 3027, 2931, 2366, 1712, 1457, 748, 735, 698 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C22H28ONa: 331.2032, found: 331.2041. 
[]22D = 4.5 (c 1.0, CHCl3); 90% ee from (S)-L1.
S–76 
N-Cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide.  To a solution of 4-
((benzyldiphenylsilyl)ethynyl)-N-cyclohexyl-3-ethyl-N-phenyloctanamide (1.450 g, 2.32 mmol, 
1.0 equiv) in anhydrous THF (11.6 mL) at room temperature was added TBAF (4.6 mL, 1.0 M in 
THF, 2.0 equiv) dropwise.  The reaction mixture was allowed to stir at room temperature for 36 
h. Next, the reaction was quenched with aqueous saturated NH4Cl (2.0 mL) and extracted
with Et2O (3  30 mL).  The combined organic layers were dried (Na2SO4), filtered, and
concentrated under reduced pressure.  The residue was purified by flash chromatography on
silica gel (1:20 EtOAc/hexanes) to afford the pure product.  Colorless oil.
(R,S)-L2: 747 mg, 93% yield, 90% ee, 99:1 dr; 
(S,R)-L2: 719 mg, 89% yield, 91% ee, 98:2 dr. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK IC column (1.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 9.4 min 
(minor), 10.9 min (major). 
1H NMR (500 MHz, CDCl3) δ 7.47 – 7.38 (m, 3H), 7.18 (d, J = 7.2 Hz, 1H), 7.10 (d, J = 7.2 Hz, 
1H), 4.66 (tt, J = 12.1, 3.6 Hz, 1H), 2.60 – 2.52 (m, 1H), 2.11 – 1.95 (m, 3H), 1.91 (d, J = 2.4 Hz, 1H), 
1.89 – 1.81 (m, 2H), 1.76 (dt, J = 13.5, 3.4 Hz, 2H), 1.60 (dt, J = 13.2, 3.3 Hz, 1H), 1.57 – 1.28 (m, 9H), 
1.23 – 1.12 (m, 1H), 1.07 (qd, J = 12.5, 3.6 Hz, 2H), 1.00 – 0.87 (m, 4H), 0.81 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 171.7, 139.1, 130.7, 130.2, 129.0, 128.9, 128.0, 86.2, 69.9, 53.9, 39.7, 
37.1, 34.9, 32.1, 31.62, 31.56, 30.1, 25.7, 25.3, 22.5, 22.1, 14.0, 11.8. 
FT-IR (film): 3306, 3243, 2930, 2857, 1651, 1595, 1394, 1072, 705 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C24H35NONa: 376.2611, found: 376.2615. 
[]22D = 37.8 (c 1.0, CHCl3); 91% ee, 98:2 dr from (S,R)-L2.
N-Cyclohexyl-3-ethyl-N-phenyl-4-vinyloctanamide (Fig. 4, reaction a).  A 40-mL vial
equipped with a stir bar was charged with N-cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide 
(70.6 mg, 0.20 mmol, 1.0 equiv), 5 wt.% Pd/CaCO3 (21.2 mg, 0.010 mmol, 0.050 equiv) and 
quinoline (36.0 mg, 0.28 mmol, 1.4 equiv).  The vial was evacuated and backfilled with nitrogen 
on Schlenk line for three times.  Next, a hydrogen-filled balloon was attached, and hexane (2.0 
mL) was added via syringe.  The reaction mixture was allow to stir at room temperature for 3 h, 
and then it was passed through a short pad of silica gel, with Et2O as the eluent (~20 mL).  The 
S–77 
resulting mixture was concentrated, and the residue was purified by preparative TLC on silica 
gel (1:6 EtOAc/hexanes) to afford the pure product.  Colorless oil. 
(R,S)-L2: 66 mg, 93% yield, 90% ee, 98:2 dr; 
(S,R)-L2: 70 mg, 98% yield, 90% ee, 99:1 dr. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 7.6 min 
(major), 10.7 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.23 (m, 3H), 6.99 (d, J = 7.0 Hz, 2H), 5.40 – 5.22 (m, 1H), 
4.90 – 4.73 (m, 2H), 4.55 (tt, J = 12.1, 3.6 Hz, 1H), 1.93 (tt, J = 8.2, 3.8 Hz, 1H), 1.86 – 1.69 (m, 5H), 
1.69 – 1.58 (m, 2H), 1.54 – 1.42 (m, 1H), 1.40 – 1.25 (m, 3H), 1.25 – 1.03 (m, 6H), 1.02 – 0.80 (m, 
4H), 0.78 (t, J = 6.9 Hz, 3H), 0.65 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.1, 140.6, 139.3, 130.3, 128.9, 127.9, 115.4, 53.9, 46.6, 40.6, 37.0, 
31.7, 31.6, 31.4, 29.9, 25.8, 25.3, 22.8, 22.4, 14.0, 11.9. 
FT-IR (film): 3065, 2932, 2857, 1659, 1650, 1595, 1493, 1453, 1393, 1072, 910, 706 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C24H37NONa: 378.2767, found: 378.2772. 
[]22D = 13.1 (c 1.0, CHCl3); 90% ee, 99:1 dr from (S,R)-L2.
N-Cyclohexyl-3,4-diethyl-N-phenyloctanamide (Fig. 4, reaction b).  A 40-mL vial
equipped with a stir bar was charged with N-cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide 
(70.6 mg, 0.20 mmol, 1.0 equiv), 5 wt.% Pd/C (43.1 mg, 0.020 mmol, 0.10 equiv).  The vial was 
evacuated and backfilled with nitrogen on Schlenk line for three times.  Next, a hydrogen-filled 
balloon was attached, and EtOAc (2.0 mL) was added via syringe.  The reaction mixture was 
allow to stir at room temperature for 18 h, and then it was passed through a short pad of silica 
gel, with Et2O as the eluent (~20 mL).  The resulting mixture was concentrated, and the residue 
was purified by preparative TLC on silica gel (1:6 EtOAc/hexanes) to afford the pure product.  
Colorless oil. 
(R,S)-L2: 67 mg, 94% yield, 90% ee, 98:2 dr; 
(S,R)-L2: 72 mg, 100% yield, 91% ee, 98:2 dr. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 7.0 min 
(major), 7.6 min (minor).
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.24 (m, 3H), 7.05 – 6.93 (m, 2H), 4.56 (tt, J = 12.1, 3.6 Hz, 
1H), 1.90 – 1.59 (m, 7H), 1.53 – 1.44 (m, 1H), 1.32 (qt, J = 13.1, 3.6 Hz, 2H), 1.13 (tt, J = 11.9, 6.9 Hz, 
6H), 1.05 – 0.71 (m, 14H), 0.68 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.5, 139.5, 130.42, 130.36, 128.9, 127.9, 53.9, 41.3, 38.3, 36.2, 
31.64, 31.62, 30.1, 29.7, 25.8, 25.4, 23.2, 23.1, 23.0, 14.1, 12.4, 12.1. 
FT-IR (film): 2956, 2933, 2858, 2356, 1652, 1595, 1493, 1455, 1391, 1073, 705 cm-1. 
 S–78 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C24H39NONa: 380.2924, found: 380.2931. 
[]22D = 6.1 (c 1.0, CHCl3); 91% ee, 98:2 dr from (S,R)-L2. 
 
 
 
N-Cyclohexyl-3-ethyl-4-(1-((2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)-N-phenyloctanamide 
(Fig. 4, reaction c).  A 4-mL vial was charged with N-cyclohexyl-3-ethyl-4-ethynyl-N-
phenyloctanamide (71.0 mg, 0.20 mmol, 1.0 equiv).  The vial was loosely capped and 
transferred into glovebox.  Then, CuTC (3.8 mg, 0.020 mmol, 0.10 equiv), toluene (2.0 mL), and 
a stir bar were added sequentially.  Next, Zidovudine (59.0 mg, 0.22 mmol, 1.1 equiv) was 
added slowly.  The vial was then capped and transferred out of glovebox.  The reaction was 
stirred at 50 ºC for 20 h, and then quenched with aqueous saturated NH4Cl (2.0 mL) and 
extracted with Et2OAc (3  20 mL).  The combined organic layers were dried (Na2SO4), filtered, 
and concentrated under reduced pressure.  The residue was purified by flash chromatography 
on silica gel (2:1 EtOAc/ CH2Cl2) to afford the pure product.  White solid. 
(R,S)-L2: 116 mg, 94% yield, 97:3 dr; 
(S,R)-L2: 120 mg, 97% yield, 3:97 dr. 
SFC analysis: The dr was determined via SFC on a CHIRALPAK AD-3 column (30.0% 2-
PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-L2: 
3.2 min (major), 3.9 min (minor). 
NMR data for the product from (R,S)-L2: 
1H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 7.57 (s, 1H), 7.45 (s, 1H), 7.39 – 7.26 (m, 3H), 7.03 
(dd, J = 31.9, 7.3 Hz, 2H), 6.26 (t, J = 6.5 Hz, 1H), 5.33 (dt, J = 10.3, 5.5 Hz, 1H), 4.50 (tt, J = 12.1, 3.6 
Hz, 1H), 4.37 – 4.25 (m, 1H), 4.17 (s, 1H), 4.01 – 3.85 (m, 1H), 3.75 (d, J = 12.1 Hz, 1H), 3.04 – 2.69 
(m, 3H), 2.04 – 1.90 (m, 1H), 1.90 – 1.79 (m, 4H), 1.79 – 1.69 (m, 3H), 1.69 – 1.53 (m, 3H), 1.53 – 
1.40 (m, 2H), 1.38 – 1.23 (m, 3H), 1.22 – 1.13 (m, 2H), 1.13 – 1.03 (m, 2H), 1.03 – 0.89 (m, 2H), 0.89 
– 0.65 (m, 5H), 0.55 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.0, 164.0, 150.5, 150.0, 139.0, 137.5, 130.5, 130.2, 129.1, 128.9, 
128.1, 121.8, 111.0, 87.8, 85.4, 61.5, 59.0, 54.1, 41.1, 38.8, 37.6, 36.7, 31.7, 31.4, 30.6, 30.1, 25.7, 25.3, 
23.3, 22.6, 13.9, 12.4, 11.6. 
NMR data for the product from (S,R)-L2: 
 S–79 
1H NMR (400 MHz, CDCl3) δ 9.61 (s, 1H), 7.58 (s, 1H), 7.47 (s, 1H), 7.40 – 7.25 (m, 3H), 7.02 
(dd, J = 18.6, 7.2 Hz, 2H), 6.28 (t, J = 6.5 Hz, 1H), 5.35 (dt, J = 9.8, 5.4 Hz, 1H), 4.51 (tt, J = 12.1, 3.6 
Hz, 1H), 4.36 – 4.26 (m, 1H), 4.21 (s, 1H), 3.94 (d, J = 12.1 Hz, 1H), 3.73 (d, J = 12.1 Hz, 1H), 3.02 – 
2.69 (m, 3H), 2.01 – 1.80 (m, 5H), 1.79 – 1.53 (m, 6H), 1.53 – 1.41 (m, 2H), 1.39 – 1.24 (m, 3H), 1.23 
– 1.12 (m, 2H), 1.12 – 1.02 (m, 2H), 1.02 – 0.80 (m, 3H), 0.75 (t, J = 7.2 Hz, 4H), 0.53 (t, J = 7.3 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 172.1, 164.1, 150.5, 149.9, 139.0, 137.5, 130.5, 130.2, 129.1, 128.9, 
128.1, 121.8, 111.0, 87.7, 85.4, 61.5, 59.1, 54.1, 41.1, 38.8, 37.6, 36.7, 31.7, 31.4, 30.8, 30.1, 25.7, 25.3, 
23.1, 22.6, 13.9, 12.4, 11.6. 
FT-IR (film): 3192, 2931, 2858, 1697, 1403, 1276, 1104, 735 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C34H49N6O5: 621.3759, found: 621.3759. 
[]22D = 19.7 (c 1.0, CHCl3); 97:3 dr from (R,S)-L2. 
[]22D = 33.1 (c 1.0, CHCl3); 3:97 dr from (S,R)-L2. 
 
 
 
 
N-Cyclohexyl-4-(((R)-2,8-dimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-
yl)ethynyl)-3-ethyl-N-phenyloctanamide (Fig. 4, reaction d).  A 4-mL vial was charged with 
N-cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide (71.0 mg, 0.20 mmol, 1.0 equiv) and (R)-6-
iodo-2,8-dimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chromane (133.0 mg, 0.26 mmol, 1.3 equiv).  
The vial was loosely capped and transferred into glovebox.  Next, Pd(PPh3)2Cl (5.6 mg, 0.0080 
mmol, 0.040 equiv), CuI (7.6 mg, 0.040 mmol, 0.20 equiv), toluene (2.0 mL), TMG (76.0 L, 0.60 
mmol, 3.0 equiv) and a stir bar were added sequentially.  Then, the vial was capped and 
transferred out of glovebox.  After being stirred at 80 ºC for 12 h, the reaction was quenched 
with aqueous saturated NH4Cl (2.0 mL) and extracted with Et2O (3  20 mL).  The combined 
organic layers were dried (Na2SO4), filtered, and concentrated under reduced pressure.  The 
residue was purified by flash chromatography on silica gel (1:20 EtOAc/hexanes) to afford the 
pure product.  Colorless oil. 
(R,S)-L2: 135 mg, 92% yield, 97:3 dr; 
(S,R)-L2: 135 mg, 92% yield, 3:97 dr. 
SFC analysis: The ee was determined via SFC on a CHIRALPAK AD-3 column (15.0% 2-
PrOH in supercritical CO2, 2.5 mL/min); retention times for compound obtained using (R,S)-L2: 
6.5 min (major), 8.3 min (minor). 
NMR data for the product from (R,S)-L2: 
 S–80 
1H NMR (500 MHz, CDCl3) δ 7.43 (t, J = 7.6 Hz, 1H), 7.37 (t, J = 7.3 Hz, 1H), 7.33 – 7.27 (m, 
1H), 7.20 (d, J = 7.9 Hz, 1H), 7.11 (s, 1H), 6.95 – 6.87 (m, 2H), 4.69 (tt, J = 12.1, 3.6 Hz, 1H), 2.82 – 
2.68 (m, 3H), 2.21 (s, 3H), 2.17 – 2.01 (m, 3H), 1.96 – 1.73 (m, 6H), 1.70 – 1.52 (m, 7H), 1.52 – 1.29 
(m, 20H), 1.29 – 1.02 (m, 11H), 0.99 – 0.90 (m, 15H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 171.9, 151.7, 139.2, 131.5, 130.8, 130.20, 130.15, 129.1, 128.8, 
127.8, 126.1, 120.2, 114.2, 89.2, 82.7, 76.3, 53.9, 40.3, 39.9, 39.3, 37.5, 37.4, 37.2, 35.8, 32.8, 32.7, 32.6, 
31.7, 31.6, 31.2, 30.3, 27.9, 25.8, 25.4, 24.8, 24.4, 24.2, 22.70, 22.67, 22.61, 22.2, 22.0, 20.9, 19.7, 19.6, 
15.8, 14.1, 11.9. 
NMR data for the product from (S,R)-L2: 
1H NMR (500 MHz, CDCl3) δ 7.43 (t, J = 7.6 Hz, 1H), 7.37 (t, J = 7.3 Hz, 1H), 7.30 (t, J = 8.2 Hz, 
1H), 7.20 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 6.96 – 6.83 (m, 2H), 4.69 (tt, J = 12.1, 3.6 Hz, 
1H), 2.82 – 2.67 (m, 3H), 2.24 (d, J = 3.8 Hz, 3H), 2.17 – 2.03 (m, 3H), 1.93 – 1.74 (m, 6H), 1.70 – 
1.28 (m, 27H), 1.28 – 1.02 (m, 11H), 1.01 – 0.90 (m, 15H), 0.86 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3)δ 171.9, 151.7, 139.2, 131.5, 130.8, 130.20, 130.15, 129.1, 128.8, 127.8, 
126.1, 120.2, 114.2, 89.2, 82.7, 76.3, 53.9, 40.3, 40.0, 39.3, 37.5, 37.4, 37.2, 35.8, 32.8, 32.7, 32.6, 31.7, 
31.6, 31.2, 30.3, 28.0, 25.8, 25.4, 24.8, 24.4, 24.2, 22.70, 22.67, 22.61, 22.2, 22.0, 20.9, 19.7, 19.6, 15.8, 
14.1, 11.9. 
FT-IR (film): 2933, 2858, 2365, 1651, 1464, 1393, 1378, 1242, 704 cm-1. 
HRMS (ESI-MS) m/z [M+H]+ calcd for C51H80NO2: 738.6184, found: 738.6164. 
[]22D = 1.2 (c 1.0, CHCl3); 97:3 dr from (R,S)-L2. 
[]22D = 16.9 (c 1.0, CHCl3); 3:97 dr from (S,R)-L2. 
 
 
 
3-Butyl-N6-cyclohexyl-4-ethyl-N6-phenyl-N1-tosylhexanediamide (Fig. 4, reaction e).  A 4-
mL vial was charged with N-cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide (71.0 mg, 0.20 
mmol, 1.0 equiv), TsN3 (47.3 mg, 0.24 mmol, 1.2 equiv), CuI (3.8 mg, 0.020 mmol, 0.10 equiv), 
and a stir bar.  The vial was evacuated and backfilled with nitrogen on Schlenk line for three 
times.  Then, CHCl3 (0.40 mL, 0.5 M), H2O (9.0 L, 0.50 mmol, 2.5 equiv) and NEt3 (34.0 L, 0.24 
mmol, 1.2 equiv) were added sequentially under nitrogen atmosphere.  After stirring the 
reaction at room temperature for 12 h, it was quenched with aqueous saturated NH4Cl (1.0 mL) 
and dituted with CH2Cl2 (2.0 mL).  The mixture was allow to stir for additional 30 min, and 
then extracted with CH2Cl2 (3  10 mL).  The combined organic layers were dried (Na2SO4), 
filtered, and concentrated under reduced pressure.  The residue was purified by flash 
chromatography on silica gel (1:2 EtOAc/hexanes) to afford the pure product.  White foamy 
solid. 
(R,S)-L2: 84 mg, 78% yield, 91% ee, 98:2 dr; 
(S,R)-L2: 86 mg, 80% yield, 92% ee, 99:1 dr. 
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HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (15.0% 
2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 8.7 min 
(minor), 10.3 min (major). 
1H NMR (400 MHz, CDCl3) δ 10.96 (s, 1H), 7.93 (d, J = 8.1 Hz, 2H), 7.39 – 7.30 (m, 3H), 7.22 (d, 
J = 8.0 Hz, 2H), 7.08 – 6.93 (m, 2H), 4.64 (tt, J = 12.2, 3.5 Hz, 1H), 2.34 (s, 3H), 2.22 (dd, J = 12.8, 5.0 
Hz, 1H), 2.09 (dd, J = 14.3, 4.1 Hz, 1H), 1.86 – 1.78 (m, 1H), 1.77 – 1.64 (m, 5H), 1.63 – 1.51 (m, 2H), 
1.50 – 1.34 (m, 3H), 1.15 – 0.86 (m, 10H), 0.72 (t, J = 6.9 Hz, 3H), 0.65 – 0.50 (m, 1H), 0.30 (t, J = 7.3 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.1, 172.1, 144.1, 138.5, 136.7, 130.0, 129.9, 129.3, 129.1, 128.9, 
128.6, 128.3, 54.6, 39.02, 38.97, 38.4, 36.8, 31.9, 31.2, 30.9, 29.4, 25.7, 25.6, 25.2, 22.9, 22.5, 21.5, 13.8, 
11.6. 
FT-IR (film): 3068, 2932, 2858, 1717, 1618, 1592, 1451, 1345, 1086, 860, 706 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C31H44N2O4SNa: 563.2914, found: 563.2914. 
[]22D = 13.6 (c 1.0, CHCl3); 92% ee, 99:1 dr from (S,R)-L2. 
 
 
 
N-Cyclohexyl-3-ethyl-N-phenyl-4-(1-tosyl-1H-indol-2-yl)octanamide (Fig. 4, reaction f, X = 
NTs).  A 4-mL vial was charged with N-cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide 
(70.6 mg, 0.20 mmol, 1.0 equiv) and N-tosyl-2-iodoaniline (74.6 mg, 0.20 mmol, 1.0 equiv).  The 
vial was loosely capped and transferred into glovebox.  Next, Pd(PPh3)2Cl (5.6 mg, 0.0080 
mmol, 0.040 equiv), CuI (7.6 mg, 0.040 mmol, 0.20 equiv), toluene (2.0 mL), TMG (76.0 L, 0.60 
mmol, 3.0 equiv) and a stir bar were added sequentially.  Then, the vial was capped and 
transferred out of glovebox.  The reaction was stirred at 80 ºC for 13 h, and then was quenched 
with aqueous saturated NH4Cl (2.0 mL) and extracted with Et2O (3  20 mL).  The combined 
organic layers were dried (Na2SO4), filtered, and concentrated under reduced pressure.  The 
residue was purified by flash chromatography on silica gel (1:2 CH2Cl2/hexanes) to afford the 
pure product.  White foamy solid. 
(R,S)-L2: 115 mg, 96% yield, 94% ee, 99:1 dr; 
(S,R)-L2: 116 mg, 97% yield, 94% ee, 99:1 dr. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (10.0% 
2-PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 12.5 
min (major), 14.0 min (minor). 
1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.2 Hz, 1H), 7.40 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 7.7 
Hz, 1H), 7.23 – 7.10 (m, 3H), 7.03 (d, J = 8.1 Hz, 2H), 6.97 (d, J = 8.0 Hz, 1H), 6.93 – 6.85 (m, 1H), 
6.82 (t, J = 7.3 Hz, 1H), 6.74 (d, J = 7.7 Hz, 1H), 6.03 (s, 1H), 4.42 (tt, J = 12.1, 3.5 Hz, 1H), 3.36 (dt, J 
= 11.1, 3.6 Hz, 1H), 2.21 (s, 3H), 2.16 – 2.02 (m, 1H), 1.95 (dd, J = 14.2, 4.8 Hz, 1H), 1.76 – 1.48 (m, 
S–82 
5H), 1.48 – 1.12 (m, 7H), 1.08 – 0.96 (m, 2H), 0.95 – 0.84 (m, 4H), 0.83 – 0.68 (m, 3H), 0.66 – 0.51 
(m, 4H). 
13C NMR (101 MHz, CDCl3) δ 172.0, 144.4, 144.1, 138.5, 137.6, 136.6, 130.3, 129.9, 129.5, 128.7, 
128.2, 127.7, 126.1, 123.6, 123.3, 119.9, 115.5, 109.3, 53.8, 40.2, 39.8, 36.2, 31.5, 31.3, 29.8, 27.9, 25.71, 
25.70, 25.3, 24.8, 22.8, 21.4, 13.9, 11.9. 
FT-IR (film): 2931, 2856, 1647, 1594, 1368, 1172, 712 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C37H46N2O3SNa: 621.3121, found: 621.3119. 
[]22D = 164.4 (c 1.0, CHCl3); 94% ee, 99:1 dr from (S,R)-L2.
4-(Benzofuran-2-yl)-N-cyclohexyl-3-ethyl-N-phenyloctanamide (Fig. 4, reaction f, X = O).  
A 4-mL vial was charged with N-cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide (70.6 mg, 
0.20 mmol, 1.0 equiv) and 2-iodophenol (44.0 mg, 0.20 mmol, 1.0 equiv).  The vial was loosely 
capped and transferred into glovebox.  Next, Pd(PPh3)2Cl (5.6 mg, 0.0080 mmol, 0.040 equiv), 
CuI (7.6 mg, 0.040 mmol, 0.20 equiv), toluene (2.0 mL), TMG (76.0 L, 0.60 mmol, 3.0 equiv) and 
a stir bar were added sequentially.  Then, the vial was capped and transferred out of glovebox. 
The reaction was stirred at 80 ºC for 13 h, and then was quenched with aqueous saturated 
NH4Cl (2.0 mL) and extracted with Et2O (3  20 mL).  The combined organic layers were dried 
(Na2SO4), filtered, and concentrated under reduced pressure.  The residue was purified by 
flash chromatography on silica gel (1:2 CH2Cl2/hexanes) to afford the pure product.  Colorless 
oil. 
(R,S)-L2: 77 mg, 87% yield, 94% ee, 98:2 dr; 
(S,R)-L2: 80 mg, 90% yield, 94% ee, 98:2 dr. 
HPLC analysis: The ee was determined via HPLC on a CHIRALPAK AD-H column (2.0% 2-
PrOH in hexanes, 1.0 mL/min); retention times for compound obtained using (R,S)-L2: 9.2 min 
(major), 14.2 min (minor). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.33 (m, 1H), 7.32 – 7.21 (m, 2H), 7.20 – 7.13 (m, 2H), 7.13 
– 7.04 (m, 2H), 7.02 – 6.85 (m, 2H), 6.21 (d, J = 0.8 Hz, 1H), 4.55 (tt, J = 12.1, 3.6 Hz, 1H), 2.88 (dt, J
= 9.8, 4.7 Hz, 1H), 2.18 – 2.04 (m, 1H), 1.91 – 1.80 (m, 2H), 1.80 – 1.69 (m, 2H), 1.69 – 1.54 (m, 3H),
1.52 – 1.25 (m, 5H), 1.24 – 1.08 (m, 4H), 1.05 – 0.79 (m, 4H), 0.75 (t, J = 7.1 Hz, 3H), 0.66 (t, J = 7.4
Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 171.8, 161.1, 154.4, 139.1, 130.4, 130.2, 128.9, 128.7, 127.9, 122.8, 
122.2, 120.0, 110.7, 103.2, 54.0, 41.9, 40.6, 36.9, 31.7, 31.6, 30.3, 30.1, 25.80, 25.79, 25.4, 23.1, 22.7, 
14.0, 11.9. 
FT-IR (film): 2926, 2856, 1658, 1649, 1595, 1493, 1454, 1392, 1254, 1072, 751, 708 cm-1. 
HRMS (ESI-MS) m/z [M+Na]+ calcd for C30H39NO2Na: 468.2873, found: 468.2877. 
[]22D = 26.3 (c 1.0, CHCl3); 94% ee, 98:2 dr from (S,R)-L2.
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IX. Assignment of Absolute Configuration
The configuration of the coupling product illustrated in Fig. 2, entry 35, using (R)-L1, was 
determined via X-ray crystallography. 
Figure S-1.  Thermal ellipsoid plot at the 50% probability level. 
 (S)-3-Ethyl-1-(indolin-1-yl)nonan-1-one.  X-ray quality crystals were obtained by slow 
evaporation of a saturated solution in hexane of a sample synthesized using (R)-L1.  A 
crystal of C19H29NO was selected and mounted in a nylon loop in immersion oil.  All 
measurements were made on a 'Bruker APEX-II CCD' diffractometer with filtered Cu-K 
radiation at a temperature of 100 K.  Using Olex2 (37), the structure was solved with the XT 
(38) structure solution program using direct methods and refined with the ShelXL (39) 
refinement package using least squares minimization.  The absolute stereochemistry was 
determined on the basis of the absolute structure parameter. 
N
OEt
n-Hex (S)
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Table S-4.  Crystal data and structure refinement for the product in Fig. 2, entry 35. 
Identification code  v18075 
Empirical formula  C19 H29 N O 
Formula weight  287.43 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 1 21 1 
Unit cell dimensions a = 10.1922(11) Å = 90° 
b = 9.4775(15) Å = 92.783(7)° 
c = 35.588(4) Å  = 90° 
Volume 3433.6(8) Å3
Z 8 
Density (calculated) 1.112 g/cm3
Absorption coefficient 0.514 mm-1
F(000) 1264 
Crystal size 0.17 x 0.15 x 0.01 mm3
Theta range for data collection 3.730 to 79.874°. 
Index ranges -12  h  12, -10  k  11, -44  l  43
Reflections collected 53983 
Independent reflections 13680 [R(int) = 0.0515] 
Completeness to theta = 67.679° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.8279 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 13680 / 46 / 782 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0487, wR2 = 0.1153 
R indices (all data) R1 = 0.0537, wR2 = 0.1179 
Absolute structure parameter [Flack] 0.11(8) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.525 and -0.221 e.Å-3
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(R)-3-Ethyl-6-phenylhexan-1-ol.  The stereochemistry of this compound has been 
established in the literature (40).  It was synthesized via the reduction of the coupling 
product of Fig. 2, entry 2, obtained with (S)-L1.  The (R) configuration was assigned by 
comparison with the published optical rotation and chiral HPLC data: 
Optical rotation: 
]24D = 2.2 (c 1.0, CHCl3); 91% ee from (S)-L1.
Lit. (40): []24D = 1.39 (c 1.1, CHCl3); 92% ee for (R) configuration.
HPLC (CHIRALPAK AD-H column, 1.0% EtOH in hexanes, 1.0 mL/min): 
17.2 min (major), 18.8 min (minor); 91% ee from (S)-L1.  
Lit. (40): 19.8 min (major), 22.4 min (minor); 92% ee (R) configuration. 
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The configuration of the desilylated terminal alkyne derived from the coupling product 
illustrated in Fig. 3, entry 1 (generated using (R,S)-L2) was determined via X-ray 
crystallography. 
Figure S-2.  Thermal ellipsoid plot at the 50% probability level.  Hydrogen atoms are omitted 
for clarity. 
(3R,4R)-N-Cyclohexyl-3-ethyl-4-ethynyl-N-phenyloctanamide.  X-ray quality crystals were 
obtained by slow evaporation of a saturated solution in pentane of a sample synthesized with 
(R,S)-L2.  A crystal of C24H35NO was selected and mounted in a nylon loop in immersion oil.  
All measurements were made on a 'Bruker APEX-II CCD' diffractometer with filtered Cu-K 
radiation at a temperature of 100 K.  Using Olex2 (37), the structure was solved with the XT 
(38) structure solution program using direct methods and refined with the ShelXL (39) 
refinement package using least squares minimisation.  The absolute stereochemistry was 
determined on the basis of the absolute structure parameter.
NCyPh
Et O
n-Bu
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Table S-5.  Crystal data and structure refinement for the alkyne in the center of Fig. 4. 
 
Identification code  v19168  
Empirical formula  C24H35NO  
Formula weight  353.53  
Temperature/K  100  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  8.0453(6)  
b/Å  11.7790(13)  
c/Å  22.674(4)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  2148.8(4)  
Z  4  
ρcalcg/cm3  1.093  
μ/mm-1  0.495  
F(000)  776.0  
Crystal size/mm3  0.29 × 0.11 × 0.09  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  7.798 to 144.662  
Index ranges  -9 ≤ h ≤ 9, -14 ≤ k ≤ 14, -28 ≤ l ≤ 27  
Reflections collected  49459  
Independent reflections  4245 [Rint = 0.0417, Rsigma = 0.0153]  
Data/restraints/parameters  4245/0/238  
Goodness-of-fit on F2  1.045  
Final R indexes [I>=2σ (I)]  R1 = 0.0266, wR2 = 0.0692  
Final R indexes [all data]  R1 = 0.0272, wR2 = 0.0697  
Largest diff. peak/hole / e Å-3  0.18/-0.14  
Flack parameter 0.06(4) 
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X.  1H-NMR and 13C-NMR Spectra; Stereoselectivity Analysis 
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